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ABSTRACT 
Retinoblastoma binding protein 6 (RBBP6) is a nuclear protein, previously 
implicated in the regulation of cell cycle and apoptosis. It is a multi-domain protein 
containing a Zinc finger, a RING finger, an Rb binding domain, a p53 binding 
domain and a novel N-terminal protein domain, the so called, Domain With No 
Name or DWNN. The RBBP6 gene encodes three isoforms of this particular 
protein. A common feature of all three isoforms of RBBP6 is the presence of the N-
terminal DWNN domain. RBBP6 isoform 3 is comprised of the DWNN domain 
only. The DWNN itself has a ubiquitin-like fold, sharing 22% similarity with 
ubiquitin. It is likely that DWNN regulates intracellular levels of the two tumour 
suppressors, Rb and p53 through the ubiquitin-proteasome pathway and as such, 
DWNN may therefore play a role in the deregulation of cell cycle control in cancer 
cells. A mouse homologue, P2P-R of the gene has been implicated in mitotic 
apoptosis.  
 
The expression of DWNN, RBBP6 and their roles in the cell cycle, apoptosis and 
human cancer were investigated. RT-PCR and real-time PCR were used to 
determine the gene expression of DWNN and RBBP6 variants in human cancer 
cells. An anti-human DWNN antibody was characterized using both Western 
Blotting analysis and MALDI-TOF mass spectroscopy to determine whether the 
antibody specifically recognizes DWNN and RBBP6 isoforms, or if it recognizes 
other proteins. Western blotting was also used to determine the nature of the 
DWNN in human cell lines. A DWNN probe and the characterized anti-human 
antibody were used to localize DWNN and RBBP6 gene products at the mRNA and 
protein levels using ISH/FISH and Immunohistochemistry respectively. Cell 
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labelling was also performed using this antibody to localize RBBP6 products in 
human cell lines. RNA interference and over-expression of DWNN and RBBP6 
gene products was carried out to further investigate the role of RBBP6 products in 
the cell cycle, apoptosis and carcinogenesis. 
 
Cloned RT-PCR products of RBBP6 binding domains, the RING finger domain, 
pRb-binding and p53-binding domains in human cancers cell lines (Hek 293T, 
MCF7, HeLa and HepG2 cells) showed no mutations, but MCF-7 cells showed the 
lowest expression of the RBBP6. Real-time PCR and Western blotting analysis 
confirmed that MCF-7 cells express very little DWNN (RBBP6 isoform 3) and 
RBBP6 gene products when compared to Hek 293T, HeLa and HepG2 cells. It was 
also shown that the anti-human DWNN antibody recognizes the DWNN domain 
(RBBP6 isoform 3) and the larger RBBP6 isoforms. Using 2D gel electrophoresis 
and MALDI-TOF spectrometry, it was also found that DWNN is associated with 
other proteins namely, Recoverin and a hypothetical protein XP_002342450. This 
result suggested that DWNN may be a ubiquitin-like protein, which may be specific 
to these proteins in human cells. FISH and IHC demonstrated that the DWNN 
domain and its relatives are down-regulated in human cancers at both mRNA and 
protein levels, respectively. In contrast, however, cell staining showed that the 
expression of the DWNN gene products was high during the G2/Mitosis transition. 
Knocking-down the DWNN domain or over-expressing it did not sensitise the Hek 
293T cells to Camptothecin (CPT)-induced apoptosis but rather slowed down cell 
growth.  
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These results strongly suggest that the DWNN gene is likely to be involved in cell 
cycle control. Up-regulation in mitotic cells and down-regulation in cancers also 
implies that RBBP6 gene products may additionally be involved in cell cycle arrest. 
Moreover, down-regulation in human cancers particularly indicates that the loss of 
its function which correlates with loss of cell cycle control in this disease may be 
involved in the pathogenesis of cancer. This was confirmed by up-regulation of the 
DWNN in arsenic trioxide induced cell cycle arrested cells specifically at G2/M 
phase where a p53-dependent cell cycle arrest ensued. It is thus proposed that the 
DWNN may be implicated both as a p53 stabilizer and additionally as a G2/M 
progression regulator. 
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Chapter one: Introduction 
 
1. Introduction 
Deregulation of apoptosis plays an important role in carcinogenesis. Many gene 
products, some of which are important regulators of apoptosis, are deregulated in 
cancers through mutations, post-translational modifications and other regulatory 
mechanisms, including for example promoter methylations (Gan et al., 2011, Kato 
et al., 2012). The list of genes that are involved in carcinogenesis is growing 
exponentially and some are tissue specific. 
 
1.1 Genes and carcinogenesis 
Transformation of normal cells into cancer cells caused by mutations of the cell’s 
genetic material is referred to as carcinogenesis. These mutations generally disturb 
the normal balance between cell proliferation and cell death resulting in 
uncontrolled cell division and tumour formation. Carcinogenesis requires more 
than one mutation in a number of genes that control cell division, DNA repair and 
apoptosis (Wickstrom et al., 2010). The gene types most likely to be affected in 
carcinogenesis include proto-oncogenes, tumour suppressors and key cell cycle 
regulating genes. Additionally, there are non-mutagenic carcinogens that are 
believed to encourage cancer initialization by stimulating high rates of cell 
division, which often results in high error rates with regard to the inherent DNA 
repair mechanisms. Viral infections may also play a crucial role in carcinogenesis, 
causing certain types of cancers, for example Human papillomavirus implicated in 
the development of cervical cancer (Mileo et al., 2009, Yoshida et al., 2008) and 
also causing a number of gene mutations (Wingo et al., 2009).  
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Although mutations are known to contribute to carcinogenesis, the cause of a 
specific cancer is not always known. However, there is a growing list of 
aetiological factors associated with the carcinogenic process, for example there 
appears to be a link between red and processed meat consumption and occurrence 
of cancer of the colon, indicating a complex aetiology (Cross et al., 2008, Sinha et 
al., 2009). So too is the list of genes implicated in cancer growing. The broad 
question that is addressed in this study is whether deregulation of the RBBP6 and 
DWNN is also involved in the process of carcinogenesis. In this regard the mouse 
homologue of the RBBP6, P2P-R was shown to be specifically expressed in 
murine oesophageal cancer cells in contrast to adjacent normal cells in mice 
suggesting a link to cancer (Yoshitake et al., 2004). 
 
1.1.1 Examples of gene regulations in specific cancers 
1.1.1.1 Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma is one of the most common abdominal cancers 
representing 80-90% of all liver malignancies worldwide. It is the fifth most 
common cancer and third most common cause of death from cancer globally (El-
Serag and Rudolph, 2007, Gadelhak et al., 2009). Liver cancer often arises from 
metastasis from other organ cancers. Secondary epidemiological factors 
associated with liver cancer include infection with hepatitis B and C viruses and 
alcoholism (El-Serag et al., 2009, Imvrios et al., 2008, Kumar et al., 2007). Liver 
cancer generally, is typified by de-regulation of hepatocyte division, often 
accompanied by de-regulation of apoptosis (Bai et al., 2010, Chang et al., 2010, 
Peroukides et al., 2010, Weber et al., 2009, Yu et al., 2008), making apoptotic-
related genes very important in HCC. p53, known as the genome guardian is often 
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de-regulated in hepatocellular carcinoma, however in certain types of cancer 
therapy like chemotherapy and radiation therapy, p53 action is restored and cell 
cycle arrest and apoptosis are resumed (Song et al., 2009, Teoh et al., 2009, Zhu 
et al., 2009). In HCC, p53 has been documented to sensitize liver cancer cells to 
cell cycle arrest and apoptosis in response to heavy ion irradiation (Liu et al., 
2008, Liu et al., 2007a).  
 
Examples of agents that result in resumed apoptotic activity in HCC include an 
anti-tumour metabolite, 20-O-(b-D-glucopyranosyl)-20(S)-protopanaxadiol (IH-
901), a novel intestinal bacterial metabolite of ginseng protopanaxadiol saponins, 
which was found to inhibit HCC cells and induce apoptosis of other cells through 
the mitochondrial pathway (Cho et al., 2009, Lee et al., 2009a, Ming et al., 2007). 
It was shown that ginseng induces the intrinsic apoptotic pathway by up-
regulation and activation of caspase-9 and caspase 3, Bax and p53 (Kumar et al., 
2009). Other anticancer agents like Spirulina platensis C-phycocyanin have been 
reported to induce apoptosis of hepatocellular carcinoma cells and other cells that 
are otherwise resistant to other anticancer agents (Chen and Wong, 2008b, Chen 
et al., 2009a, Roy et al., 2007).  
 
Although p53 is not able to halt liver carcinogenesis, it does sensitize 
hepatocellular cancer cells to apoptosis during chemotherapy, at least with the use 
of irinotecan, a topoisomerase I inhibitor. Irinotecan activates p53 resulting in 
more p53-dependent apoptosis in hepatocellular carcinoma cells (Takeba et al., 
2007a, Takeba et al., 2007b). There are other genetic factors that could contribute 
to desensitization of cells to apoptosis. Survivin has been documented to be over-
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expressed in HCC and its over-expression may be involved in the inhibition of 
apoptosis (Duan et al., 2005, Li et al., 2009b, Pellerito et al., 2010, Zhang et al., 
2009a).  
 
1.1.1.2 Breast cancer 
Breast cancer is the most common cancer seen in women worldwide. It follows 
lung cancer as the leading cause of death from cancer (Wang et al., 2009c). Here 
too, the inhibition of apoptosis plays a role. Some types of breast cancer results 
from aberrations in pathways driving cellular proliferation and from the inhibition 
of apoptosis, which are both mediated by the phosphatidylinositol 3-kinase (PI3-
K) induced activation of protein kinase B (PKB)/Akt (Pearson and Hunter, 2009, 
Siddiqa et al., 2008, Torbett et al., 2008, Vestey et al., 2005). Another cause of 
breast cancer arises from gene aberrations that inhibit the tumour suppressors, 
BRAC 1 and 2. BRAC 1 and 2 are the most researched tumour suppressor 
proteins in breast cancer, but there are other players like p53 and pRb proteins. 
Currently there is no literature linking the RBBP6 with breast cancer but P2P-R, a 
mouse homologue has been implicated in cell cycle regulation and apoptosis, 
while its interaction partners p53 and pRb have been implicated in breast cancer 
through their inactivation (Cao et al., 2009b, Elayat et al., 2009, Guo et al., 2007, 
Hedau et al., 2004, Henriquez-Hernandez et al., 2009, Macaluso et al., 2007).  
 
It has been reported that the de-regulation of p53 and pRb leads to breast cancer 
due to the loss of cell cycle checkpoints and subsequent suppression of apoptosis 
(Heminger et al., 2009, Liu et al., 2009b, McGahren-Murray et al., 2006). Besides 
these tumour suppressors, caspases also play a role important in breast carcinoma 
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development as seen in the breast cancer cell line, MCF-7. These breast cancer 
cells were shown to be resistant to irradiation mediated-apoptosis because they do 
not express caspase-3 (Essmann et al., 2004), which is central to the apoptosis 
pathway. In an independent study (Cui et al., 2007), caspase-9 and p53 were also 
shown to play a role in apoptosis induction in breast cancer cells. Re-introduction 
of caspase-3 in MCF-7 cells enhanced the apoptotic response of these cells to 
apoptotic stimulus, for example after genistein-treatment (Ferenc et al., 2010, Li 
et al., 2009c, Yang et al., 2007).  
 
Bcl-2 family members are also important in breast cancer development 
significantly Bcl2, Mcl-1 and Bcl-XL. The Bcl2 family of anti-apoptotic, pro-
survival proteins have been reported to be up-regulated in primary breast tumours 
and breast cancer (Cao et al., 2009a, Valladares et al., 2006) with high expression 
levels of Bcl-2 resulting in the inhibition of apoptosis (Arakawa et al., 2009, Arun 
et al., 2003, Liu et al., 2009b). Over-expression of Mcl-1, an anti-apoptotic 
protein, in breast cancer is correlated with high grade tumours (Ding et al., 2007), 
normal expression of Mcl-1 can be achieved by the use of chemotherapeutic 
agents, for example taxol and tetraiodothyroacetic acid (Glinskii et al., 2009, Lu et 
al., 2009). Additionally herceptin antibody and granzyme B has also been reported 
to sensitize breast cancer cells to apoptosis by reducing the expression of Mcl-1 
(Germain et al., 2008, Henson et al., 2006). Granzyme B was also reported to 
activate pro-caspase-3 through degradation of Mcl-1; freeing Bim from Mcl-1 
sequestration, consequently resulting in “freed” Bim initiating mitochondrial-
mediated apoptosis (Germain et al., 2008, Han et al., 2005).  
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1.1.1.3 Cervical carcinoma 
Cervical cancer is rated the second most common malignant tumour globally, and 
is aetiologically highly linked to the human papillomavirus [HPV] (Pisani et al., 
2002, Stamataki et al., 2010). South Africa is reported to have the highest 
incidence of cervical cancer in the world. It is the most common cancer in Black 
(31.2%) and Coloured (22.9%) South African women (Denny, 2006, Gaym et al., 
2007). The HPV viral genes in squamous cells prevent apoptosis by affecting p53 
and pRb cellular functions and consequently lead to cancer of the cervix 
(Ganzenmueller et al., 2008, Liu et al., 2007b, Nees et al., 2000). It is noted that 
HPV infection may not be the sole aetiological factor leading to cervical 
carcinoma since cancer is a multi-aetiological disease.  
 
The most studied tumour suppressor genes, p53 and pRb, are very important in 
cancer cell growth prevention. The hindered function of p53 and pRb is intrinsic 
in cervical cancer progression. The restoration of p53 and pRb function restores 
cell proliferation control and apoptosis induction (Liu et al., 2009a, Masamha and 
Benbrook, 2009). HPV’s involvement in cervical carcinogenesis involves the 
reduction of p53 and pRb protein levels, which is reversible in SiHa cells. This 
can be achieved by using antisense RNA to target HPV’s E6 and E7 genes, result 
in the increased expression of p53; accumulation of hypophosphorylated pRb (in 
SiHa cells) and possibly increased apoptosis of these cells (Morandell et al., 2008, 
Sima et al., 2007). These studies corroborate other studies, which demonstrated 
that repression of E6 and E7 proteins causes cellular senescence and apoptosis 
with a stabilized p53 expression (Bai et al., 2006, De Filippis et al., 2003, Liu et 
al., 2009a).  
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It is apparent that cervical carcinoma cells have altered apoptosis regulation 
accompanied by altered expression of apoptotic-related proteins as well as de-
regulation of p53 and pRb tumour suppressor expressions and functions. Bcl-2 
and other anti-apoptotic family members are very important in any carcinogenesis 
and cervical cancer is no exception. Two situations seem to exist in cervical 
cancer; either Bcl-2 is co-expressed with p53 in HPV positive cancer cases (used 
as a diagnostic marker for early cancer development) (Bhushan et al., 2009, Singh 
et al., 2009) or neither p53 nor Bcl-2 are present. This seems surprising as these 
proteins have opposing functions. An explanation for this situation would be that 
Bcl-2 both regulates and suppresses the p53-Bax pathway. Additionally, Bcl-2 
over-expression not only suppresses apoptosis, but also promotes carcinogenesis 
in some other unknown way.  
 
1.1.1.4 Research motivation 
It was previously demonstrated that the loss of DWNN expression in Chinese 
Hamster Ovary (CHO) cells resulted in resistance to staurosporine-induced 
apoptosis (George, 1995, Pretorius, 2007). DWNN, which is both a standalone 
domain and associated with RBBP6 gene products, has so far not been implicated 
in apoptosis. This therefore raises a number of queries/questions, including: is 
DWNN another example of a gene that is deregulated in human cancers? Is the 
RBBP6 gene a potential candidate for tumour suppressor for de-regulation or is 
this gene an oncogene? 
 
Human cancers are characterized by resistance to apoptosis and cell cycle 
deregulation (Chang et al., 2006, Lu et al., 2009, Poulsen et al., 2010). The 
PhD - Z Mbita Chapter One: Introduction 
8 
 
expression of cell cycle- and apoptosis-related gene products is crucial in cancer 
development and treatment. The relative expression of p53- and pRb-binding 
RBBP6 in human cancer cell lines has not been examined before. However, while 
RBBP6 has been detected in HeLa cells using a PACT antibody (Simons et al., 
1997) and P2P-R has been over-expressed in MCF-7 cells (Gao and Scott, 2002), 
the existence of DWNN, the smallest member of the RBBP6 family of proteins 
has not so far been shown to be a human endogenous protein and further, has not 
been detected. Although it has also been previously reported that the recombinant 
DWNN domain has a ubiquitin-like fold (Pugh et al., 2006), its function is still 
un-elucidated. The research question asked here is; does DWNN tag other 
proteins in a similar fashion to ubiquitin in the human proteomes, in both 
cancerous and non-cancerous cells?  
 
The up-regulation of the P2P-R, a murine RBBP6 homologue, in oesophageal 
carcinoma and a loss of the gene expression in the corresponding normal tissue 
has been reported (Yoshitake et al., 2004). The expression pattern of this gene 
suggests that it is involved in cancer, however, the role of RBBP6 in cancer is not 
understood and this study was aimed at further elucidating the role of this gene in 
cancer.  
 
It was reported that RBBP6 binds p53 and pRb, two tumour suppressor proteins 
(Sakai et al., 1995, Simons et al., 1997). These tumour suppressor proteins both 
regulate the cell cycle. As the DWNN domain in RBBP6 has a ubiquitin-like fold 
and ubiquitin-like activity, it is queried here whether DWNN regulates p53 and 
pRb levels through ubiquitination? RBBP6 and DWNN may therefore be targets 
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of mutagenesis resulting in cancer. Moreover, does DWNN play a role in 
apoptosis or/and cell cycle regulation in human cancers?  
 
The information currently available strongly suggests that DWNN and RBBP6 
and its relatives are involved in protein stabilization, ubiquitination, cell cycle 
regulation and apoptosis.  
 
1.2  Hypothesis  
The expression and regulation of DWNN/RBBP6 is targeted during 
carcinogenesis in human organs. 
 
1.3 Broad objectives 
This research is aimed at determining a consensus of gene expression pattern of 
the RBBP6 in human cancers at both mRNA and protein levels using ISH/FISH; 
ICC, RT-PCR and Western blotting, with an emphasis on breast cancer, cervical 
cancer and liver cancer. It was also of interest to determine the involvement of 
RBBP6 in cell cycle regulation and apoptosis. The specific objectives were as 
follows: 
 
1.4 Specific objectives 
 To investigate mutational status of RBBP6 using PCR, cloning and sequences 
in some selected human cancer cell lines, focussing on different coding regions 
of the gene, predominantly; the RING finger domain of the RBBP6, 
Retinoblastoma-binding domain and p53-binding domains. 
 This study was also targeted at characterizing the anti-human DWNN antibody 
and testing the specificity of this antibody using one-dimensional, two-
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dimensional gel electrophoretic and Western blot techniques to investigate the 
endogenous expression levels of RBBP6 iso3/DWNN in human cancer cells. 
MALDI-TOF mass spectrometry was used to confirm the identity of the 
protein spots obtained from the two-dimensional gel electrophoresis and were 
detected by the anti-human DWNN antibody. This was done to address the 
question of DWNN’s ubiquitin-like activity.  
 Determination of the expression pattern of the gene products at the mRNA 
level was also investigated. This was performed to determine whether there is 
RBBP6 expression in human cancer cells, to elucidate its expression status that 
is whether it is down- or up-regulated in the selected cancers. Since the mouse 
homologue has been shown to be highly expressed in oesophageal cancer, it 
was thought that the RBBP6 gene products could be present in both cancer 
tissues and cancer cell lines (at the protein level). 
 RNA interference was used to target RBBP6 transcripts in order to knockdown 
the expression of this gene in Hek 293T cells. This technique was used to 
evaluate the apoptotic response in Hek 293T cells with reduced levels of 
RBBP6. These knock-down derived cells were then treated with known 
apoptotic inducers, that is, camptothecin, arsenic trioxide and staurosporine and 
the extent of apoptosis was evaluated using the APOPercentage staining with 
the flow cell sorter (FACS). The percentage of apoptotic cells were analyzed 
using the CELL QUEST Pro software (Beckon Dickson, Biosystems, USA). 
 
 Over-expression of the DWNN domain and RBBP6 was used in human cancer 
cells (MCF-7 and HepG2) to further investigate the function of the RBBP6 in 
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cell homeostasis particularly with regard to cell cycle and apoptosis regulation. 
The cell cycle analysis was done using the propidium iodide method that 
measures the DNA content and the percentages of cells in different phases of 
the cell cycle were analyzed using the CELL QUEST Pro software (Beckon 
Dickson, Biosystems, USA). 
 
1. 5 Organisation of the thesis 
The thesis is organized into seven chapters including this introductory chapter 
(Chapter one), and they are described as follows: 
Chapter two 
This chapter covers the literature review addressing important information 
relevant to the study. This chapter also highlights the knowledge and the gaps that 
exist in our understanding of the role of RBBP6 and the mechanisms that it may 
play a role in.  
 
Chapter three 
Chapter three covers the materials and methodology used in the study. This 
chapter is complemented by several appendices. Recipes for the solutions required 
for the methods are given in Appendix A1 and chemicals and their suppliers are 
given in Appendix A2. A list of the equipment used is given in Appendix A3. 
Several other method appendices are associated with this chapter. 
 
Chapter four 
Chapter four describes the mutational analysis of the RBBP6 gene products and 
characterization of a novel anti-human DWNN uncharacterized antibody in 
human cancers. This anti-human DWNN polyclonal antibody (section 3.2.4) was 
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the only available reagent for staining and localization of the all RBBP6 gene 
products. 
 
Chapter five 
In this chapter, expression pattern analysis of the DWNN and RBBP6 variants and 
isoforms was investigated using Fluorescent in situ hybridisation (FISH) (section 
3.3.10), immunohistochemistry (IHC) and immunocytochemistry (section 3.3.9) 
to detect the RBBP6 transcripts and isoforms in situ respectively. A DWNN RNA 
probe (section 3.3.10.1-2) and purified DWNN antibodies were used to detect 
RBBP6 mRNA and protein respectively. The variant 3 (figure 2.1A) fragment of 
the DWNN cDNA was cloned into pGEM-T Easy vector and sequenced (Inqaba 
Biotech. Co, South Africa). The antibody that was characterized and purified as 
reported in chapter four was used in the immunohistochemistry and 
immunocytochemistry experiments. This chapter is complemented by Appendix 
G. 
 
Chapter six 
In chapters four and five, it was demonstrated that the RBBP6 gene is expressed 
at both mRNA and protein levels in both human tissues and human cancer cell 
lines. There was differential expression and localization of the RBBP6 mRNAs 
and proteins between cancer and normal cells/tissues. The polymerase chain 
reaction coupled with the sequencing of the RBBP6 RING finger, RBBD and 
p53BD in chapters three, demonstrated that the full length RBBP6 transcripts and 
isoforms are expressed, with no evidence of mutations and truncations 
respectively. Western blotting analysis (chapter three) showed that RBBP6 
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isoforms 1 and 3 are expressed at very low levels in both non-cancerous and 
cancerous cells although Hek 293T, a non-cancerous cell line had higher 
expression levels than the cancerous cell lines (figure 4.4). Localization studies 
using Fluorescent In Situ Hybridization and immunocytochemistry (chapter 5) 
revealed a differential expression of RBBP6 between normal and cancerous cells. 
It was found that RBBP6 is down-regulated in cancers, while normal cells showed 
nuclear localization of RBBP6 mRNA and proteins. When immunolocalized, 
RBBP6 proteins (chapter five) were found to be up-regulated in mitotic cells, as 
well as apoptotic cells and this prompted an investigation of RBBP6 in normal 
cells. RNA knock-down technology was chosen to further elucidate the function 
of RBBP6 in cell homeostasis and RNA interference (3.3.11) was used to further 
investigate the role of RBBP6. 
 
It has thus far been established that cancer cells when compared to normal cells, 
had down-regulated RBBP6 levels and therefore the following questions were 
addressed: (1) What would be the effect of RBBP6 knock-down in normal human 
cells (Hek 293T cells)? (2) What would be the effect of RBBP6 iso3 over-
expression in human cancer cells that had been shown to have low expression of 
the RBBP6 isoforms 1 and 2 and 3? (3) Is there is a correlation between the 
expression of RBBP6, cell cycle and apoptosis induction in human cells? 
 
Briefly, the RNAi oligos (Appendix F) were designed (section 3.3.11.1), annealed 
(section 3.3.11.3) and cloned into pEGFP-C1-U6 vector (Appendix E3). The 
colonies were screened by colony-PCR (section 3.3.6.4) using the RNA 
interference colony PCR primers (section 3.2.3.6) for plasmid containing the 
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annealed oligos (3.3.11.3). Plasmid DNA containing annealed oligos was purified 
(section 3.3.6.5) and subjected to sequence analysis (3.3.7). The purified plasmid 
DNA containing the RNAi annealed oligos (RNAi molecules) were used to 
transfect (section 3.3.11.5) Hek 293T cells. The effectiveness of gene knockdown 
was evaluated by PCR (section 3.3.4) and real-time PCR (section 3.3.8). Equal 
amounts of the cDNAs from the knock-downs and control samples were used. 
The effect of RBBP6 knock-down on apoptosis was investigated by inducing 
apoptosis with camptothecin, arsenic trioxide and staurosporine (Frese et al., 
2009, Kang and Lee, 2008, Wang et al., 2009e) [section 3.3.13]. The levels of 
apoptosis were measured using the MTT assay (3.3.15) and the APOPercentage 
FACS technique (section 3.3.13.1). The chapter is complemented with two 
appendices, I1 and I2. 
 
Chapter 7 
This chapter covers the general discussion and conclusion of the study. It also 
summarizes the core findings and areas that require further attention and 
investigation. 
 
Chapter eight 
Chapter eight gives the list of scientific sources used in this thesis to support the 
scientific arguments used. 
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Chapter Two: Literature review 
 
2.1. Retinoblastoma binding protein 6 (RBBP6) 
In humans, the retinoblastoma binding protein 6 (RBBP6) gene, localized on 
chromosome 16p12.2 codes for the RBBP6 protein products (Gao and Scott, 2002, 
Gao et al., 2002, Sakai et al., 1995), which bind two tumour suppressor proteins, 
retinoblastoma protein (pRb) and p53 (Simons et al., 1997, Witte and Scott, 1997). 
The RBBP6 gene encodes three protein isoforms, 1, 2 and 3 that are from two mRNA 
transcripts, a 1.1 kb and 6.1 kb transcript. Isoform 1 is encoded by the 6.1 kb 
transcript, while alternative splicing of the 6.1 kb transcript results in isoform 2. 
Isoform 3 encoded by a 1.1 kb transcript is also known as a Domain With No Name 
(DWNN) (Pugh et al., 2006). The coding region of this gene is composed of 18 
exons; isoform 1 is translated from all the 18 exons, while isoform 2 is coded for by 
17 exons (exon 16 is absent, due to alternative splicing) and isoform 3 consists of 
only the first 3 exons (Figure 2.1A). These three exons that encode DWNN are the 
same first three exons found in transcripts 1 and 2. Consequently, all three RBBP6 
isoforms share a common N-terminal domain, DWNN (figure 2.1B).  
 
DWNN was first identified through genetic screening aimed at identifying novel 
components of the antigen processing and presentation pathway via major 
histocompatibility class I (MHC class I) molecules (George, 1995). This initial study 
showed that somatic cell mutants lacking DWNN were resistant to cytotoxic T cell 
killing (George, 1995). A more recent study demonstrated that mutant Chinese 
Hamster Ovary (CHO) cells lacking the DWNN protein product were also resistant 
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Figure 2.1: – The gene structure of the RBBP6: Figure 2.1A shows the differences between the three RBBP6 variants, 1, 2 and 3. Variant 3 is made up of the first 3 
exons only (DWNN) while variant 1 has all the 18 exons and variant 2 has 17 exons, where exon 16 is missing. Figure 2.1B shows the domain arrangement of the three 
isoforms. Adapted from Altschul et al., 1997. 
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to staurosporine-induced apoptosis (Pretorius, 2007). Together, these studies reflect 
the importance of the DWNN protein in cell death.  
 
The DWNN domain is a novel ubiquitin-like cell death-related protein, that only 
makes up RBBP6 isoform 3 (Pugh et al., 2006). RBBP6 isoform 1 and 2 also contain 
a zinc finger, RING (Really Interesting New Gene) finger, Rb-binding domain, p53-
binding domain and Nuclear Localization Signal (NLS) downstream of the DWNN 
domain (figure 2.1B).  
 
The DWNN domain is highly conserved across different species as shown in figure 
2.2 (Pugh et al., 2006). For example, SNAMA is a fly homologue of the human 
RBBP6 and also contains the DWNN domain (Mather et al., 2005). However, unlike 
human RBBP6, a Drosophila SNAMA has so far been shown to have only a single 
gene product possessing E3 ubiquitin ligase activity (Antunes, 2009).  
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Figure 7.2 - DWNN domain alignment from different organisms: This figure shows the conservation of the RBBP6’s DWNN domain in different 
eukaryotic organisms and notes the high level of conservation seen in this domain (Pugh et al., 2006). 
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At present not much is known about the function of DWNN. However, RBBP6’s 
DWNN domain has a ubiquitin-like fold and shares 22% similarity with ubiquitin, 
suggesting a function in regulating protein turn-over in the cell, and additionally, 
RBBP6 appears to be involved in both cell cycle regulation and camptothecin-
induced apoptosis (Gao and Scott, 2003, Gao et al., 2002, Pretorius, 2007). 
Pretorius (2007) showed that when RNA interference technology was applied to 
mouse 3T3 cells, targeting RBBP6 transcript 1, the 3T3 cells appeared resistant to 
camptothecin-induced apoptosis. Equally in the study of Gao and Scott (2003), 
when P2P-R over-expression was induced, this sensitized the MCF-7 cells to 
camptothecin-induced apoptosis (Gao and Scott, 2003). Moreover, the presence of 
the ubiquitin-like fold in RBBP6 suggests a possible role similar to ubiquitin for 
RBBP6 and it may therefore be involved in ubiquitin ligase-like activities. Indeed, 
RBBP6 was reported to have ubiquitin ligase-like activity through its RING finger 
domain by ubiquitinating YB-1 protein, thereby reducing its transactivational 
ability (Chibi et al., 2008). Since RBBP6 binds to p53 and pRb (Sakai et al., 1995, 
Simons et al., 1997), it is likely that RBBP6 regulates the levels of these proteins 
in the cell through the DWNN.  
 
The function of the three RBBP6 isoforms is not fully understood. This work 
explores some of the functions of this little known gene and its products, 
specifically isoform 3 and its role in the regulation of cell cycle, apoptosis and 
carcinogenesis. 
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2.2 Interaction of RBBP6 with tumour suppressor proteins (pRb and 
p53) 
RBBP6 can interact with both p53 and pRb. This has been documented by several 
research groups, where they have shown that P2P-R, a mouse homologue of 
RBBP6 lacking the N-terminal DWNN domain, can bind the two tumour 
suppressors, p53 and pRb (Sakai et al., 1995, Simons et al., 1997, Witte and Scott, 
1997). Since p53 and pRb are known regulators of the cell cycle, it is thought that 
RBBP6 may be involved in the regulation of the cell cycle through its association 
with p53 and pRb and may therefore also play a role in regulating carcinogenesis. 
The role of p53 and pRb in cell cycle control and cancer is well known (Burkhart 
et al., 2010, Lee et al., 2009b, Mukherjee et al., 2009, Ramzi et al., 2009, Seoane 
et al., 2008, Shangary et al., 2008, Zhang et al., 2010b). However, to elucidate the 
role of RBBP6 in cancer regulation, an understanding of the role of the two 
tumour suppressors that interact with RBBP6 is needed.  
 
2.3 The role of RBBP6 in human cells 
RBBP6 has been reported to localize in the nucleus (Gao and Scott, 2002, Gao et 
al., 2002, Sakai et al., 1995). As a protein that interacts with two of the most 
studied and important tumour suppressors, pRb and p53, RBBP6 is hypothesized 
to play an important role in cell number homeostasis, that is, in cell cycle 
regulation, influencing/regulating both apoptosis and cell proliferation. In support 
of this view, Topors, a protein similar to RBBP6, binds p53 (Lin et al., 2005, 
Weger et al., 2002, Weger et al., 2005, Zhou et al., 1999) and RbQ-3 that interacts 
with pRb, preferentially when in an under-phosphorylated form (Saijo et al., 
1995).  
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2.4 RBBP6 homologues and their functions 
Earlier studies erroneously described RBBP6 as being RbQ-1 (Sakai et al., 1995). 
RbQ-1 is described as consisting of a Zinc finger domain, Rb-binding domain 
(RbBD) and p53-binding domain (p53BD). These studies found a mouse 
homologue of RBBP6, called PACT that binds p53 (Simons et al. 1997). Witte 
and Scott (1997) reported a murine p53 and pRb interactor, P2P-R and 
subsequently a yeast homologue of the RBBP6, Mpe-1, was reported to be 
involved in RNA processing (Vo et al., 2001). No DWNN domain was reported in 
any of these molecules. 
 
Of all these similar molecules, P2P-R has also been implicated in apoptosis and 
mitosis (Gao and Scott, 2003, Scott and Gao, 2002, Zhang et al., 2005a). SNAMA, 
a Drosophila RBBP6 gene homologue, is abundantly expressed in early 
embryogenesis where apoptosis is essential but surprisingly has not been 
demonstrated to interact with either p53 or pRb (Mather et al., 2005). However, 
SNAMA sequences notably do not show close homology to either the RbBD or 
p53BD. Li et al. (2007) linked murine RBBP6 to apoptosis and cell cycle 
regulation (Li et al., 2007a), suggesting that this homologue may play a role 
specifically, in apoptosis during embryonic development, similarly, SNAMA.  
 
2.5 Possible role of the RBBP6 in apoptosis 
The literature indicates that RBBP6 may have multiple functions in cell 
homeostasis, including RNA processing (Simons et al., 1997, Vo et al., 2001), cell 
cycle regulation, apoptosis (Gao and Scott, 2002, Gao and Scott, 2003) and 
probably ubiquitin ligase activities (Chibi et al., 2008, Pugh et al., 2006). The role 
of RBBP6 in apoptosis and cancer is of particular interest. The main focus of this 
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study is aimed at gaining a better understanding the role of the human RBBP6 in 
apoptosis and cell cycle regulation in human cancer.  
 
RBBP6’s involvement in cancer is implied by its known role in oesophageal 
carcinoma cells where it is up-regulated when compared to normal oesophageal 
epithelial cells (Yoshitake et al., 2004). To date this is the only report of the 
involvement of the human RBBP6 in the development of cancers. It is postulated 
that the up-regulation of RBBP6 in oesophageal cancer is linked to overcoming 
the cancerous phenotype.  
 
Although there are suggested functions for RBBP6 in mice where P2P-R regulates 
apoptosis and is possibly a player in regulating mitosis; and in drosophila where 
the SNAMA gene is thought to regulate apoptosis in early development. The 
function of the highly conserved DWNN domain in different organisms (figure 
2.2) generally remains elusive, and therefore is the focus of this study. 
 
2.6 Tumour suppressors pRb and p53 
Tumour suppressors balance the effect of oncogenes, and essentially function to 
modulate the cell cycle, providing a fine balance between cell proliferation and 
apoptosis. Oncogenes promote tumour cell proliferation resulting in undesirable 
conditions as manifested by human cancers. Conversely, tumour suppressors 
suppress cell growth when conditions are undesirable; for example, when DNA is 
damaged or when there are insufficient growth factors present, or if the cell 
division apparatus is faulty (Chatterjee et al., 2010, Coppé et al., 2008, Enari et 
al., 2006, Yuan et al., 2005). 
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There are many known tumour suppressor genes encoding proteins that inhibit the 
growth of potential cancerous cells by effecting cell cycle regulation and 
apoptosis (Gras et al., 2001, Liggett Jr and Sidransky, 1998, Rusan and Peifer, 
2008, Scully, 2000, Tommasi et al., 2008, Toyooka, 1995). It is when tumour 
suppressors lose their ability to regulate the cell cycle that cancer can develop. 
Table 2.1 demonstrates the abundance of tumour suppressor genes identified in 
several different cancers. Of these genes, Rb and p53 are the most studied and are 
often implicated in cancer progression.  
 
p53, pRb and p73 have been shown to be typical Knudson tumour suppressors, 
defined by a two-hit hypothesis, (while p63 is not a typical Knudson tumour 
suppressor). The two-hit hypothesis requires that that both alleles that code for a 
particular gene must be affected before an effect is manifested (Akers et al., 2009, 
Meric-Bernstam, 2007, Segditsas et al., 2009). 
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Table 2.1: Different tumour suppressors and their functions with resultant 
cancers after loss of function. 
Name  Function Resultant cancer from 
loss of function 
Reference 
IRF-4 Inhibits cell growth through the cell 
cycle and apoptosis 
B cell lymphoma (Acquaviva et al., 2008, 
Hoefnagel et al., 2005) 
BRCA3 Possible transcriptional regulation of 
DNA repair 
Breast cancer and 
colorectal carcinoma 
(Bergman et al., 2007, Seitz et al., 
1997, Sivarajasingham et al., 
2006) 
BLCAP Inhibits growth by inducing apoptosis. 
Transcription factor that regulates gene 
expression in BC 
Bladder cancer (BC) (Valleley et al., 2007, Zuo et al., 
2006) 
DCC Controls cell growth, cell differentiation 
and development of metastases 
Colorectal carcinoma, 
renal clear carcinoma 
(Dekel et al., 2004, Lui Park et 
al., 2008) 
DPC4 Mediates signalling from GF receptors 
Suppresses epithelial cell growth 
Colorectal tumours 
Pancreatic Neoplasia 
(Koliopanos et al., 2008, Wang et 
al., 2006a) 
MARS2/JV
18 
(SMAD2) 
Also mediates signalling from GF 
receptors 
Colorectal tumours 
Lung cancer 
(Riggins et al., 1996, Uchida, 
1996) 
BARD1 Involved in G1/S-phase check point, 
apoptosis after DNA damage 
Breast and ovarian cancer (Sauer and Andrulis, 2005, 
Shakya et al., 2008, Wu et al., 
1996) 
Jade-1  Promotes apoptosis Renal cancer (Chitalia et al., 2008, Zhou et al., 
2005) 
VHL Transcriptional regulation of apoptosis 
Plays a role in mammalian oxygen-
sensing pathway.  
Renal clear  cell carcinoma (Kim and Kaelin, 2004, Linehan 
et al., 2009) 
GAS1 Cell cycle regulator. Metastasis and 
tumour suppressor 
Melanoma (Gobeil et al., 2008, Lee et al., 
2001, Sal et al., 1994) 
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2.6.1 Retinoblastoma protein (pRb) in cancers 
Retinoblastoma protein was the first protein to be identified as a tumour 
suppressor in humans in a study that demonstrated that loss of function of the 
protein leads to retinoblastoma in children (Friend et al., 1986). Additionally 
pRb’s functional loss has also been implicated in other malignancies such as 
ovarian cancer (Armes et al., 2005, Li et al., 2007c, Masamha and Benbrook, 
2009), head and neck squamous cell carcinoma (Golam Sabbir et al., 2006) and 
soft-tissue sarcoma (Pereira et al., 2009, Polsky et al., 2006). These findings 
suggest that pRb loss plays a pivotal role in the progression of a range of different 
cancers. 
 
2.6.1.1 Retinoblastoma protein as a tumour suppressor 
The anti-cancer function of pRb involves the regulation of cell cycle progression 
through the inhibition of E2F activity. E2F transcription factors are proteins that 
regulate the cell cycle through repression or progression (Watabe et al., 2010). 
They are constantly under the control of pRb tumour suppressor, which controls 
their ability to activate cell cycle progression (Amato et al., 2009, Zhang et al., 
2010a). Cell cycle progression or regression depends on levels and the status of 
the pRb tumour suppressor proteins that are either hyper- or hypophosphorylated. 
In its inactive state, the pRb proteins are hyperphosphorylated and cells are able to 
express genes that facilitate the progression from G1 to the S phase transition of 
the cell cycle. This process is facilitated by the release of E2F factors from pRb 
inhibition (Adams, 2001, Parisi et al., 2008, Xiao et al., 2003). In its active state, 
hypophosphorylated, pRb is able to halt cell cycle progression by binding E2F 
transcription factors rendering them incapable of directing transcription of the 
genes required for cell cycle progression from the G1 to the S phase (Arakawa et 
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al., 2008, Hu et al., 2008, Knudsen and Knudsen, 2006, Lin et al., 2009). pRb is 
thus a key regulator of the cell cycle and also a suppressor of cancer. The 
relationship between RBBP6 and p53 has not thus far been explored in human 
cells. Furthermore, it should be noted that genes that interact with p53 are 
potentially good targets for cancer research and novel cancer therapy. 
 
2.6.2 p53 Family of tumour suppressors  
The apoptotic machinery in the cell is partly controlled by the p53 tumour 
suppressor, which is also involved in cell cycle control, in both the intrinsic and 
extrinsic apoptotic pathways (Baltaziak et al., 2009, Choi et al., 2010a, Kircelli et 
al., 2007). p53 was the first protein characterized in the p53 family of proteins that 
include p63 and p73 (Chatterjee et al., 2010, Sasaki et al., 2009). The other 
members of the p53 family have different splice variants and have mostly been 
shown to be involved in developmental and differentiation functions. Although, 
loss of function has also been indicated in the development of human cancers, for 
example bladder cancer and thus may also have a protective role against cancer 
(Guo et al., 2009, He et al., 2008, Urist et al., 2002).  
 
2.6.2.1 p53 as a tumour suppressor 
Mutations to, or the silencing of the p53 gene is evident in more than half of 
human cancers, studied to date (Castedo et al., 2005, Ling et al., 2010a, Petitjean 
et al., 2007, Yamada et al., 2007). If p53 is silenced or mutated, cancerous cells 
either tend to evade cell cycle control, or fail to activate p53-dependent cell cycle 
arrest or apoptosis, resulting in the accumulation of cancer-causing mutations that 
can contribute ultimately towards tumour formation (Ling et al., 2010a). p53 is an 
important cellular tumour suppressor and responds mainly to different forms of 
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cellular stresses; for example, cellular stresses that include DNA damage and 
hypoxia, where p53 targets and activates genes involved in growth arrest in G0 or 
G2/M phase, cell cycle progression and cell death (Cheng et al., 2008, Choi et al., 
2010a, Hahm and Singh, 2007). p53 suppresses tumour growth by modulating 
apoptosis and the cell cycle through the regulation of expression levels of its 
transcription targets (Ko et al., 2005, Ko et al., 2004, Lee et al., 2008, Sinha et al., 
2010). p53 induces the expression of pro-apoptotic proteins of the bcl-2 family, 
resulting in the induction of apoptosis in cells that cannot be repaired (Achanta et 
al., 2001, Ismail et al., 2007, Ouyang et al., 2009, Woo et al., 2002, Yoda et al., 
2008).  
 
The p53 responses to damaged DNA (for example) are carried out by the 
transcription of various p53 response genes, including p21 and Bax (Schmidt et 
al., 2008, Steinbach and Weller, 2004). It should be noted that there are many 
different cellular pathways that regulate the expression and stability of tumour 
suppressors including the ubiquitin-proteasome pathway, which plays a key role 
in the life span of both pRb and p53. p53 is a target of 26S proteasomal 
degradation through E3 ligase-mediated ubiquitination. It has been suggested that 
p53 may be either protected against ubiquitin-proteasome pathway (UPP) or 
regulated by RBBP6, since RBBP6 is a potential ubiquitin ligase (Pugh et al., 
2006). However, there is little evidence for this concept in the current literature. 
 
2.7 Ubiquitin-proteasome pathway (UPP)  
The ubiquitin-proteasome pathway is crucial in controlling the levels of different 
proteins in order to maintain normal cell function (Girao and Pereira, 2007, Huang 
et al., 2009, Kaur et al., 2005). De-regulation of this system may result in 
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degradation of key proteins that maintain cell homeostasis. Imbalances of certain 
proteins due to the disruption of the UPP has been reported in some cancers, for 
example, in brain tumours and ovarian cancers (Berlingieri et al., 2006, Jiang et 
al., 2010b, Jiang et al., 2008, Okamoto et al., 2003), in Parkinson’s Disease 
(Bedford et al., 2008, Ghee et al., 2005, McNaught and Jenner, 2001) and in 
Alzheimer’s disease (AD) (Lopez Salon et al., 2000, Muñoz et al., 2008, Rosen et 
al., 2010). The E3 Ubiquitin ligases are fundamental elements of the UPP 
pathway and have been reported to play a role in tumourigenesis (Chitalia et al., 
2008, Jin et al., 2009, Neil et al., 2009). The E3 ubiquitin ligases are sometimes 
over-expressed in cancers leading to the degradation of tumour suppressor 
proteins (Bromberg et al., 2007, Yen et al., 2006, Zhu et al., 2007). The ubiquitin 
ligases target a wide range of substrates for degradation, including regulators of 
the cell cycle, apoptosis and transcription, proto-oncogenes, transcription factors 
and tumour suppressors (Di Marcotullio et al., 2007, Glickman and Ciechanover, 
2002, Munoz et al., 2007, Xu et al., 2007). 
 
2.7.1 6S Proteasome pathway: Ubiquitin ligases (ULs) 
The core element of the UPP is the multi-subunit protease complex, 26S 
proteasome (Sato et al., 2009), which consists of a 20S core complex that is the 
catalytic region flanked by a 19S regulatory complex (Nickell et al., 2007). In 
order for the proteasome pathway to operate, enzymatic activities are necessary 
and E3 ubiquitin ligases are key elements in this process (Kim et al., 2007, 
Mastrandrea et al., 1999, Uchiki et al., 2009). The UPP (figure 2.3) has two steps 
involving firstly the conjugation of ubiquitin to the target protein, followed by the 
degradation of the target protein. The conjugation process makes use of the 
ubiquitin-activating enzyme (E1) which requires ATP. The activated ubiquitin is  
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Figure 2.8 - UPP pathway: A complete UPP process requires the action of an enzymatic 
cascade of ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (E2) and a 
ubiquitin ligase (E3). Free ubiquitin is recruited to E1 by thioester bond formation in a 
ATP-dependent manner. The activated ubiquitin is then transferred to E2 by the 
formation of a second thioester bond. E2 in conjunction with E3 transfers ubiquitin to a 
target protein. Several cycles of ubiquitinations lead to the target protein being recognized 
by 26S proteasome for subsequent degradation with ubiquitin molecules being recycled. 
Adapted from (Berke and Paulson, 2003, Glickman and Ciechanover, 2002). 
 
then carried to ubiquitin ligase (E3) by a carrier protein (E2) that transfers the 
ubiquitin to the E3, which is then bound to the target protein. Several cycles of 
conjugation and ubiquitin transfer result in poly-ubiquitination. The poly-
ubiquitin target protein is then recognized by 26S proteasome and the degradation 
process commences with ubiquitin being recycled (Ivantsiv et al., 2006, Leong et 
al., 2007, Ryu et al., 2008, Song et al., 2010). Many different cellular protein 
concentrations are regulated by this mechanism. Aberrations in the regulation of 
the UPP normally results in the pathogenesis of diseases like cancer (Choi et al., 
2010b, Heriberto et al., 2010, Nikseresht et al., 2010, Zhao et al., 2010).  
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The most important and well documented UPP enzymes to date are the ubiquitin 
ligases that have been shown to influence cell fate by targeting key proteins for 
degradation. Ubiquitin ligases possess a RING finger domain that is essential for 
their function. This RING domain is necessary for the interaction between E2s 
and E3s (Kim et al., 2007, Uchiki et al., 2009, Van Wijk et al., 2009). 
Significantly, it has been reported that mutations in this domain abolish this 
interaction (Balastik et al., 2008, Das et al., 2009, Han et al., 2008, Makishima et 
al., 2009, Martinez-Noel et al., 2001).  
 
Functionally, ubiquitin ligases can be divided into two major classes. These are 
homologous to the E6-AP C-terminus (HECT) family of ubiquitin ligases 
including the HECT-containing proteins; and the RING finger-containing 
proteins; the most well-known and frequently associated with diseases. The RING 
finger domains found in these ubiquitin ligases are classified into C3H2C3; 
C3HC4 and least abundant C2H2C4 (Beitel et al., 2002, Furukawa et al., 2002, 
Furukawa and Xiong, 2005, Kostic et al., 2006, Stone et al., 2005, Wawrzynow et 
al., 2009). 
 
2.7.2 The role of ubiquitin ligases in the regulation of apoptosis  
Ubiquitin ligases can regulate apoptosis either negatively or positively. Their 
negative effect in terms of cancer, is exerted by targeting tumour suppressors and 
cell cycle regulators for degradation, leading to the down-regulation of apoptosis 
and cell cycle checks (Abe et al., 2008, Privette et al., 2008). The degradation of 
tumour suppressors (p53 and pRb) by ubiquitin promotes cell survival and cell 
growth which can lead to tumourigenesis (Min et al., 2010, Min et al., 2009, 
Zhang et al., 2005b). Their positive effect is exerted by targeting proliferation 
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signal proteins for degradation thus leading to down-regulated proliferation 
(Makki et al., 2008). Most ubiquitin ligases exert their effect via their RING 
finger domain. The number of documented ubiquitin ligases is growing and a new 
family of ULs has been described and includes Caspase-8/-10 associated RING 
domain proteins (CARP) (Yang and El-Deiry, 2007). These proteins are also 
associated with apoptosis inhibition. Table 2.2 shows some of the known 
inhibitors of apoptosis that depend on their RING finger domains for their 
ubiquitin ligase activities. 
 
Table 2.3: A list of apoptosis Inhibitors that depend on the RING finger 
domain. 
Apoptosis Inhibitor Presence/Absence of a 
RING finger domain 
Number of 
RING fingers 
Survivin No - 
XIAP Yes 1 
cIAP1 Yes 1 
cIAP2 Yes 1 
NIAP No - 
ML-IAP Yes 1 
Bruce No - 
ILP2 Yes 1 
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Mdm2, an E3 Ubiquitin ligase, provides a good example of ubiquitin ligase 
involvement in cancer progression. Figure 2.4 demonstrates how the PI3K/Akt 
pathway stabilizes Mdm2 and destabilizes p53 and thus apoptosis. Degradation of 
tumour suppressor proteins mediated by E3 ligases such as Mdm2, always inhibit 
apoptosis and promote cell survival leading for example, to hypertrophy in 
cardiomyocytes (Foo et al., 2007, Toth et al., 2006). In one study, Mdm2 
demonstrated protection against cell death of ischemic or endogenous 
cardiomyocytes, suggesting that this E3 ubiquitin ligase may be involved in 
cancer development and cancer progression (Abe et al., 2008, Li et al., 2007b, 
Toth et al., 2006, Zhang and Zhang, 2008). Mdm2 is protected from degradation 
by the 26S proteasome pathway through the phosphatidylinositide 3’-hydroxyl 
kinase/protein kinase B (PKB) Akt pathway (Feng et al., 2004, Gama et al., 2009, 
Shankar et al., 2008) through mdm2 phosphorylation at serine 166 and 188. These 
phosphorylations protect Mdm2 from self-ubiquitination which results in 
increased accumulation of Mdm2 and consequently results in an increased p53 
degradation and reduced apoptosis (Feng et al., 2004). Recently, however, it has 
been shown that Mdm2 poly-ubiquitination of p53 is inhibited by ATM (Cheng 
and Chen, 2010, Cheng et al., 2009). Evidence suggests that Mdm2 also promotes 
cell cycle progression, whereby Mdm2 antagonists are able to restore normal cell 
cycle regulation (Ambrosini et al., 2007, Carvajal et al., 2005, Van Maerken et al., 
2009). This suggests that mdm2 promotes cancer progression by not only 
targeting tumour suppressors for degradation and subsequently inhibiting 
apoptosis, but also by promoting cell proliferation which results in carcinogenesis. 
Although Mdm2 is one example, there are many other emerging E3 Ubiquitin 
ligases that regulate tumour suppressors, targeting mainly p53 and pRb. 
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Figure 2.9 – A network of the Akt, Mdm2 and p53: This figure shows the survival pathway mediated by phosphatidylinostol 3-kinase (PI3K). PI3K 
phosphorylates Akt, a process inhibited by PTEN; Akt phosphorylates mdm2, which prevents its self-ubiquitination. The stabilized mdm2 promotes p53 
ubiquitination and subsequent degradation that result in the abolition of p53-dependent cell cycle responses and apoptosis. PTEN inhibition of PI3K resulting in 
mdm2 self-ubiquitination, which restores p53-dependent responses. Adapted from Mayo and Donner, 2002. 
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These include MdmX (Mancini et al., 2009), which binds pRb and protects it from 
ubiquitination and its subsequent degradation through the 26S proteasome 
pathway (Uchida et al., 2006). MdmX is a positive co-factor for p53 degradation 
and inhibits p53 transcriptional activities (Mancini et al., 2009, Okamoto et al., 
2009, Uchida et al., 2006, Zhang et al., 2009b). Another E3 ubiquitin ligase 
involved in p53 and pRb regulation through degradation is gankyrin. Although its 
role in p53 and pRb degradation and consequent tumourigenesis (Qiu et al., 2008) 
is poorly understood, it is however especially prominent in hepatocyte 
proliferation (Iwai et al., 2003, Shan et al., 2006).  
 
Mdm2 has a similar domain composition to RBBP6, where they both have RING 
finger domains and pRb and p53 binding domains. The question that arises is 
whether RBBP6 also regulates cell cycle and apoptosis through p53 and pRb. 
 
2.8 Apoptosis and its pathways 
As apoptosis research is a very broad field, this section will focus on apoptosis 
and the role it plays in cancer development and progression. Apoptosis pathways 
and their involvement in cancer manifestation and prevention will also be 
discussed.  
 
2.8.1. Apoptosis  
Apoptosis is widely defined as programmed cell death, which is a regulatory 
mechanism for the deletion of unwanted, aged, damaged or dysfunctional cells 
(Doonan and Cotter, 2008, Fadeel and Orrenius, 2005, Kerr, 2002, Kerr et al., 
1972). In the past this mechanism was seen as simply cell shrinkage. In the 1970’s 
it was defined as a series of predetermined events resulting in what is now defined 
PhD - Z Mbita Chapter Two: Literature review 
 
35 
 
as apoptosis. In some diseases, a high or elevated level of apoptosis may result in 
the development of harmful effects, while in other cases low levels of this process 
may also be detrimental (Bohsali et al., 2010, Dupont-Versteegden, 2005). 
Various cell homeostasis mechanisms for example, may detect certain cells to be 
threatening to the body and employ apoptosis for the destruction of those cells. An 
imbalance between cell proliferation and cell death may also give rise to cancer 
(Koster et al., 2010, Mazan-Mamczarz et al., 2008, Oh et al., 2010, Subauste et 
al., 2009), this being the focus of this section. 
 
A hallmark of cancer cells is their resistance to apoptosis (Fulda, 2009, Peter et 
al., 1997). Other important features seen in cancer include chromosome 
abnormalities for example, deletions and/or other alterations (Carén et al., 2008, 
Debernardi et al., 2004, Weigel et al., 1998). Apoptosis usually plays a very 
important role in the prevention of cancer progression by targeting these damaged 
pro-cancerous cells. The manipulation of apoptotic cell death pathways is a 
prospective therapeutic strategy to treat cancer. Possible ways of achieving this 
include relieving apoptosis inhibition by apoptosis inhibitors (Arora et al., 2007, 
Crnkovic-Mertens et al., 2010, Crnkovic-Mertens et al., 2007, Tomicic et al., 
2010). Examples of some compounds that are used to activate apoptotic pathways 
include Camptothecin (Frese et al., 2009, Hsu et al., 2009, Jimenez-Lara et al., 
2010, Wang et al., 2009a), staurosporine (Gregory-Bass et al., 2008, Wang et al., 
2009e) and arsenic trioxide (Ge-ping et al., 2009, Kang and Lee, 2008, Li et al., 
2009a). These compounds are able to induce either the receptor-mediated 
apoptotic pathway or the mitochondrial-mediated pathway (Antonsson and 
Persson, 2009, Du et al., 2009, Lunghi et al., 2008, Nakamura-López et al., 2009, 
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Uo et al., 2009, Wang et al., 2009d). The discovery of new genes that are involved 
in the apoptotic pathways induced by these compounds can almost certainly 
improve therapeutic strategies. 
 
2.8.1.1 The receptor-mediated pathway 
Signalling of apoptosis by many members of the death receptor subfamily appears 
to follow common basic rules that are initiated in a sequential manner (Amrán et 
al., 2007, Cai et al., 2010a, Muppidi et al., 2006) as figure 2.5 demonstrates. 
Ligand binding initiates the cascades, often followed by receptor trimerization and 
subsequent formation of the death inducing signalling complex (DISC). When 
DISC is formed it attracts and is joined by the adaptor molecule, FADD (Fas-
associated death domain). The DISC-FADD complex then associates with 
procaspase-8, with the resultant autocatalytic cleavage of pro-caspase-8 to form an 
active caspase-8. The active caspase-8 then activates downstream executioner 
caspases that cleave cellular death substrates, resulting in morphological and 
biochemical changes that are often observed in apoptotic cells (Liu et al., 2005, 
Nohara et al., 2007, Sohn et al., 2005), including cell blebbing, cell shrinkage, 
chromatin condensation, DNA fragmentation and formation of apoptotic bodies. 
These changes constitute the morphological hallmarks of apoptosis (Chaube et al., 
2005, Giri et al., 2006, Reich III and Pisetsky, 2009). 
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Figure 2.10 - Death receptor-mediated apoptotic pathway: This figure shows the death receptor-mediated apoptotic pathway initiated by the binding of different 
death ligands to their respective death receptors. Upon ligand binding to the death receptor, an interaction between the death domain of the receptor and that of the 
adaptor protein, that is, Daxx, Fadd, Tradd, Dap3, etc; is formed. This results in information being passed through to the intracellular mechanisms such as caspase 
activation, leading to apoptosis or signal regulating kinase pathways and that leads to apoptosis inhibition, for example, the NF-κB apoptotic inhibition signalling 
pathway. Adapted from (Ashkenazi and Dixit, 1998, Ashkenazi and Herbst, 2008). 
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The death receptors initiate apoptosis by linking, through their cytosolic death 
domains (DD) to adaptor proteins such as FADD, which in turn bind through their 
death effector domain (DEDs) to initiator caspases (-8 and -10) that contain DEDs 
in their N-terminal pro-domains. Death domains seem to be the key for the death 
receptors to direct cells to the apoptotic pathway. Downstream effector caspases 
such as caspase-3, -6, and –7 are then activated through their cleavage by 
activated initiator caspases (Kumar et al., 2008, Kuribayashi et al., 2006). These 
downstream effector caspases next cleave and activate enzymes that cause 
morphological and molecular changes observed in apoptotic cells (Kawai et al., 
2007). These proteins (which include ICAD and acinus) have been shown to be 
associated with both biochemical and morphological changes that characterize 
apoptosis (Joselin et al., 2006, Kovacsovics et al., 2002, Wu et al., 2004). 
However in some instances they may interact with molecules that have non-
apoptotic functions (Chen et al., 2009b). This property is demonstrated by the 
receptor interacting protein (RIP) [which also has the death domain] that 
stimulates the pathways that lead to activation of NF-κB and an inhibition of 
apoptosis (Krieg et al., 2009, Palacios et al., 2010, Thakar et al., 2006, Wang et 
al., 2007). 
 
2.8.1.2 Mitochondrion-mediated apoptotic pathway 
The death receptor-mediated apoptotic pathway is not the sole means of cellular 
apoptosis, there is also the mitochondrial or intrinsic pathway. The mitochondrion 
harbours a family of pro-apoptotic proteins that play a very significant role in the 
demise of the cell. These pro-apoptotic proteins include cytochrome c, Smac 
(Second mitochondria-derived activator of caspases) and AIF (Apoptosis-
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inducing factor) (Brustovetsky et al., 2005, Engel et al., 2010, Li et al., 2010a). 
AIF is believed to play a pivotal role in caspase-independent apoptosis (Lo et al., 
2010, Mahmud et al., 2009, Zhang et al., 2009c). Although the intrinsic pathway 
also makes use of apoptotic executioner caspases, it is triggered primarily by the 
release of cytochrome c, which in turn is dependent on the Bcl-2 family of pro-
apoptotic proteins (Li et al., 2010b, Wu et al., 2010, Yun et al., 2009). This 
apoptotic pathway is predominant in cases of cellular stresses and in development 
and its first step is thought to be the translocation of the pro-apoptotic Bcl-2 
family members, such as Bax to the mitochondrion (Paschen et al., 2007, Salvesen 
and Duckett, 2002, Zhang et al., 2007). 
 
Mitochondrial DNA mutations are especially prevalent in human cancers and are 
associated with mitochondrial dysfunction (Jakupciak et al., 2008, Tseng et al., 
2006, Wallace, 2005). Mitochondrial dysfunctions may be linked to deregulation 
of apoptosis in cancer cells, therefore targeting the mitochondrion for drug 
development is a step in a logical step towards the treatment of cancer. Indeed 
some studies have shown that some drugs can induce cytochrome c release from 
the mitochondria in cancer cells, so triggering the intrinsic apoptotic pathway 
(Kim et al., 2008, Yan et al., 2007). 
 
The release of cytochrome c and Smac, both pro-apoptotic molecules, is caused 
by the induction of the mitochondrial permeability transition, which is associated 
with the disruption of mitochondrial inner transmembrane potential (Δψm) and 
then the disruption of the outer membrane (Li et al., 2008, Pastorino et al., 1998, 
Tafani et al., 2002). This event is controlled by members of the Bcl-2 family of 
proteins and is central to initiating the intrinsic pathway where they control the 
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release of pro-apoptotic molecules in the mitochondria. There are several Bcl-2 
family members of pro-apoptotic proteins with their anti-apoptotic counterparts as 
shown in table 2.3. The pro-apoptotic family members are divided into two sets; 
the Bcl-2-homologue (BH) 123 multi-domain proteins, for example, Bax and the 
second set, proteins with the BH3-only domains, for example, Bid. The 
mitochondrial permeability transition pore (PTP) that results in the release of 
cytochrome c, is regulated by Bax expression (Birbes et al., 2005, Li et al., 2008, 
Pastorino et al., 1999) and conversely Bcl-2 inhibits the release of cytochrome c. 
Upon cytochrome c release, the apoptosome complex is formed by cytochrome c, 
caspase-9 and apaf-1 as shown in figure 2.6. It is the apoptosome that activates 
effector caspases (Liu et al., 2005).  
 
Table 2.4: Table of Bcl-2 family of pro- and anti-apoptotic proteins. 
Pro-apoptotic members Anti-apoptotic members 
Bax, Bak, Bnip3, Hrk and BH3 only 
(Bad, Noxa, Puma, Bid, Bim) 
Bcl-2, Bcl-XL, Mcl-1, A1, Bcl-W 
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Figure 2.11 - Schematic representation of the mitochondrial-mediated apoptotic pathway: Upon apoptotic stimulus, the mitochondrial permeability transition 
pore is formed, resulting in the release of the cytochrome c, Smac/Diablo and apoptosis inducing factor (AIF). AIF induces the caspase independent pathway while 
cytochrome c and Smac are involved in the caspase-dependent apoptosis pathway. The release of these pro-apoptotic molecules is controlled by the Bcl-2 family of 
pro-apoptotic members. When pro-apoptosis Bcl-2 proteins (Bax and Bad) are expressed in excess of Bcl-2 anti-apoptosis proteins (Bcl-2 and BclXL), mitochondrial 
pore formation occurs and cytochrome c is released. Receptor-mediated apoptosis can enhance this pathway through Bid cleavage by caspase-8, enhancing the 
cytochrome c release from the mitochondria. This process has been discussed in a review based on targeting apoptosis as a therapeutic strategy. Adapted from 
(Dlamini et al., 2005). 
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2.8.1.3 Caspase-independent apoptotic pathway 
Caspase-independent cell death through the mitochondrial pathway occurs when 
an apoptosis inducing factor (AIF) is released to the cytosol and the nucleus. AIF 
is the main mediator of caspase-independent apoptosis and this mitochondrial 
flavoprotein is associated with chromatin condensation and DNA fragmentation 
(Krantic et al., 2007). This apoptosis inducer is synthesized in the cytoplasm and 
remains in an inactive state until it is imported into the mitochondrial 
intermembrane space where it is activated. Activation of the AIF is achieved by 
the removal of an amino terminal mitochondrial targeting sequence, and the 
attachment of a flavin adenine dinucleotide group (Daugas et al., 2000). Upon 
apoptosis induction, AIF translocates from the mitochondria back to the cytosol 
and the nucleus causing chromatin condensation and DNA fragmentation, 
hallmarks of the caspase-independent apoptosis (Candé et al., 2002). AIF, 
therefore has the potential to be used as a therapeutic target (Lorenzo and Susin, 
2007). It has also been reported that AIF is involved in the induction of apoptosis 
in many diseases including cancer (Scharstuhl et al., 2009, Vittar et al., 2010), 
Alzheimer’s disease (Landshamer et al., 2008, Polser et al., 2005, Slemmer et al., 
2008) and HIV infections (Bellet et al., 2004).  
 
2.8.1.4 The potential of using apoptotic pathways for cancer therapy 
The cancer research community is showing an increasing interest in compounds 
or agents that induce apoptosis through both extrinsic and intrinsic pathways 
(Chen and Wong, 2008a). Regulation of apoptosis and its own pathway regulators 
are prominent in the fight against cancer. Understanding cell death pathways that 
result in apoptosis may contribute to the eradication of diseases, such as cancer 
where apoptosis is inhibited. There is a growing body of literature describing how 
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anticancer compounds eliminate tumour cells by inducing the death-receptor 
mediated pathway (Kang et al., 2006, Raja et al., 2008, Scholz et al., 2005). The 
mechanism of how this occurs is varied and may be due to the up-regulation of 
the death receptors themselves or of downstream components of this extrinsic 
pathway. Chemical or herbal compounds or natural products are known to be able 
to induce extrinsic apoptosis by modulating protein function (Lo et al., 2010, 
Wang et al., 2006b, Zaidman et al., 2007).  
 
Any drug that is able to induce any of the apoptotic pathways at an effective point 
either within the intrinsic or extrinsic pathway, can potentially be used to reverse 
most cancerous phenotypes (Fetz et al., 2009, Puca et al., 2008).  
 
There is crosstalk between these two main pathways, that is, the induction of one 
can lead to the activation of the other. This is exemplified by the induction of 
cytochrome c release through the activation of Bid, a pro-apoptotic Bcl-2 family 
protein. Bid is cleaved by caspase-8 bound to the adaptor protein, FADD, linked 
to the death receptor. The active Bid then translocates to the mitochondria where 
it causes the release of cytochrome c, which then leads to activation of intrinsic 
apoptotic cell death (Oh et al., 2004, Tang et al., 2000, Wu et al., 2005). These 
apoptotic pathways are often inactivated by apoptosis inhibitors. Targeting these 
apoptosis inhibitors for drug development could potentially be used to reactivate 
apoptosis in cancer cells (Ashkenazi and Herbst, 2008, Dlamini et al., 2005). 
 
2.8.1.5 Apoptosis: A prospect for cancer therapy 
From the few cancers that have been described above, there is a consistent pattern 
demonstrating the inhibition of apoptosis and deregulation of cell and tissue 
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homeostasis in carcinogenesis. There is a growing body of literature implicating 
apoptosis and different apoptosis-related genes and their products in cancer 
development. It is hoped that the elucidation of the apoptotic pathways in cancer 
progression and their inhibition in carcinogenesis may lead to a better 
understanding of the mechanics of cancer development. Currently, chemotherapy 
and radiation-mediated cancer therapy involve apoptosis induction in their mode 
of action against cancer development and progression and p53 is involved in the 
induction of apoptosis in both these treatments (Han et al., 2009, Holownia et al., 
2003). The present study investigated if RBBP6 therapy or DWNN could enhance 
p53 activity in apoptosis induction and cell cycle regulation. 
 
Any method targeting the reversal of apoptosis inhibition and tumour suppressor 
proteins inhibition should in principle be able to restore cell cycle control and 
apoptosis. Down regulation of anti-apoptotic genes have been targeted for 
apoptosis induction (Cheung et al., 2009, Naderi et al., 2010). All these reports 
demonstrate that cancer results as a consequence of inhibited apoptosis and 
improper cell cycle regulation. Most of the bcl-2 family members are 
transcriptionally regulated by p53. This tumour suppressor is down-regulated in 
breast cancer (Kuo et al., 2009). This work specifically investigates if the DWNN 
domain is de-regulated in apoptosis and cell cycle and do these de-regulations 
contribute to carcinogenesis? 
 
2.9 Apoptosis Inhibition 
Inhibition of apoptosis may be as a result of many factors that include tumour 
suppressor inactivation (Heminger et al., 2009, Lee et al., 2009c, Ling et al., 
2010b, Santer et al., 2007, Tsao et al., 2008), oncogene activation (Costa et al., 
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2010, Lowe et al., 2010, She et al., 2008), expression of inhibitors of apoptosis for 
example, survivin, NF-κB activation (Bian et al., 2002, Chow et al., 2010, Kang et 
al., 2009, Kim et al., 2010) and deregulation of kinase signalling pathways 
(Matallanas et al., 2007, Oka et al., 2008, Pang et al., 2010, Whittaker et al., 
2004). Some proteins are highly expressed in cancers and exert an inhibitory 
effect on apoptosis. Survivin, a member of the inhibitor of apoptosis protein (IAP) 
family, is an example of proteins that are involved in the inhibition of apoptosis 
and manifestation of cancer (Tamm, 1998, Zhou et al., 2010). Other IAPs, that is, 
cIAP 1 and 2 and XIAP also inhibit apoptosis by exerting their influence through 
inhibiting caspase activation (Cillessen et al., 2008, Deveraux et al., 1999, Iijima 
et al., 2009, Sun et al., 2009, Takahashi et al., 1998, Wang et al., 2004). There are 
also other mechanisms that cancerous cells employ to evade elimination through 
apoptosis and these include NF-κB and Akt survival pathways shown in figure 
2.7. Additionally, the action of IAPs can be reversed by inhibiting these proteins 
(Carter et al., 2005, Morioka et al., 2009, Wang et al., 2009b, Ziegler et al., 2008) 
 
PhD - Z Mbita Chapter Two: Literature Review 
 
46 
 
 
Figure 2.12 - Apoptosis inhibition pathways: NF-κB is generally retained in the cytoplasm with IκBs. Signals for example from Akt activity and TNFs, NF-κB are 
activated with concomitant phosphorylation of IκB and its subsequent degradation through the proteasome pathway. The TNF/TNFR1 complex recruits RIP which 
attracts TRAF2. This then recruits NF-κB-Inducible Kinase (NIK) that activates the IκB Kinase complex (IKK). IKK complex phosphorylates IκB exposing NF-κB’s 
NLS after its degradation leading to NF-κB translocation to the nucleus where it activates its anti-apoptotic genes resulting in apoptosis inhibition. (B) Upon growth 
factors binding to their receptor tyrosine kinases (RTK) or G protein-coupled receptor (GPCR), initiating the phosphorylation of phosphatidylinositol 3-kinase (PI3K). 
This action then causes the conversion of phosphatidylinositole-4,5 biphosphate [PI(4,5)P2] to phosphatidylinositole-3,4,5 tri phosphate [PI(3,4,5)P3]. This product with 
PDK1&2, [PI (3, 4, 5) P3] phosphorylates Akt thereby activating it. An activated Akt is translocated to the cytoplasm and nucleus and phosphorylate a number of anti-
apoptotic proteins, thus inactivating them i.e. Bad, Bax, FasL and Bim. This action is reversed by PTEN, which dephosphorylates [PI (3, 4, 5) P3] to [PI (4, 5) P2] thereby 
inhibiting the activation of Akt and thus prevents the inhibition of apoptosis. Adapted from (Wullaert et al., 2006). 
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Chapter Three: Materials and methods 
 
3.1 Introduction 
Recipes for the solutions required for the methods are given in Appendix A1 and 
chemicals and their suppliers are given in Appendix A2. A list of the equipment 
used is given in Appendix A3. Several other method appendices are associated 
with this chapter. 
 
3.2 Materials 
3.2.1 Ethics Approval 
Human Ethics approval was granted for use of the human tissues and arrays, 
Number R14/49 Mbita (Appendix B). 
 
3.2.2 Sample Materials 
The following cell lines: Hek 293T cell line (human embryonic kidney, 
transformed cells); HeLa cell line (cervical carcinoma); HepG2 (hepatocellular 
carcinoma) and MCF-7 (Breast cancer) were used in this study; for RNA 
extraction, RNA interference, over-expression experiments and to localize the 
DWNN/RBBP6 proteins. All the cell lines were originally sourced from ATCC 
and donated by Prof Rees’ laboratory from the University of the Western Cape. 
 
3.2.3 Primers 
In this section, primers used in the analysis of the RBBP6 will be described so that 
in subsequent sections each primer set is just referred by its short name without 
describing what the primer should amplify. Appendix C (primer sets 1-7) 
summarizes the primer sequences and their product sizes in base pairs (bp). The 
primers were either designed manually or using the online Primer3plus software 
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(www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and synthesized at 
Inqaba Biotech., South Africa.  
 
3.2.3.1 RBBP6 Iso3 forward and reverse primers  
This set of primers (Appendix C, primer set 1) was designed to amplify a 
fragment of the translated region from the DWNN domain of the isoform 3 of the 
RBBP6. The fragment that these primers amplify is found in all three isoforms; 
therefore this primer set was used to amplify all the RBBP6 fragments from the 
three transcripts of this gene; for amplifying the fragment used for making probes 
for in situ hybridization; and for real-time quantitative PCR, to monitor the 
expression of all three RBBP6 transcripts. This set of primers was designed using 
the online Primer3Plus software and synthesized at Inqaba Biotech., South Africa. 
 
3.2.3.2 Iso2&1 Real-Time PCR forward and reverse primers 
These primers (Appendix C, primer set 2) specifically amplify fragments in both 
variants 1 and 2 of the RBBP6 gene but not variant 3. They were used to 
differentiate RBBP6 variants 1 and 2 expressions from variant 3 expression. This 
primer set was designed using Primer3 software and synthesized at Inqaba 
Biotech., South Africa. 
 
3.2.3.3 RING finger reverse and forward primers 
This primer set (Appendix C, primer set 3) was used to amplify the RING finger 
domain of the RBBP6 for cloning into pGEM T-Easy vector (see section 3.2.5, 
Appendix C, vector map 1) for sequencing and subsequently for mutational 
analysis. This primer set was designed manually and synthesized at Inqaba 
Biotech., South Africa. 
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3.2.3.4 Rb-binding domain forward and reverse primers  
This primer set (Appendix C, primer set 4) was used to amplify the RbBD of the 
RBBP6 for cloning into pGEM T-Easy vector (see section 3.2.5, Appendix C, 
vector map 1) for sequencing and subsequently for mutational analysis. This 
primer set designed manually was synthesized at Inqaba Biotech., South Africa. 
 
3.2.3.5 p53-binding domain forward and reverse primers 
This set of primer (Appendix C, primer set 5) was used to amplify the p53BD of 
the RBBP6 for cloning into pGEM T-Easy vector (see section 3.2.5, Appendix C, 
vector map 1) for sequencing and subsequently for mutational analysis. This 
primer set was also designed manually and synthesized at Inqaba Biotech., South 
Africa. 
 
3.2.3.6 RNAi colony PCR forward and reverse primers  
These primers were used for screening of the RNAi clones. They were donated by 
Prof. Rees (Biotechnology Department, University of the Western Cape). The 
Primer sequences are given in Appendix C, primer set 6. This primer set was also 
manually designed in Prof. Rees’ Laboratory and synthesized at Inqaba Biotech., 
South Africa. 
 
3.2.3.7 RNAi Oligos 
RNAi targets were generated by using the sequences for all 3 RBBP6 variants in 
the RNAi design engine: 
(http://www.ambion.com/techlib/misc/siRNA_finder.html). Appendix D (table 1) 
shows the single stranded RNAi oligos (forward and reverse) generated against 
the RBBP6 transcripts. The RNAi oligos were synthesized in such a manner that 
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when annealed (Appendix D, table 2) they could be cloned between the Bgl II site 
(Forward oligo) and the Hind III site (Reverse oligo) of the pEGFP-C1-U6 vector 
(Appendix D, vector map 2 from Pretorius, 2007). 
 
3.2.4 Antibodies 
GST-RBBP6 fusion proteins were used to generate antibodies of different 
domains of RBBP6 in rabbits according to Bellstedt’s method (Bellstedt et al., 
1987). Antibodies were raised against the DWNN domain as illustrated in figure 
2.2 in Chapter Two. They were donated by Prof. Rees, Department of 
Biotechnology, and University of the Western Cape (UWC). This antibody had 
not been characterised previously so this study also focused on characterizing the 
specificity of the GST-DWNN antibody in both cell culture-derived protein 
lysates and the recombinant DWNN protein using Western blotting analysis on 
both one-dimensional (1D) and two-dimensional (2D) acrylamide gel 
electrophoresis. The anti-human-DWNN antibody was also used for localisation 
of the DWNN both in situ and in in vitro situations. The purified anti-human 
DWNN antibody was used for both immunohistochemistry; cell staining and 
Western blotting. Anti-human DWNN antibody detects all of the RBBP6 
isoforms. 
 
3.2.5 Cloning Vectors 
Different vectors were used in this study; pGEM T-Easy (Appendix C, vector map 
1) and pGEX 6P-2 (Appendix E, vector map 3) were used for cloning and 
expression of RBBP6 fragments respectively. The pEGFP-C1-U6 vector 
(Appendix D, vector map 2) was used for RNA interference work and was a gift 
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from Professor Rees. The pGFP-DWNN-13 (Appendix E, vector map 4) and 
pDsRed1-C1-DWNN-200 (Appendix E, vector map 5) were used to over-express 
the DWNN domain and RBBP6 isoform 2 respectively in the human cell lines. 
 
3.3 Methods 
3.3.1 Cell culture 
3.3.1.1 Preparation of complete cell culture medium 
The complete (Dulbecco’s Modified Eagle’s Medium) DMEM, Hams F-12 and 
RPMI 1640, 10% foetal calf serum (FCS), 1% Penicillin-Streptomycin and in 
RPMI 2 mM Glutamine was added. The media were then stored at 4ºC and pre-
warmed to 37ºC before being added to the cell cultures. All the cell culture media 
and Dulbecco’s buffered saline were purchased from Lonza Rockland Inc., USA. 
 
3.3.1.2 Cell culture 
The cells (section 3.2.2) were grown up to 60–70% confluence as a monolayer in 
Dulbecco's medium or RPMI 1640 (Jurkat cells) and Ham’s F-12 (CHO cells) 
supplemented with 10% foetal calf serum and 1% Penicillin and streptomycin in 
an atmosphere of 5% CO2. The cells were cultured in 25 cm
3
 flasks (Greiner Bio-
One, Germany). 
 
3.3.1.3 Trypsinization 
Confluent 25 cm
3
 flasks of cells were washed with 1X 0.1M phosphate buffered 
saline (PBS) pH 7.3 and trypsinized with 0.125% trypsin in PBS (Lonza Rockland 
Inc., USA). FCS-containing medium was added to deactivate the trypsin followed 
by centrifugation at 3000 rpm in a Sorvall TC6 centrifuge (American Instrument 
Exchange, Inc., USA) for four min. The supernatant was discarded and the cells 
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were resuspended in the desired media. These cells were either re-plated or frozen 
in complete medium containing 10% DMSO. 
 
3.3.2 RNA extraction 
Total RNA was isolated from cultured cells using a High Pure RNA isolation Kit 
[11828 665001] (Roche Biochemicals, Germany). The manufacturer’s 
instructions were followed. Briefly, cultured cells were detached by scrapping the 
cells off the cell culture flasks using a cell scrapper (Greiner Bio-one, Germany). 
The cells were pelleted and resuspended in 1X PBS. Resuspended cells were then 
lysed in lysis-Binding Buffer (Roche Biochemicals, Germany) by vortexing for 15 
seconds. A High Pure Filter tube + collection tube was assembled as described by 
the manufacturer. The entire sample was then transferred into the High Pure Filter 
tube-assembly and incubated for one min and then centrifuged for 15 seconds at 
6720 x g at room temperature. The flow-through liquid was discarded and the 
High Pure Tube + collection tube were re-assembled. Wash buffer I (Roche 
Biochemicals, Germany) was added and centrifuged for 15 seconds at 6720 x g. 
The flow-through was then discarded and the High Pure Tube + collection tube 
was re-assembled and the washing was repeated with Wash Buffer II (Roche 
Biochemicals, Germany). A third wash was done with Wash Buffer II (Roche 
Biochemicals, Germany) followed by centrifugation at 11700 x g for two min. 
The collection tube was discarded and the High Pure Filter Tube was transferred 
into a sterile 1.5 ml micro centrifuge tube. RNA Elution Buffer (Roche 
Biochemicals, Germany) was added to this assembly to elute the total RNA and 
incubated for one min. The elution was carried out by centrifugation at 6720 x g 
for one min. The total RNA was then electrophoresed to assess the integrity and 
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the quality of RNA. The RNA was stored at -80ºC in aliquots of 10 µl for future 
use. 
 
3.3.2.1 RNA Gel electrophoresis 
3.3.2.2 Preparation of RNA agarose 1% gel 
A 1% agarose solution was prepared in 1X MOPs (prepared in DEPC water), 
0.6% (37% (v/v) formaldehyde), 0.3 µg/ml ethidium bromide (EtBr) (Promega, 
USA). The RNA sample (1µg) was mixed with an equal volume freshly prepared 
formaldehyde gel loading buffer. The mixture was heated at 65ºC for five 
minutes, cooled on ice and then loaded onto a 1X MOPS equilibrated gel. The 
RNA was electrophoresed at 100 volts for one hour in 1X MOPS. 
 
3.3.2.3 Quantification 
Quantification of both RNA and cDNA was done using a Nanodrop 
spectrophotometer (NanoDrop technologies, USA). Readings were taken at 260 
nm and 280 nm as described by the manufacturer. A 260/280 ratio of 1.8 or more 
was regarded as pure quality. 
 
3.3.3 Reverse transcription (RT) 
Reverse transcription was performed using the ImProm-II-Reverse Transcription 
System (A3802) (Promega, USA). The manufacturer’s instructions were 
followed. First, 1 g of total RNA sample was mixed with either 0.5 µg/reaction 
oligo (dT)15 or random primers and incubated at 70ºC for five min in order to 
denature any secondary structures and to allow the primers to anneal. This was 
followed by chilling the template preparation on ice for five minutes. This 
preparation (Appendix F, table 3) was then mixed with the rest of the components 
PhD - Z Mbita Chapter Three: Materials and methods 
 
54 
 
of the cDNA synthesis reaction (Appendix F, table 4). The samples were mixed 
and briefly centrifuged. Following this; the samples were incubated at 25ºC for 
five minutes to allow the primers to anneal at their sites. This was followed by the 
incubation of the samples at 42ºC for an hour to allow reverse transcription to 
occur. After this incubation the reverse transcriptase was inactivated by 
incubation at 70ºC for five minutes and the samples were cooled on ice. The 
samples were either used immediately for Polymerase Chain Reaction (PCR) or 
Real-time PCR or stored at -20ºC for later use. 
 
3.3.4 Polymerase Chain Reaction (PCR) 
The cDNA obtained through reverse transcription was used as a DNA template 
using sequence specific primers for different fragments of the RbBBP6 gene. The 
PCR was performed using a master mix from Promega (USA) [50 units/ml of Taq 
DNA polymerase in a PCR reaction buffer; 400 µM dATP; 400 µM dGTP; 400 
µM dCTP; 400 µM dTTP and 3mM MgCl2]; 1 pg-0.5 µg template DNA and 
nuclease-free water to make up to a required reaction volume. The reactions were 
then subjected to 30 cycles consisting of the three PCR steps (denaturation, 
annealing and extension), after the initial denaturation step and followed by a final 
extension step. The steps were as follows with some variation in annealing 
temperature and extension time depending on the nucleotide sequence of the gene 
of interest: 
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95ºC for 3 min 
94ºC for 30 min 
 Tm-5 for 0.5-1 min 
72ºC for 1 min 
72ºC for 10 min 
Note: The actual temperature used was the calculated temperature (Tm) minus 
5ºC. 
 
The products were either stored at 4ºC for further use or electrophoresed on 0.8-
2% agarose gels. 
 
3.3.5 Agarose gel electrophoresis of DNA 
The DNA samples were electrophoresed on 1% agarose gel containing 0.3µg/ml 
Ethidium bromide and then visualized using UV light. A 100 bp DNA molecular 
weight marker (Fermentas, USA) was used. Gels were then subjected to 70 Volts 
for one hr in 1X TBE buffer.  
 
3.3.6 Cloning of PCR products into pGEM-T-Easy vector  
3.3.6.1 DNA Ligation  
A ligaFast cloning system (Promega, USA) was used to clone PCR products in 
pGEM-T-Easy vector for both sequencing and probe synthesis. For the 
experimental ligation, ~ 3 ng PCR product was added to 2X Ligation buffer 
(60mM Tris pH7.8; 20mM MgCl2; 20mM DTT; 2mM ATP) to 1X final 
concentration; 10 ng of pGEM-T-Easy vector; 3 units of T4 DNA ligase and 
sterile distilled water. A background control (no insert/fragment DNA of interest) 
25-30 cycles 
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was also run as well as a positive control supplied with the kit. The components 
were mixed and quickly centrifuged to collect all the components to the bottom of 
the tube. These ligations were incubated at room temperature for one hr, then 
transformed into an MC1061 (F
-araD139 Δ (araA-leu) 7696 ΔlacX74 galK16 
galE15 (GalS) λ- e14- mcrA0 relA1 rpsL150 (strR) spoT1 mcrB1 hsdR2) 
Escherichia coli (E. coli) cloning strain. 
Note: Negative control was a transformation with no plasmid DNA transformed. 
Positive control (Promega Corp., USA) consisted of a DNA fragment that had 
been optimised to ligate to pGEM-T-Easy vector. The background control was a 
pGEM-T Easy vector with no insert (used to check if the vector would ligate to 
itself). 
 
3.3.6.2 Preparation of competent cells (Super competent protocol) 
Sixteen hours before preparing the competent cells, a desired strain (for example, 
an MC1061 strain of E.coli (for cloning) or a BL21 (DE) pLysS strain of E.coli) 
was streaked out on a nutrient agar plate containing 10 mM MgCl2. All glassware 
used in the preparation of competent cells was washed with concentrated HCl, 
rinsed with dH2O and autoclaved. A single fresh colony of the desired strain of 
E.coli was grown for two hrs in 20 ml TYM broth in a 200-500 ml flask shaken at 
300 rpm, at 37C up to an OD550= 0.2; then diluted five times with fresh TYM 
broth in a 2 litre flask. This was shaken for a further two to three hrs until the 
OD550= 0.2; then further diluted four times with a fresh TYM broth in a 2 litre 
flask. This was then shaken for a further two to three hrs until the OD550=0.4-0.6. 
The cells were then rapidly cooled in ice water with swirling and collected by 
centrifugation at 1380 x g for 10 min in polypropylene tubes. The medium was 
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drained and discarded and the cells were resuspended in 125 ml Tfb 1. The cells 
were then incubated for 30 min and centrifuged for 10 min at 4C and gently 
resuspended in 50 ml Tfb 2, aliquoted in micro-centrifuge tubes and frozen on dry 
ice. The cells were then stored at -70C. 
 
3.3.6.3 Transformation 
Competent MC1061 E. coli cells were thawed on ice, then mixed with 1 ng of 
plasmid and incubated at 4ºC for 30 minutes. This mixture was immediately 
incubated at 37ºC for five minutes, and then incubated on ice for two min. Nine 
hundred millilitre Luria broth (LB) without ampicillin was added to the mixture. 
This was followed by incubation at 37ºC for one hour to allow all the cells to 
grow. After one hour, a tenth of each transformation mix was plated on pre-
warmed LB plates containing 100 µg/ml ampicillin. The plates were incubated at 
37ºC overnight. 
 
3.3.6.4 Screening for positive clones using colony Polymerase Chain 
Reaction 
Individual colonies were picked from LB agar plates and resuspended in sterile 
water. A fraction of this mixture was then used as a template for a PCR reaction 
(Appendix F, table 5). The PCR conditions were dependent on the fragment of 
interest and the primers in question but generally universal primers (M13 
universal primers) were used. Those colonies that showed the presence of the 
DNA fragment of the expected size were selected for the plasmid extraction 
procedure. The remainder of the colony mix was used as an inoculum for making 
an overnight culture for plasmid extraction. 
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3.3.6.5 Mini-preparation Plasmid DNA extraction 
In order to get high quality plasmid DNA for further experiments including, 
restriction digestion, sequencing and probe synthesis, plasmid DNA was extracted 
using the Wizard Plus SV Miniprep DNA Purification System (Promega, USA). 
Manufacturer’s instructions were followed (Appendix H, schedule 1).  
 
3.3.6.6 Restriction digestion of plasmid DNA 
Two restriction endonucleases (REN) were used for restriction analysis of the 
clones following the manufacturer’s instructions. Pst I and Apa I were used to 
linearize the clones and EcoR1 was used to release the insert. Five hundred 
nanograms of plasmid DNA of each clone was restriction digested with these 
three RENs. The restriction digests are tabulated in Appendix F-table 6. 
 
3.3.7 Sequencing analysis 
The sequencing was done by Inqaba Biotech (Pretoria, South Africa). The 
sequences were analyzed using Sequencher DEMO (www.genecodes.com) and 
BLAST basic alignment tool (www.ncbi.nlm.nih.gov). 
 
3.3.8 Real-time polymerase chain reaction (real-time PCR) 
3.3.8.1 Real-time efficiency by hHPRT and DWNN standard 
amplification 
DNA of known concentration was serially diluted by a dilution factor of 10 to 
1000. These dilutions were then used in the real-time PCR set up. Real-time 
efficiencies were obtained from the Roche Lightcycler 1.5 (Roche Diagnostics, 
Germany). 
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3.3.8.2. Real-time PCR quantification by standard curve analysis 
The house-keeping genes chosen were β-actin, GAPDH, 28S and hHPRT1 
(Toegel et al., 2007). 
 
There are 2 ways to quantify the real-time PCR results, either by using a standard 
curve, which is used as a reference for extrapolating quantitative information for 
target mRNAs of unknown quantities, or by the use of comparative cycle number 
cross point (Ct) method (Livak and Schmittgen, 2001). The later uses the 
comparison of the Ct values of the samples of interest with a control sample such 
as an untreated sample and the Ct values are then normalised to an appropriate 
house-keeping gene. Any of the two methods may be used and the results from 
both are comparable. 
 
3.3.8.3 Real-time quantification setup 
cDNAs from different responses were quantified using a Nanodrop 
spectrophotometer (NanoDrop Technologies, USA). Concentrations of 200-500 
ng of DNA were subjected to real-time reactions. The Sybr Green technology 
(Roche Applied Science, Germany) was used to quantify the results and the 
reactions were prepared as shown in Appendix F, table 7 in triplicates in three 
independent experiments. 
 
3.3.8.4 Real-time PCR thermal conditions 
The LightCycler FastStart DNA Master SYBR Green I (Roche, Germany) was 
used in this study. It was used for the amplification, detection and quantification 
of the DNA or cDNA target. Recommendations from the manufacturer for 
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thermal conditions (Appendix F, table 8) were followed with minor adjustment 
depending on the primer sets used. 
 
3.3.9 Immunohistochemistry (IHC) 
The anti-human-DWNN antibody that was used for this study was obtained from 
Prof. Reesʹ laboratory (Biotechnology Dept., University of the Western Cape). It 
was raised in rabbit against the recombinant GST-DWNN domain fusion and had 
not been characterized prior to this study. It was designed to localize to all three 
RBBP6 isoforms. In this study the antibody was first characterized prior to 
experimental use (Chapter 4).  
 
To avoid repetition, the IHC procedure given below was used throughout for all 
the tissue arrays analysed, unless otherwise stated. Tissue arrays (US Biomax Incl. 
and Cybrd Tissue Array Tech, USA) were used to localize the RBBP6 proteins in 
different cancers. The cancers, six cases each (Listed in Appendix G) studied 
included Breast cancer, cervical cancer, and hepatocellular carcinoma; these were 
the ones of major interest. Also studied were oesophageal cancer, colon, stomach, 
rectum, lung, kidney and uterine cervix. 
 
3.3.9.1 Colorimetric method 
Immunohistochemical localization was carried out with the antibody for human 
DWNN. Tissue arrays (Cybrdi-CC00-11-001 and Biomax.us-BC 001111) from 
both cancer and normal tissue spots were used. The staining was performed using 
strep-avidin-anti-peroxidase-peroxidase method using an LSAB+ Kit peroxidase 
(DAKO, Denmark). Briefly, the tissue arrays were dewaxed (Appendix H-
schedule 2) and antigen retrieval was performed using microwaving. The primary 
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antibody (0.2µg/µl) was applied and left overnight at 4˚C. The next day the 
sections were washed in Tris buffered saline (TBS) buffer and the secondary 
antibody incubation (ready-to-use, DAKO, Denmark) was carried out at room 
temperature for 15 min, the colour was developed with Diaminobenzidine-DAB 
(DAKO, Denmark) and counterstained with haematoxylin. The tissue arrays were 
examined for DWNN reactivity in the tumour islands, non-cancerous and tumour 
associated areas. (See appendix H, schedule 2 for a detailed description of the 
procedure) 
NOTE: Controls that were used were as follows: 
1) Negative control: omitted primary antibody was replaced by PBST/TBST 
containing 1% BSA and pre-absorbed recombinant DWNN antibody.  
2) The positive controls were a section from the normal testis tissue, which had 
been shown to express the DWNN (Mbita, 2004) and oesophageal carcinoma 
tissue, which was reported to express the murine P2P-R (Yoshitake et al., 2004). 
EST database analysis suggests that RBBP6 is highly expressed in this tissue and 
has been documented that this tissue has the highest expression of the PACT 
(Simons et al., 1997).  
3) The secondary antibody did not show non-specific staining when the primary 
antibody was omitted. 
 
3.3.9.2 Cell staining: Immunocytochemistry (ICC) 
The cells (HepG2, HeLa, MCF-7, and Hek 293T) were grown in Dulbecco’s 
Essential Minimal Medium while CHO cells were grown in Ham’s F-12 to a 
required confluence (80-90%) and then washed with 0.1M PBS, pH 7.4 at room 
temperature.  
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Briefly, cells were grown on cover slips in 6-well cell culture plates. After 24 hrs 
the cells were washed twice with PBS containing 0.5% BSA then fixed in 4% 
paraformaldehyde (PFA) in PBS at room temperature for 15 min. The cells were 
then washed three times with PBS before permeabilization in PBS containing 
0.1% Triton X-100 for 10 min. The cells were again washed twice in PBS and 
non-specific binding was blocked with PBS containing 0.5% BSA for one hr at 
room temperature. The cells were then incubated with the DWNN antibody 
(1:10000 dilution in PBS containing 0.5%BSA) for one hr; washed twice in PBS-
BSA and incubated (in the dark) at room temperature in the secondary antibody 
(Anti-rabbit IgG-AlexaRed) 1:1000 dilution for one hr. The cells were washed 
twice in 1X PBS and then mounted in vector shield mounting medium (Vector 
Laboratories Incl., USA), containing DAPI (a nuclear counterstain). The mounted 
cells were examined under the fluorescence microscope (Axioplan 2 imaging, 
Zeiss, Germany) using the excitation at 590 nm and emission at 617 nm or using a 
light filter. 
 
The characterization of the DWNN antibody was carried out by using Western 
blotting techniques described in section 3.3.12 using both the 1D and 2D 
electrophoresis methods. 
 
3.3.10 In situ hybridization (ISH)  
Tissue arrays (Appendix G) were used for the in situ hybridization (ISH). The 
Digoxigenin (DIG) labelling system from ROCHE, Germany, was used for 
labelling RNA probes for both ISH and Fluorescent in situ hybridization (FISH). 
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3.3.10.1 DWNN Probe preparation 
Different DWNN fragments were amplified and cloned into pGEM-T Easy 
vector. The clone for probe synthesis was then sequenced and linearized with 
appropriate enzymes to generate antisense and sense RNA probes as shown in 
Appendix F, table 9. The enzymes used to linearize the DWNN clones were Pst I 
and Apa I generating antisense and a sense probe respectively. The direction of 
cloning (5’ to 3’ or 3’ to 5’) was assessed from the sequence results. Based on 
these results, either T7 or Sp6 promoter was used to generate sense or antisense 
probes. The linearized clones were electrophoresed on a 0.8% agarose gel. The 
DNA bands of interest were visualized using a UV lamp and purified from the gel 
using a Promega Wizard SV gel and PCR clean-up system (Appendix H, 
Schedule 3).  
 
3.3.10.2 DIG Labelling of the DWNN probes 
The linearized plasmids containing DWNN fragment were used as templates for 
the labelling reaction to generate antisense and sense DWNN RNA transcripts as 
tabulated in Appendix F, table 10. One microgram of linearized and purified 
plasmid containing the DWNN gene was incubated with a mixture containing DIG 
dUTP (deoxyuridine triphosphate) for two hrs at 37ºC with T7 RNA polymerase 
or Sp6 RNA polymerase (Roche Diagnostics, Germany) to generate both 
antisense and sense probes, respectively. The specificity of the labelling reaction 
was determined by generating a DIG labelled control cRNA probe from DNA 
PSPT 18-Neo/Pvu II supplied in the labelling kit (Roche Diagnostics, Germany). 
The reaction mixture of DIG labelling of antisense, sense and control RNA probes 
was generated by adding the reagents as tabulated in Appendix F, table 10 into 1.5 
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ml micro-centrifuge tube. These mixtures were incubated in a thermocycler for 
two hr at 37ºC. The reactions were then stopped with 0.2 M EDTA (pH 8.0). 
These were mixed and pulse-centrifuged to collect all the constituents at the 
bottom of the tubes. The precipitation of the labelled RNA probes was achieved 
by the addition of 1/10 volume 4 M Lithium chloride and 5 volumes cold absolute 
ethanol. These were mixed, pulse-centrifuged and incubated at -20ºC for two hrs. 
The precipitate was pelleted by centrifugation at 7571 x g for 15 min at 4ºC and 
decanting the supernatant. The pellet was washed with cold 70% ethanol and 
centrifuged at 11708 x g for 15 min at 4ºC after which the supernatant was 
removed with a pipette to avoid dislodging the pellet. The pellet was dried in the 
laminar flow cabinet. It was then dissolved in 50 µl sterile DEPC treated water. 
This was left for one hr at 4ºC to allow the pellet to completely dissolve. The DIG 
labelled probes were stored at -70ºC in aliquots of 10 µl in 500 µl screw-capped 
tubes. The concentrations of the probes were then estimated using guidelines 
described in DIG user’s guide (Roche, Germany). 
NOTE: RNAse inhibitor was not added because it requires high concentrations of 
DDT (dithiotretiol) which may affect Sp6 and T7 polymerase activity. DNAse 
was not used either because there was no assurance that it was RNAse free.  
At the end of labelling there was approximately 0.2 µg/µl of probe. 
 
3.3.10.3 Estimation of the concentration of the probes  
To estimate the probe concentration of the synthesized probes, dilutions were 
made as tabulated in Appendix F, table 11. Dilutions for control labelled RNA 
(supplied); antisense and sense DWNN RNA and DIG labelled cRNA to control 
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DNA pSPT-18-Neo. DIG user’s guide was used (Roche Diagnostics). Spot points 
were marked lightly with a pencil on a nylon membrane (Hybond, Amersham, 
USA), and the manufacturer’s instructions were followed (Appendix H, schedule 
4). 
 
3.3.10.4 In situ hybridization (ISH) and Fluorescence ISH (FISH)  
Before starting the procedure, a fresh 4% paraformaldehyde (PFA) solution was 
prepared. The PFA was dissolved at 60ºC with stirring, not allowing the 
temperature of the solution to exceed 60ºC. Once the solution cleared, it was 
allowed to cool to room temperature. 
 
The tissue arrays were dewaxed, rehydrated and pre-treated for in situ 
hybridization (Appendix H, schedule 5). Hybridization was performed with 100 
pg/µl and 3 pg/µl antisense and sense DWNN RNA probes respectively and 
incubated overnight at 55˚C in a Hybaid Omnislide Flat Block Humid Chamber 
(Hybaid, USA) containing 5X SSC (3M NaCl, 0.3 M Na-citrate, pH 7.0) buffer 
and 50% formamide. Hybridization was carried out in hybridization buffer (2 X 
SSC, 10% Dextran (v/v), 0.2% SDS (w/v), 50% formamide) containing 0.01 
µg/µl Herring Sperm DNA. The hybridization buffer + HSD were used as a 
negative control for the sense probe. After hybridization the tissue arrays were 
subjected to a post-hybridization treatment (Appendix H, schedule 6). The probes 
were either visualized colorimetrically or fluorescently. Colorimetrically, the 
probes were visualized using with 5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium [NBT/BCIP] (Roche Diagnostics, Germany), 
counterstained with haematoxylin (Sigma, Germany) and mounted with aqueous 
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mounting medium (Serotec, UK). For the fluorescence studies, the slides were 
incubated with anti-DIG conjugated with FITC (Roche Diagnostics, Germany) 
after the blocking step. The probes and the slides were then mounted with 
SlowFade Light AntiFade (Molecular Probes, USA). They were then viewed with 
a fluorescence microscope using a 490 nm excitation filter. A minimum of three 
images for each tissue was taken with 40X objective and were used for a 
quantitative analysis of the FISH results. Labelled cells were counted for the 
analysis. Statistical software (GraphPad Prism 5, USA) was used to analyze the 
FISH data from tumour associated tissues and islands of the tumours. A One-way 
ANOVA and non-parametric column analyses was used. 
 
3.3.11 Ribonucleic acid interference (RNAi) 
The RNAi oligos were designed as shown in Appendix D under RNAi oligo 
design subheading. 
 
3.3.11.1 RNAi vector digestion  
Promega restriction enzymes were used and manufacturer’s instructions were 
followed with optimisation where necessary. The pEGFP-C1-U6 vector (500ng) 
[Prof. Rees, Department of Biotechnology, University of the Western Cape]; 
shown in Appendix D, vector map 2 was digested with Hind III or Bgl II. A 
doubly digested vector was purified from agarose gel as described in Appendix H, 
schedule 3. The purified digested vector was quantified using a Nanodrop 
(Nanodrop Technologies, USA) and used in the cloning of annealed RNAi oligos 
into RNAi vector. 
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3.3.11.2 Annealing RNAi oligos 
Before cloning the RNAi oligos (Appendix D, table 1) into RNAi vectors, the two 
oligos (forward and reverse from Inqaba Biotech) were annealed. They were 
annealed by adding 4 pmoles of each oligo in 1X TE buffer and 0.05 M sodium 
chloride. This was subjected to the following thermal steps: 
 Denature at 94 ºC for 5 min 
 Cool at room temperature for 4 hrs, or overnight 
 Store at -20 ºC or use for cloning step. 
 
3.3.11.3 RNAi oligos cloning into pEGFP-C1-U6 vector 
Cloning was done as previously described with other fragments cloned in this 
study (section 3.3.6). The setup of the cloning reaction was described in Appendix 
H.  
 
3.3.11.4 Transfection of RNAi clones into human cells 
3.3.11.4.1 Introduction 
In this research a better and less toxic reagent, Metafectene Pro (Biontex, 
Germany) was used to transfect the RNAi constructs into Hek 293T cells and the 
RBBP6 constructs into MCF-7 cells.  
 
3.3.11.4.2 Transfection protocol 
Manufacturer’s instructions were followed and the optimal DNA concentration 
was found to be 2 µg for each transfection, setup was done as shown in Appendix 
H, table 12. The tubes containing the DNA and transfection reagent were 
combined into 1 tube for each RNAi plasmid DNA. The addition was done in 
such a manner that the DNA tube constituents were added to transfection reagent 
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tube constituents drop by drop. The mixed samples were incubated at room 
temperature for 25 min. Cells were cultured in 6 well plates until approximately 
60-80% confluent, washed with PBS and a serum-free medium was added. The 
transfection mixture was added drop-wise onto the cell cultures and after 4 hrs the 
medium was substituted with complete medium and the cells were left to grow for 
a further 24 or 48 hrs. For transient transfections, the cells were then assessed for 
the efficacy of the RNAi molecules.  
 
3.3.12 Western blot analysis 
3.3.12.1 Total protein extraction  
Total protein was extracted using RIPA and 9 M urea buffers with the latter used 
for 2D gel electrophoresis. Briefly, cultured cells were washed with 1X PBS and 
scrapped off the culture dishes with a scrapper (Greiner Bio One, Germany) and 
put into PBS containing protease inhibitors. Detached cells were then centrifuged 
at 1132 x g at room temperature, and then resuspended in (10X volume of the 
pellet) RIPA or 9M Urea buffer. The cells were then vortexed for 15 seconds and 
incubated on ice for 30 min with occasional vortexing. The samples were then 
centrifuged at 11708 x g at room temperature for 5 min. The centrifugation 
resulted in the soluble proteins from the cells being transferred to the supernatant 
which was then transferred to a new 1.5 ml centrifuge tube. The protein 
concentration was determined using the Bradford assay. The protein solution was 
then mixed with 2X sample buffer containing 10 mM DTT and stored at -70 ºC 
until further use.  
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3.3.12.2 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
(SDS PAGE) 
Protein samples were separated on a 12% separating PAGE gel. For the SDS 
PAGE gel, these samples were thawed and boiled, and 20-50 µg of protein was 
loaded onto a 12% SDS PAGE gel. The protein electrophoresis system was then 
set at a constant voltage of 120V and allowed to run for one hr in 1X SDS-PAGE 
running buffer. 
 
3.3.12.3 Protein quantification using a Bradford assay 
The Bradford assay was used in this study to determine protein concentrations 
because it is a fast efficient and accurate method and uses very little sample. A 
Bovine Serum Albumin Fraction V was used as a standard. 
 
The standards were prepared as tabulated in Appendix F, table 13 as described by 
the manufacturer with minor modifications. The preparation of the protein 
samples was done as shown in Appendix F, table 14. 
 
3.3.12.4 Preparation of 12% SDS PAGE 
The SDS PAGE gel was prepared with 12% Acrylamide/Bis (40%-37:5:1), 0.375 
M Tris-Cl (pH 8.8); 0.1% SDS; 0.1% ammonium persulphate (APS); 0.005 ml of 
TEMED and made up to the required volume with distilled water. This mixture 
was poured into the acrylamide gel casting apparatus (BioRAD, USA). It was then 
overlaid with water and after solidifying the water was discarded. A stacking gel 
(0.125 M Tris, pH 6.8; 0.5% Acrylamide/Bis (40%-37:5:1); 0.1% SDS; 0.1% 
APS; 0.005 ml TEMED) was made up to the required volume with distilled water 
and added on top of this separating gel. 
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3.3.12.3 Electroblotting  
An electro-blotting cassette (BioRAD, USA) was assembled according to the 
manufacturer’s instructions to transfer proteins onto the polyvinylidene fluoride 
membrane (PVDF) [Sigma] in transfer buffer for two hrs. After the transfer the 
membrane was stained with Poncheau S stain (Sigma-Aldrich, Germany) to 
confirm the transfer. The stain was removed with several washes in water and 
TBST. 
 
3.3.12.4 Probing the blot with antibodies 
Before probing with the primary antibody, the membrane was incubated in 
TBSMT overnight at 4ºC or at room temperature for two hrs. Then the membrane 
was probed with anti-human DWNN primary antibody (1:5000 in TBSMT) and 
incubated for one hr on the shaker at room temperature. After an hour the 
membrane was washed three times, (10 min for each), with 1X PBS containing 
0.1% Tween 20. After washing, the membrane was incubated in a secondary 
antibody (1:2000 in TBSMT), Anti-rabbit IgG peroxidase conjugated (DAKO) for 
one hr. This was followed by washing the membrane six times (10 min) with 1X 
PBS containing 0.1% Tween 20. 
 
3.3.12.5 Detection and exposure  
Detection of the antibody binding was done using autoradiography. To visualize 
the bands that the primary antibody bound to, the membrane was immersed in a 
solution containing Super Signal West Pico Chemiluminescent Substrate 
(PIERCE, USA) for five min. The blot was then exposed to CL X-Posure film 
(Thermo Scientific, USA) for an appropriate period (30 seconds; one min; 10 min; 
30 min and one hr). The x-ray film was then developed in the dark. 
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3.3.12.6 Blot stripping protocol 
In most instances a specific blot was stripped to be probed with a different 
antibody. Stripping was done by washing a membrane with dH2O for five min at 
room temperature. This was followed by washing with 0.2 M Sodium hydroxide 
for a further five min at room temperature. A stripping method was concluded 
with another five min-wash with distilled water. The membrane was then ready 
for blocking and detection using a different antibody. 
 
3.3.12.7 Two dimensional (2D) gel electrophoresis 
A total of 1-2X 10
7
 cells for each of the cell lines (Hek 293T, MCF-7 and HeLa, 
HepG2) were collected by trypsinization, then centrifugation and lysed in 2D gel 
lysis buffer (9M urea, 2M thiourea, 4% 3-[(3-Cholamidopropyl) 
dimethylammino]-1propanesulfonate (CHAPS) and a tablet of protease inhibitors 
cocktail (Roche, Germany). First dimension electrophoresis was performed using 
the Ettan IPGphor II (GE Healthcare, UK). Precast 7 cm immobilized pH gradient 
(IPG) with pH ranges from 3-10 and 4-7 were purchased from BioRad, USA. Cell 
lysates (100-500 µg) were thawed and mixed with rehydration buffer (9M, 2M 
thiourea, 4%CHAPS, 50 mM DDT, 2% Ampholytes and 0.01% Bromophenol 
blue). 200 µg of protein sample mixture was loaded to each of the IPG strips. The 
strips were rehydrated with the sample mixture and overlaid with a layer of 
mineral oil overnight (12-16 hours). Iso-electric focussing was carried out in three 
steps: 250 V for 15 min, 8000 V for 3 hours and 8000 V rapid ramp to achieve 
10000 V-hours in 4 hours. 
 
The second dimension was performed in the BioRad Protean II system (BioRad, 
USA). The IPG strips were equilibrated in 1% DTT equilibration buffer (6 M 
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Urea, 2% SDS, 0.05 M Tris pH 8.8 and 20% glycerol) for 10-15 min with 
shaking. Equilibration was repeated with 0.25 M iodoacetamide (BioRAD, USA) 
for a further 10-15 min on a stirrer. The strips were rinsed in 1X SDS running 
buffer and were placed on top of a 12-14% SDS gel. A protein marker filter paper 
was also placed on top of the gel. These were then sealed with 0.5% agarose 
solution containing 0.0001% bromophenol blue. This was then run as a normal 
SDS-PAGE at 50V increasing gradually to 120V. After the SDS PAGE was done, 
gels were either stained with coomassie brilliant blue or blotted for Western 
blotting. The spots that showed reaction to the DWNN antibody were located and 
analyzed by Mass spectroscopy. 
 
3.3.12.8 Matrix-assisted laser desorption/ionization Time-of-flight 
(MALDI-TOF) Mass spectrometry (MS) 
Spots of interest were picked from the 2D gels with sterile yellow tips and 
transferred to clean sterile 1.5 ml centrifuge tubes. The gel pieces were washed 
twice with 50 mM ammonium bicarbonate for 5 min each, discarding the wash 
solution after each wash. The washing was repeated with 50 mM ammonium 
bicarbonate for a further 30 min with occasional vortexing. The gel pieces were 
washed twice with 50% 50 mM ammonium bicarbonate/50% acetonitrile for 30 
min each with occasional vortexing, discarding the wash solution at the end of 
each wash. The distaining of the gel pieces was completed by the addition of 
100% acetonitrile and incubated for 5 min at room temperature. The gel pieces 
were dried completely in a speed vac for 10 min at a medium setting. The dried 
protein gel pieces were incubated with 10µg/ml trypsin solution in 25 mM 
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ammonium bicarbonate for 6 hours at 37˚C. The digestion solution was then 
transferred to 4˚C until the MALD-TOF MS analysis.  
 
The trypsinized spots were mixed with the MS matrix and loaded onto an MS 
plate. In-between the samples, the calibration mix (Calmix 2 and the matrix) was 
loaded. These were allowed to dry on the MS plate for few min up to an hour. The 
MS plate was then loaded into the Voyager-DE Pro MALDI-TOF system 
(Applied Biosystems, UK). The peptide masses were measured with the MALDI-
TOF and the protein identities were searched for from a Mascot server 
(www.matrixscience.com/server.html).  
 
3.3.13 Detection of Apoptosis - Rationale 
Apoptosis was detected using different techniques depending on the sample that 
was used. Conventionally, DNA laddering was the chosen method for detecting 
apoptosis where DNA was extracted and electrophoresed on an agarose gel. DNA 
laddering/fragmentation is normally evident when the cells die as a result of 
apoptosis. There are commercially available kits that have been developed to 
detect this DNA laddering on both fixed tissue sections and cultured cells. One 
example of such kits is a Terminal deoxynucleotidyl Transferase Biotin-dUTP 
Nick End Labelling (TUNEL) kit available from many different companies 
(Promega Corp., USA; Roche Diagnostics, Germany). Alternatively, apoptosis 
can be detected using kits like ANNEXIN V (Sigma-Aldrich, Germany) and 
APOPercentage (Biocolor Ltd., UK) that use a different principle from TUNEL. 
While TUNEL detects DNA fragmentation, the latter two detect the 
externalization of phosphatidylserine (in the plasma membrane) seen in apoptotic 
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cells. In this project, APOPercentage assay using a FACScan (Becton Dickson, 
USA) was used to detect apoptosis in cultured cells, under controlled conditions 
and after apoptotic stimulus. The APOPercentage assay works by showing the 
cellular uptake of APOPercentage dye when a change in the asymmetric 
composition of the membrane phospholipids occurs. The asymmetric composition 
of the membrane phospholipids is essential in maintaining a ‘viable’ cell 
membrane and cell and is maintained and controlled by flippase. Flippase control 
is negated by the action of another enzyme; floppase or scramblase during 
apoptosis (Zhao et al., 1998). The APOPercentage Dye enters the cell once the 
phosphatidylserine residues, usually present only in the inner plasma membrane 
leaflet, are externalized to the outer membrane surface. The dye uptake continues 
until blebbing of the cell occurs after which no further dye can enter the apoptotic 
cell and the dye that has accumulated within the cell is retained. Dye-uptake can 
be visualised by transmission light microscopy. Apoptotic cells can also be 
quantified by flow cytometry (Keter et al., 2008). In this study flow cytometry 
was also used to quantify apoptosis. 
 
3.3.13.1 Apoptotic induction 
Apoptosis was induced with Staurosporine, Camptothecin and Arsenic trioxide. 
These compounds have been shown to induce high levels of apoptosis (Charlot et 
al., 2006, Debret et al., 2008, Mei et al., 2007). Untreated cells grown for 24 hrs 
were used as the negative control. To make sure that equal numbers of cells were 
plated at the start of inductions, the numbers of cells plated were counted using a 
Fuchs haemocytometer.  
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3.3.13.2 APOPercentage Assay (Flow cytometry Method) 
The instructions of the manufacturer were followed with minor changes (Meyer et 
al., 2008). The assay was done as follows: The APOPercentage was diluted 1:160 
in complete medium. From the culture plate or wells, the supernatant (SN) was 
removed and retained. The cells were washed with 1X PBS and trypsin (0.125%) 
was added to each well. The cells were washed off in trypsin and added to SN and 
PBS. These were centrifuged for three min at 7043 x g. The pellet was 
resuspended in APOPercentage dye (250 µl) and incubated at 37ºC for 30 min. 
The cells were washed with 2ml PBS and centrifuged at 7043 x g for three min. 
The supernatant was removed and the pellet was solubilised in 300 µl FACS Flow 
liquid (BD Biosystems, USA). This was then used for analysis in the flow 
cytometer (Beckon Dickson, Biosystems, USA). 
 
Flow Cytometry 
After APOPercentage staining (3.3.12.2), the cells were acquired and analysed on 
a FACScan instrument equipped with 488 nm Argon Laser as a light source 
immediately or within one hr. Acquisition was done by setting forward scatter 
(FSC) and side scatter (SSC) on a log scale Dot Plot to differentiate population of 
cells and cellular debris. On a linear histogram dot plot, APOPercentage (FL-3 
channel) was measured against relative cell numbers. Negative control cells were 
used to set the cells in the negative quadrant before all samples were acquired and 
analysed using CELLQUEST Pro software (Beckon Dickson, Biosystems, USA).  
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3.3.14 Cell cycle analysis with Propidium iodide (PI) 
Cancer is a disease that is fundamentally characterized by the existence of too 
many cells. This may be due to ferocious cell cycles with a decrease in sensitivity 
to signals that indicate to a cell to adhere or differentiate or die (Collins et al., 
1997). This process is gene-regulated and p53 plays a major role in this control. In 
this study, a cell cycle blocker, arsenic trioxide was used to investigate the role of 
the DWNN in cell cycle regulation. 
 
Hek 293T, HeLa, HepG2 and MCF-7 cells were seeded at a density of 2.5 X10
5 
cell per well in 6 well culture plates. After a further 24 hours, the cells were 
treated with 12.5μM arsenic trioxide. After 24 hours the cells were harvested by 
trypsinization and washed with 2 ml PBS. The cells were resuspended in 1 ml 1% 
(w/v) paraformaldehyde in PBS, pH 7.4. The cells were placed on ice for 30 
minutes. 5ml PBS was added and the cells were pelleted by centrifugation at 4000 
rpm for 10 minutes. The wash was repeated with PBS and the pellet was 
resuspended in residual PBS. 4 ml 70% ethanol was added slowly while mixing. 
Cells were placed at -20°C for at least 48 hours up to several weeks prior to 
Propidium (PI) staining and flow cytometric analysis. Cells were pelleted at 4000 
x g for 10 minutes, washed twice in PBS and were resuspended in 1 ml PI master 
mix and incubated at 37°C for 30 minutes. The cells were kept on ice until 
analysed by flow cytometry. 
 
3.3.15 MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide] assay 
The cytotoxicity of the compounds (Arsenic trioxide, Staurosporine and 
Camptothecin) used in this study was measured using the MTT assay. Briefly, the 
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cells were seeded on 96 well polystyrene cell culture plates at a density of 1 X 10
4
 
cells per well and allowed to attach overnight. Various dilutions of each 
compound and the blank controls were applied to the cells in triplicate for 24 
hours. After the incubation time with the compounds the medium was removed 
and the cells were rinsed three times with 1X PBS. Cell viability was measured by 
the addition of 5mg/ml MTT solution and incubation for 4 hours at 37˚C in the 
dark. The resultant crystals were dissolved by the addition of DMSO. The 
absorption wavelength of 560 ± 10nm of each well was read in a plate reader 
(Struers, Germany). 
 
3.3.16 Statistical analysis 
The data from the real-time PCR, in situ hybridization, FACS and MTT assay 
presented in this study was analyzed using GraphicPad Statistical software, USA 
and presented as mean ± SD. A one-way ANOVA (analysis of variance) and non-
parametric column tests were used. 
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Chapter Four: RBBP6 variants and isoforms in human 
cell lines, cancerous and non-cancerous 
 
An uncharacterized anti-human DWNN polyclonal antibody (section 3.2.4) was 
available for this study and the first part of the study was aimed at characterizing 
it. Before the uncharacterized antibody raised against the DWNN domain was 
used to label the different cell lines used in this project, it was important to 
confirm the genotype of the RBBP6, which was expected to be detected by this 
antibody. As some mutations can result in truncated protein products or higher 
molecular weight products, it was therefore important to determine the mutation 
status in the RBBP6 binding domains (section 4.1) before detecting protein 
products, in case unexpected bands were found.  
 
Once the genotype status was established, the relative expression of RBBP6 
(section 4.2) was conducted in order to choose appropriate cell lines that could be 
utilized for the characterization studies. The next question was whether the anti-
human DWNN polyclonal antibody recognized the recombinant DWNN domain, 
endogenous DWNN and RBBP6 in low and higher expressing cell lines (sections 
4.3) using Western Blotting analysis. Due to the recognition of multiple proteins 
from the human cell lines, it was of further importance to extensively investigate 
these proteins (section 4.4).  
 
RT-PCR (section 3.3.3) was used to detect RBBP6 domains for mutational 
analysis in Hek 293T, HeLa, HepG2 and MCF-7 cell lines. This was performed to 
determine whether the cell lines used in this study have the expected RBBP6 
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transcripts. One (1D) and two (2D) dimensional polyacrylamide gel 
electrophoresis (sections 3.3.12.2 and 3.3.12.7 respectively) were used to separate 
total proteins extracted from the human cancer cell lines (MCF-7, HeLa and 
HepG2) and the normal Hek 293T cells. The total protein was extracted using 
both RIPA buffer and Urea buffer (Appendix A1) and Western blotting was 
carried out (section 3.3.12) on both 1D and 2D gels.  
 
Four rabbits were immunised with a Glutathione S Transferase (GST)-DWNN 
recombinant protein as shown in Appendix J. It was expected that the sera from 
these animals would contain antibodies against the DWNN/RBBP6 proteins 
(figure 2.1). Western blotting demonstrated that the anti-human DWNN antibody 
recognises other unexpected proteins and Matrix-assisted laser 
desorption/ionization Time-of-flight (MALDI-TOF) mass spectrometry was 
carried out on these proteins to identify them. 
 
4.1 Mutational analysis of RBBP6 binding domains 
The cell lines that were used in this study were the Hek 293T, a normal cell line 
and the cancerous cell lines (HeLa, HepG2 and MCF-7); all expressed all three 
RBBP6 transcripts. This was evident when RBBP6 domains were amplified using 
PCR with specific primers to the four domains. Figures 4.1 (A-D) show PCR 
products of the DWNN, RING finger, Rb- and p53-binding domains of the 
RBBP6 gene. These results suggest that in cancers, DWNN domain and its related 
RBBP6 products are expressed as full gene products. This also suggests that the 
DWNN domain (also known as RBBP6 isoform 3) may be found in the human 
proteome. According to NCBI nucleotide database (figure 2.1), the anti-human 
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DWNN antibody should detect both DWNN and its associated RBBP6 isoforms. 
Successful amplification of the first RBBP6 domain and the last three binding 
domains, as well as no detectable mutations, suggests that RBBP6 may exist as 
wild-type in these cancers. The amplification of the RING finger, RbBD+ and 
p53BD in MCF-7 cells was visible only after nested PCR. This result suggested 
that the RBBP6 gene may be down-regulated in breast cancer cells, or at least, in 
MCF-7 cells. Lane 3 in figure 4.1 D shows a very faint PCR product in MCF-7 
cells, which is better visualized when nested PCR is performed. 
 
The DWNN domain, RING finger domain, RbBD and p53-binding domains were 
amplified from HepG2, HeLa and MCF-7 cells and the normal control Hek 293T 
cells were cloned into a pGEM T-Easy vector and sequenced. The sequencher 
demo software was used to assemble two sequences from the sequencing primers 
(Sp6 and T7) against the NCBI reference sequence (RBBP6- NM006910). The 
NCBI blast tool was also used to align the sequences from the cells against the 
reference sequence. The sequence alignments of the sequenced domains versus 
the reference sequence (APPENDIX K) showed that the RBBP6 domains had no 
mutations which suggested that RBBP6 transcripts were expressed as normal in 
the cell lines investigated unless mutations are in-between these domain 
sequences.  
PhD- Z Mbita Chapter Four: RbBP6 variants and isoforms in human cell lines, cancerous and non-cancerous 
 
81 
 
 
 
Figure 4.1 – Amplification of the RBBP6 domains: Agarose gel images showing the 
amplification of RBBP6 domain, that is, DWNN (A), RING finger (B), Rb-binding 
domain (C) and p53-binding domain (D). Figure 4.1A shows a marker (lane M), DWNN 
amplification in MCF-7 (lane 1), in HeLa (Lanes 2, 3), HepG2 (lane 4 and 5), WHCO 
(Lanes 6 and 7), Hek 293T (Lanes 8) and blank control (lane 9). Figure 4.1B shows the 
amplification of RING finger domain in HeLa (Lane 1), HepG2 (Lane 2), Hek 293T 
(Lane 3), MCF-7 (Lane 4), Blank control (Lane 5) and a molecular weight marker (Lane 
M). Figure 4.1C shows the amplification of RbBD in HeLa (lane 1), HepG2 (lane 2), 
MCF-7 (lane 3), Hek 293T (lane 4) and negative control (lane 5). Figure 4.1D shows 
p53BD amplification in HeLa (Lane 1), HepG2 (Lane 2), MCF-7 (Lane 3) where there 
was very little amplification and Hek 293T (Lane 4). Lane 5 represent a blank control 
where there was no template added.  
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4.2 Relative expressions of the RBBP6 transcripts in human cancer cell 
lines 
For both characterization of the anti-human DWNN antibody and functional 
analysis of the DWNN and its RBBP6 family members, it was important to 
analyse the relative expression of the RBBP6 transcripts in different cell lines, so 
that an appropriate cell line could be used for knock-down analysis by RNA 
interference. This verification was also required to transfect the appropriate cell 
line with the DWNN and RBBP6 transcript 1 for over-expression studies (see 
chapter 6).  
 
Relative Real-time PCR (section 3.3.8), using equal amounts of cDNA prepared 
from six cell lines as a starting template, showed that two cell lines, Hek 293T 
(non-cancerous kidney embryonic cells) and Jurkat cells (an immortalized line of 
T lymphocytes) had a higher expression of RBBP6 transcripts than the solid 
tumour cell lines investigated (HeLa, HepG2, MCF-7 and WHCO [an 
oesophageal carcinoma cell line]). The relative expression of DWNN and RBBP6 
mRNAs was calculated using the comparative threshold cycle (Ct) method, a 
variation of Livak and Schmittgen’s (2001) method. The relative expression 
formula: Ratio (reference/target) = 2
Ct (Reference)-Ct (Target)
 was used to normalize the 
expression using the reference housekeeping gene, hHPRT1. Table 15 (Appendix 
I) shows the average DWNN Ct values normalized with hHPRT1 and delta Ct for 
different cell lines. Table 16 (Appendix I) shows the average RBBP6 variants 1 
and 2 Ct values normalized with average hHPRT1 Ct values for different cell 
lines. Figure 4.2 shows the calculated relative expressions comparing Hek 293T 
expression with the solid tumour cells; Hek 293T has a higher DWNN expression 
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than the solid tumour cell lines (figure 4.2A). Hek 293T also has a higher RBBP6 
variant 1 expression than the solid tumour cell lines (figure 4.2B). Jurkats cells 
show a tenfold higher expression of both DWNN and RBBP6 variant 1 when 
compared to Hek 293T cells. Jurkats cells were the only cells that have a higher 
expression level of DWNN than the Hek 293T cells (figure 4.2C). Using 
GraphPad Prism (GraphPad Software, Inc., USA), a one way ANOVA was 
performed and the data was found to be statistically significantly different (P < 
0.05). The MCF-7 cells were found to have the lowest expression of DWNN and 
RBBP6 variant 1 and 2. The hHPRT1 primers were used as an internal control for 
these experiments. Raw data shows that hHPRT1 was expressed at similar levels 
in all the cell lines while the DWNN and RBBP6 demonstrated reduced levels 
consecutively in HeLa, HepG2, WHCO and MCF-7 cells. The WHCO cell line 
was also included as a positive control because the mouse RBBP6 homologue was 
reported to be highly expressed in oesophageal cancer (Yoshitake et al., 2004). 
 
As this data suggest that DWNN and RBBP6 are down-regulated in human 
cancers at the mRNA level. The next logical query is whether DWNN and RBBP6 
protein levels actually corroborate this?  
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Figure 4.2 (A-D) – The expression of the RBBP6 transcripts in human cell lines: showing the relative expression of the DWNN and the RBBP6 transcript 1 using 
the optimised real-time PCR (Appendix I) in the different human cell lines used in this work in comparison to Hek 293T. The data was analyzed and presented in the 
graph as the mean ± SD. A 1 way ANOVA test was performed and the data was found to be statistically significantly different (P < 0.05) from three independent 
experiments. The DWNN and RBBP6 data was normalized to that of the house keeping gene, hHPRT1. 
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4.3 The anti-human DWNN antibody recognizes DWNN proteins and 
unknown proteins 
The DWNN polyclonal antibody was raised in rabbits against GST-DWNN fusion 
protein (Appendix J).  
 
One dimensional gel electrophoresis and Western blotting showed that the anti-
GST-DWNN antibody recognized the recombinant GST-DWNN protein (figure 
4.3A) and the cleaved-off GST (figure 4.3B). The antibody additionally 
recognized a 15 kDa protein (thought to be the DWNN domain), and a ladder of 
bands that included a 120 kDa protein (unknown proteins) and 250 kDa protein 
bands (probably the RBBP6 isoforms 1 or 2). Figure 4.3C shows the absence of 
the 250 kDa protein in MCF-7 cells compared to Hek 293T cells. Figure 4.3D 
shows that equal quantities of the protein lysates were loaded. The ladder of bands 
could either be non-specific bands that may include human GST-related proteins 
or a DWNN domain attached or tagged to other protein products. The pre-immune 
serum did not show the DWNN domain, or the 120 kDa and the 250 kDa bands. 
This result suggested that the antibody was detecting the DWNN domain, the 120 
kDa protein, possibly a GST-related or DWNN tagged protein and one of 
RBBP6’s bigger isoforms. It is possible that the extra protein bands are due to the 
recognition of GST-related proteins. Figure 4.3B shows that the anti-GST-DWNN 
antibody recognized the cleaved GST tag suggesting that this antibody could also 
detect human GST-related proteins. To confirm this, a GST antibody (Santa Cruz 
Biotechnology, USA) was used on the human cell lysates to investigate whether it 
would recognize these GST-related antibodies.  
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Figure 4.3 – The recognition of multiple proteins by the Anti-GST-DWNN antibody: Figure 4.3A shows the recombinant expression of the GST-DWNN (Lane 
2) confirmed by Western blotting. Lane M represents a protein molecular weight marker. Lane 1 shows an uninduced bacterial total protein lysate and lane 2 shows 
an induced total bacterial lysate showing an induced protein band between 35 kDa and 40 kDa. Figure 4.3B shows Western blot with anti-human DWNN antibody 
on a 39 kDa GST-DWNN recombinant protein (lanes 1-2) and a 26 kDa recombinant GST protein (Lanes 3 and 4). Figure 4.3C shows a Western blot result with the 
anti-human DWNN antibody on MCF-7 cell lysate (Lane 1) and Hek 293T cell lysate (Lane 2). In both lanes there were either GST-related proteins or non-
specifically bound proteins and in addition three proteins were detected in Hek i.e. 15 kDa; ~120 kDa and 250 kDa proteins. In lane 1 there was no 250 kDa protein 
detected. Figure 4.3D shows loading control using actin antibody. 
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A pre-absorbed antibody with GST-DWNN fusion protein served as a negative 
control. A second negative control was the use of pre-immune serum from all the 
rabbits immunised to raise this antibody. To determine whether the antibody 
detects GST-related proteins in human, an anti-GST antibody was used on MCF-7 
and Hek 293T total protein lysates using a Western blot analysis. An identical 
Western blot was probed with anti-Human DWNN antibody. Figure 4.4A shows 
anti-human DWNN polyclonal antibody reactivity to two protein bands on one-
dimensional SDS PAGE gel. One of these proteins is approximately 120 kDa and 
is most probably a DWNN domain associated protein, while the second protein is 
approximately 50 kDa and is most likely to be a human GSTs or GST related 
protein. Figure 4.4B also confirms that the 50 kDa protein is a mammalian GST-
related protein as this band was labelled when an anti-GST antibody was used on 
the same cell line protein lysates. Pre-absorption of the polyclonal anti-human 
DWNN antibody with GST recombinant protein also confirmed that the smaller 
second band was a GST-related protein band as figure 4.4C showed that only the 
larger DWNN-associated protein band was labelled. All the RBBP6 isoforms 
contain the DWNN domain and should therefore be detected by the antibody 
against the DWNN domain. The RBBP6 isoforms have been both predicted to, 
and reported to give rise to 250 kDa proteins (Altschul et al., 1997, Simons et al., 
1997), while the DWNN domain is predicted to be 13 kDa (www.expasy.org) as 
shown in figure 4.3 and most probably a 15 kDa protein due to post-translational 
modification of a 13 kDa DWNN domain. The results obtained were both 
expected and unexpected in the sense that the 15 kDa and approximately 250 kDa 
proteins were expected, while the suspected GST-related and the 120 kDa proteins 
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were unexpected. Figure 4.4 C confirms that the bigger protein detected contained 
DWNN, though the signal was weak because the GST-preabsorbed antibody 
could no longer detect the GST-related proteins while it could still detect the 
DWNN-associated proteins.  
 
 
 
Figure 4.4- Reaction of the DWNN polyclonal antibody with GST- and DWNN-
related proteins: This figure shows Western blot results using the anti-Human DWNN 
antibody on MCF-7 and Hek 293T cell lysates (A), an anti-GST antibody applied to 
MCF-7, HeLa and Hek 293T cell lysates (B) and a GST pre-absorbed anti-Human 
DWNN applied to the same lysates (C). 
 
In all the human cancer cell lines used, a DWNN associated protein product was 
observed. The DWNN domain and its associated proteins were detectable with the 
GST–related band labelled in all of these cell lines. These included cervical 
carcinoma cells (HeLa), kidney embryonic epithelial (Hek 293T), breast cancer 
(MCF-7), hepatocellular carcinoma (HepG2) and acute T cell leukaemia (Jurkat) 
cell lines. These results suggested that a pure anti-DWNN antibody could be 
obtained by binding anti-GST isotopes to immobilised glutathione molecules. In 
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figure 4.4 (C) it was shown that the purification step reduces the signal of the 
DWNN associated protein. It is suggested that the DWNN associated protein 
labelled could be associated with the DWNN domain by attaching to these other 
proteins through the ubiquitination-like process, as the DWNN has a ubiquitin like 
fold (Pugh et al., 2006). 
 
4.3 DWNN domain may bind and modify other proteins 
Ubiquitination plays a role in protein stability and stable proteins are important in 
the execution of different biological functions that are involved in cell 
homeostasis (Amemiya et al., 2008). Ubiquitin protein molecules are attached to 
ubiquitin proteasome targeted proteins for degradation (Schreiner et al., 2008). 
There are many other ubiquitin-like proteins that are also protein modifiers and 
play roles in either degradation or stabilization of proteins. These include Sumo-1 
(Matic et al., 2008) and Nedd8 (Bornstein et al., 2006). It has also been suggested 
but never been shown, that the DWNN domain is a ubiquitin-like protein modifier 
(Chibi et al., 2008, Pugh et al., 2006). The detection of multiple bands (figure 4.3) 
suggested that this protein may either be tagged to other or posttranslationally 
modified. The purification of the antibody using affinity purification suggested 
that the 120 kDa protein (figure 4.4) may be posttranslationally modified RBBP6 
isoform 3 (DWNN) or tagged to another protein. Using two dimensional gel 
electrophoresis, anti-DWNN antibody and MALDI-TOF Mass spectrometry, the 
possible DWNNylation (possible tagging of other protein with DWNN domain) 
was investigated. 
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4.3.1 DWNN domain may be endogenously associated with other 
protein products 
The purified anti-Human DWNN polyclonal antibody demonstrated that the 
DWNN exists in human cells and is either covalently attached to a bigger protein 
product or posttranslationally modified as well as a DWNN protein. It was 
expected that the anti-human DWNN antibody would detect the three RBBP6 
isoforms as shown in figure 4.3C. As previously suggested that the DWNN 
domain shares a similar protein structure with ubiquitin, the possibility of the 
DWNN being tagged to and modifying other proteins was not discounted.  
 
Two-dimensional gel electrophoresis coupled with Western blotting was used to 
determine whether this association could be further clarified, or alternatively, it 
was investigated whether denaturing conditions would release the DWNN domain 
from complexes postulated.  
 
Using one dimensional SDS PAGE, figure 4.5 shows that the purified anti-human 
DWNN polyclonal antibody detected high molecular proteins in different cell line 
lysates extracted with 9M Urea buffer. In all the cell lines, the DWNN domain at 
the 15 kDa region and the higher molecular weight protein bands were also 
detected, which suggested that there might still be DWNN domain bound to a 
bigger protein or posttranslational modification protein. While the possibility of 
this higher molecular weight protein consisting of degradation products of the 
RBBP6 isoforms 1 and 2 was highly unlikely because this protein band seemed 
stable, with no visible smearing, suggestive of degradation. Urea denatures 
proteins and disassembles protein complexes. The use of 9M urea extraction 
buffer showed a size decrease of the 120 kDa proteins (seen with RIPA buffer) to 
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approximately 100 kDa as shown in figure 4.5A. This suggested that DWNN may 
be a covalent modifier of certain proteins and confirms that the high molecular 
protein band is an antibody reaction to DWNN associated with another protein or 
possible posttranslational modified DWNN. This result also suggested that this 
association could be with more than one DWNN associated protein molecule, 
because dissociation of the DWNN domain from the unknown protein should 
have resulted in the loss of signal altogether. Figure 4.5 shows that in all the cell 
lysates extracted with the urea buffer, the DWNN was observed and possibly had 
been released from protein complexes. This further suggested the attachment of 
the DWNN domain molecules to more than one protein. 
 
Figure 4.5 shows that all the human cell lines express all the human RBBP6 
proteins with a notable low expression in breast cancer cell line, MCF-7. Both the 
high percentage acrylamide gel (figure 4.5A) and the low percentage gel (figure 
4.5C) showed a ladder of bands, with MCF-7 cells showing low expression of the 
RBBP6 proteins. Figures 4.5B and D shows an actin loading control. Together, 
this data suggests that the DWNN domain/RBBP6 is a ubiquitin-like modifier. 
Two dimensional gel electrophoresis was employed to attempt the identification 
of the possibly “DWNNylated” proteins. 
 
Western blotting of the two dimensional protein gel confirmed that the anti-
human DWNN protein detected other proteins besides the DWNN domain and 
RBBP6 bigger isoforms. The proteomes for the human cell lines were established 
and used to investigate the identity of the possibly “DWNNylated” proteins in the 
human cell lines.  
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Figure 4.5 – A possible protein “DWNNylation”: This figure shows that the anti-human 
DWNN antibody recognizes all the RBBP6 isoforms. Figure 4.5A shows the detection of 
±100 kDa proteins and 15 kDa proteins in human cell lines on a high percentage 
acrylamide gel. Low expression of the DWNN domain and its associated protein were 
observed in MCF-7 cells by using an actin antibody loading control (figure 4.5B). The 
antibody (figure 4.5C) detected the 250 kDa RBBP6 protein and other proteins. Again 
MCF-7 showed low expression when compared to the actin antibody loading control 
(figure 4.5D). 
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4.3.2 Human cancer cell line 2D proteome establishment 
The observation that the DWNN domain/RBBP6 isoform 3 may be covalently 
linked to another protein or proteins instigated the more sensitive blotting of 2D 
gels, in order to determine which proteins the anti-human DWNN antibody 
detects. The cell lines used to extract proteins for Western blotting were Hek 293 
cells (normal), HeLa cells (cancerous), HepG2 cells (cancerous) and MCF-7 cells 
(cancerous) 
 
Figure 4.6 shows proteomes of a non-cancerous human embryonic kidney cell 
(Hek 293T) and that of a cancerous human cell (MCF-7) respectively. There was 
a noticeable difference between the two proteomes in respect to protein 
distribution. These may be different in terms of protein composition between 
proteomes, but Coomasie Blue and Flamingo Pink staining was not sensitive 
enough to detect the less abundant proteins. The proteins from these 2D gels were 
subjected to Western blotting to determine whether the anti-human DWNN 
antibody (both the GST-contaminated and purified) would react with more 
proteins or just the protein detected in the one dimensional gel electrophoresis and 
to further confirm non-specificity of the contaminated antibody. 
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Figure 4.6 – Non cancerous human embryonic kidney cell proteome and cancerous 
cell proteome: This figure shows two proteomes of Hek 293T and MCF-7 cells. 
 
4.3.3 Confirmation of non-specificity of the GST-contaminated anti-
human DWNN antibody 
For the purpose of determining whether the DWNN antibody detects more than 
one protein or just the DWNN proteins, a 2D gel technique (3.3.12.7) was used. 
The denaturating conditions of this method make it possible to separate proteins 
into individual protein spots for further characterization. The urea extraction 
buffer disrupts hydrogen and hydrophobic bonds denaturing proteins, producing 
suitable samples for isoelectric focussing and separating proteins according to 
their charges before the second dimension separation according to size. This 
method should make it possible to disrupt any protein complexes and results in 
isolated proteins (Chevalier et al., 2009, Ludvigsen et al., 2009). Figure 4.7 shows 
that the non-specific anti-Human DWNN antibody reacted with a number of 
proteins from non-cancerous Hek 293T cells and MCF-7 cells. Both results 
demonstrate a non-specific reaction. These results suggested that DWNN may be 
covalently linked or bound to other proteins in human cell systems and that the 
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contaminating GST antibodies results in non-specific reaction in both proteomes. 
The presence of more than two protein spots suggests that the DWNN domain 
may be a ubiquitin-like modifier and is tightly bound to other proteins. In both the 
Hek cells and the MCF-7 cells, there were two spots in the 15 kDa region. These 
spots may be two DWNN domain products with the larger one due to post-
translational modifications, that is, phosphorylation or glycosylation, the two most 
common post-translational modifications (Liang et al., 2006, Yamakoshi et al., 
2008). The anti-human DWNN antibody was raised against the GST-DWNN 
fusion protein and that is the reason it detects both DWNN-associated and GST-
related proteins. Protein spots detected at the 15 kDa and 100 kDa regions could 
be DWNN-containing protein because the Western blot on 1D gel detected 
proteins at the same regions (figure 4.5). 
 
Figure 4.7 - 2D Western blot on Hek 293T and MCF-7 cells: These figures show a 
number of protein spots detected by anti-human DWNN antibody in both Hek 293T and 
MCF-7. The circled protein cluster shows what could be non-specific detection. At 15 
and 100 kDa strong protein spots were detected by the anti-human DWNN antibody in 
Hek 293T cells while in MCF-7 cells the higher molecular weight protein at 
approximately 100 kDa shifted from the neutral to the more acidic PI.  
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4.3.4 Anti-DWNN antibody reacts with GST related proteins, DWNN 
and its related proteins 
Purification of the anti-DWNN by GST pre-absorption resulted in a more specific 
antibody that reacted with fewer spots. Figure 4.8 shows anti-human DWNN 
reacting with two protein spots at the 15 kDa region at a PI of about 4.5; one spot 
at about 100 kDa at a PI of approximately 5 and a spot at approximately 40 kDa at 
a PI of 7. This procedure reduced the unidentified proteins detected by the 
contaminated un-purified antibody. This result suggested that the polyclonal anti-
human DWNN antibody contained non-specific antibodies which were removed 
by pre-absorbing the antibody with GST.  
 
It was observed that the anti-human DWNN antibody showed a reaction to GST 
related proteins as the use of an anti-GST antibody labelled most of the spots 
detected by the un-purified anti-human DWNN antibody. To confirm that the non-
specific proteins were due to the effects of contaminating GSTs, an anti-GST 
antibody was used on Hek 293T proteome. Figure 4.8 also shows that most of the 
protein spots detected by the unpurified anti-human DWNN antibody were human 
GST-related proteins, thus demonstrating that the antibody was also reacting with 
GSTs and related proteins (compare with figure 4.7). Additionally, protein spots 
of approximately 50 kDa were detected with the anti-GST antibody further 
suggesting the non-specificity of the un-purified anti-human DWNN polyclonal 
antibody. 
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Figure 4.8 – 2D Detection of the DWNN domain by partially purified anti-human DWNN antibody and GST-related antibodies by anti-GST antibody: This 
figure shows that a partially purified anti-human DWNN antibody detects a few protein spots that include two spots, 1 of approximately 15kDa and the second one 
of just above 15kDa. The antibody also detected few protein spots between 35 kDa and 70 to 100 kDa range. The anti-GST antibody detects some of the spots 
detected with the DWNN antibody in Hek 293T cells. 
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In figure 4.8, the purified anti-human DWNN antibody detected two protein spots 
at the 15 kDa region where the DWNN was expected to be detected. There were 
two spots, with one just smaller than 15 kDa, suggesting that this 15 kDa spot 
could be a DWNN domain post-translationally modified. To investigate this, the 
DWNN-expressing plasmid was introduced into Hek 293T cells so that the 
DWNN protein would over-express, to determine if the same pattern of protein 
distribution would be evident, thus testing/assessing whether the over-expressed 
protein would have a similar pattern of electrophoretic migration to the two 15 
kDa spots detected by the purified anti-human DWNN antibody. 
 
Figure 4.8 shows that the DWNN domain was positive to anti-DWNN antibody. 
This figure also shows that the DWNN protein exists in two sizes of small 
difference that were migrating at the 15kDa range on the 2D gels. This result 
suggests that these spots were DWNN domain spots with one possibly 
phosphorylated (figure 4.9) or glycosylated (figure 4.10). This figure 
demonstrates that the anti-DWNN antibody does recognize the DWNN domain 
and its related proteins.  
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Figure 4.9 - NetPhos 2.0 server prediction phosphorylation sites in the DWNN 
domain: This figure shows that the DWNN has 10 hot phosphorylation sites as gauged 
by the threshold horizontal line. There are 4 serine, 2 threonine and 4 tyrosine 
phosphorylation sites, making up 10 phosphorylation sites. 
 
 
Figure 4.10 - Glycosylation prediction using a NetGly 1.0 server in the DWNN 
domain: This figure shows the single glycosylation site in the DWNN domain that is 
above the threshold for glycosylation. 
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4.3.5 Identification of the unknown proteins detected by the anti-
human DWNN using Mass Spectrometry 
The mass spectrometric techniques would have been easier if the spots recognized 
by the anti-DWNN antibody were visible on the 2D gels. The Matrix-assisted 
laser desorption/ionization top-of-flight (MALDI-TOF) mass spectrometer at the 
University of the Western Cape had been optimized for Coomassie Blue and 
Flamingo-Pink-stained gels and these were not sensitive enough to detect the 
smaller protein spots. The silver staining method, which is the most sensitive 
stain, could not be used as it was not compatible with the MALDI technique used. 
The protein spots stained with three gradient concentrations of Coomassie Blue 
(to increase visibility of faint protein spots) that were detected by anti-human 
DWNN antibody were excised from the 2D Western blotting. These spots were 
subjected to mass spectrometric analysis (section 3.3.12.8) and this technique was 
chosen to solve the identity of the protein spots unexpectedly detected by the anti-
human DWNN antibody (figure 4.11). 
 
After the protein spots were subjected to MALDI-TOF, peptide masses were 
obtained and were used to search the Mascot server for protein identities. Six 
spots were positively identified. The Mascot server uses Protein score as a -
10*Log (P), where P is the probability that the observed match is a random event 
and Protein scores greater than 67 are significant (p<0.05) 
[http://www.matrixscience.com]. Different spots (figure 4.11A and B) showed 
different results identifying different proteins (figure 4.12), suggesting that the 
DWNN domain may be forming complexes with different proteins and may be 
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either part of the immune system or reacting non-specifically with human IgGs. 
The summary of proteins identified is given in table 4.1. 
 
The MS data showed that the anti-human DWNN antibody may not be detecting 
human GST as suspected. These results suggest a very complex network of 
proteins that the DWNN domain may interact with. Some of the identified 
proteins are hypothetical proteins and some are unknown proteins. Recoverin and 
hypothetical protein XP were identified with the DWNN peptides. This result 
suggests either that the DWNN could be a modifier of these two proteins or these 
proteins are involved in DWNN regulation or there is covalent attachment of 
DWNN to these proteins.  
 
The absence of DWNN peptides in spot 1, identified to contain peptides of 
Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 11 protein 
isoform 4 and unnamed protein, suggests either that the DWNN could be 
modifying these proteins or the DWNN domain is regulated by these proteins, but 
could not identify its peptides may be because this technique is not sensitive 
enough for purposes of the present study. Another possibility is non-specificity on 
the other spots. These results therefore further suggest the possibility of the 
DWNN being a novel ubiquitin-like modifier of the above mentioned proteins.  
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Figure 4.11 – Identification of proteins recognized by the anti-human DWNN antibody: This figure shows several prominent protein spots detected 
by the anti-human DWNN antibody. Figure A shows the number of spots that were subjected to MALDI-TOF because of their reaction with the 
antibody on figure B. 
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Figure 4.12 – Mascot protein scores for protein identification: Figures showing protein scores for the identification of protein identities from the MALDI-TOF 
mass spectrometry. The numbers next to each protein score correspond to spot ID given in figure 4.11 and table 4.1. Two significant protein scores for spot 1 were 
obtained, while spot 2 had 1 significant protein score and so forth. 
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Table 4.1: Identification summary of the protein spots detected by the anti-
human DWNN antibody. 
Spot 
ID 
Accession No. Protein Identification Mowse 
score 
Theoretical 
Mw 
Theoretical 
pI 
Expert 
error 
Sequence 
coverage 
No. Of 
matching 
peptides 
 
1 
NP_001161688 
 
1. Amyotrophic lateral sclerosis 2 
chromosomal region candidate gene 11 
protein isoform 4 
91 45198 Da 6.81 0.00019 49% 13 
16554102 2. Unnamed human protein 81 45189 Da 6.77 0.002 44% 12 
NP_116015 amyotrophic lateral sclerosis 2 
chromosomal region candidate gene 11 
protein isoform 3 
66 62372 5.73 0.071 31% 12 
2 3293409 Immunoglobulin heavy chain FW2-JH 
region 
72 7725 8.07 0.015 52% 3 
3 NP_116015 1. RBBP6 isoform 3 70 13227 9.08 0.034 48% 6 
XP_002342450 
 
2. Hypothetical protein XP_002342450 46 28901 12.07 6.3 34% 4 
4 41393490 Unknown protein 69 13516 6.20 0.029 58% 6 
 
5 
6010164 
 
T-cell receptor delta chain 
 
126 10686 8.59 6.3e-08 80% 7 
221044630 Unknown protein 68 15866 9.34 0.04 35% 5 
6 RECO_HUMAN Recoverin 77 23116 5.06 0.0054 38% 5 
NP_116015 RBBP6 isoform 3 43 13227 9.08 12 21% 4 
BSA ABBOS Bovine serum albumin precursor 77 69225 5.78 0.026 19% 12 
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Chapter Five: Localization and Expression of the DWNN in 
human cancers 
 
5.1 Introduction 
In chapter three, it was demonstrated that DWNN and other RBBP6 variants and 
isoforms are expressed in different human cancer cell lines. In this chapter, 
expression pattern analysis of the DWNN and RBBP6 variants and isoforms was 
investigated using Fluorescent in situ hybridisation (FISH) (section 3.3.10), 
immunohistochemistry (IHC) and immunocytochemistry (section 3.3.9) to detect the 
RBBP6 transcripts and isoforms in situ respectively. A DWNN RNA probe (section 
3.3.10.1-2) and purified DWNN antibodies were used to detect RBBP6 mRNA and 
protein respectively. The variant 3 (figure 2.1A) fragment of the DWNN cDNA was 
cloned into pGEM-T Easy vector and sequenced (Inqaba Biotech. Co, South Africa). 
The antibody that was characterized and purified as reported in chapter four was used 
in the immunohistochemistry and immunocytochemistry experiments.  
 
A DWNN domain coding region was shown to have been successfully labelled with 
digoxigenin (DIG). This probe specifically detects the DWNN containing mRNAs. 
This data is based on BLAST analysis and was used to localize the RBBP6 mRNAs 
in breast cancer, cervical cancer, hepatocellular carcinoma and other neoplasias. An 
anti-human DWNN antibody was used to localize RBBP6 proteins containing the 
DWNN domain in these human cancers. 
 
5.2 The generation and characterization of the labelled DWNN probe and 
specificity  
The DWNN domain coding region was successfully amplified by PCR (section 
3.3.4), cloned into pGEM-T-Easy vector (section 3.3.6) and sequenced (section 
3.3.7). The cloned DWNN fragment was prepared for DIG labelling as described in 
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section 3.3.10.1 and labelled with DIG as described in section 3.3.10.2. The labelled 
RNA probes were then used in both in situ hybridization techniques (ISH and FISH). 
Appendix I1 shows the purification of the DNA fragment that was used for preparing 
the DWNN probes (antisense and sense probes). Figure 5.1B shows the specificity of 
the probe by sequence alignment using BLAST. The sequence alignment shows a 
100% identity to RBBP6 transcripts in the DWNN domain coding region. 
 
5.3 Estimation of the DWNN probe 
The DWNN and control RNA probes were labelled with DIG as described in section 
3.10.1-2 and the concentration of the labelled probes was estimated as described in 
section 3.10.3. Appendix I2 shows the detected probes labelled with anti-DIG Fab 
conjugated to alkaline phosphatase. The bound antibody was visualized with 
NBT/BCIP (purple colour precipitate on the nylon membrane). The labelled RNA 
probes were estimated by comparing the spot intensity to that of the control labelled 
probes (Appendix I2).  
 
5.4 Expression pattern of the DWNN domain containing mRNAs in 
human cancers 
DIG labelled RNA probes were used for the detection of the RBBP6 mRNAs. After 
hybridization, these were then detected using anti-DIG-alkaline phosphatase or anti-
DIG-Flourescein secondary antibodies. The alkaline phosphatase tag is visualised via 
hydrolysis of Nitro blue tetrazolium chloride/5-bromo-4chloro-indolyl phosphate, 
toluidine salt (NBT/BCIP) resulting in purple precipitate, thus indicating a probe-
target hybrid. Using fluorescence microscopy, the anti-DIG-Flourescein is excited at 
a wavelength of 490 nm to emit a green fluorescence at the site of the probe-target 
hybrid.  
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A comparison between the different cancers tested (figures 5.1 to 5.6) shows that 
DWNN-containing mRNAs (RBBP6) are expressed only in small quantities in the 
solid tumours that have been investigated in the present study. This result was 
obtained with both ISH and FISH. ISH and FISH demonstrated little localization of 
RBBP6 mRNA in the cytoplasm and cell surface indicating the position of the 
DWNN mRNAs in these tumours. In the corresponding normal tissues however, the 
DWNN mRNA is expressed by few cells around the island of the tumour, showing 
nuclear staining, while the island of the tumours did not show any staining. 
 
To address the issue of non-specific detection and to establish whether the antisense 
probe was specific, an RBBP6 sense probe was used to determine whether it would 
detect non-specific mRNAs as there was no fluorescent signal. Figure 5.1A shows 
that the sense probe did not detect any mRNA. In oesophageal carcinoma the RBBP6 
gene products have been shown to be highly expressed when compared to normal 
oesophageal cells (Yoshitake et al., 2004). Figure 5.1A shows that there is no 
labelling of RBBP6 mRNAs in oesophageal carcinoma compared to the antisense 
probed oesophageal carcinoma (Fig 5.1B). 
 
In oesophageal carcinoma tissue (a positive control in this study), RBBP6 has been 
reported to be expressed although it is not expressed in normal cells (Yoshitake et al., 
2004). In the present study, RBBP6 mRNA was detected in some nuclei while other 
cells showed cytoplasmic localization of the RBBP6 mRNA; Figure 5.1B shows that 
the positive control had RBBP6 mRNA nuclear localization. This is clearly 
illustrated in figure 5.1B wherein the positive control has cells with nuclear 
localization of RBBP6 mRNA, and cells with cytoplasmic staining for this mRNA. 
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Figure 5.1 – Micrographs showing localization of the RBBP6 mRNAs in oesophageal carcinoma (Sense and antisense): Micrograph A shows a negative 
control with the sense probe showing no staining. Micrograph B shows the localization of the RBBP6 in oesophageal carcinoma where white arrows point to nuclear 
localization, while yellow arrows show cytoplasmic localization in the poorly differentiated tumour of the oesophagus. Stain: Fluorescein isothiocyanate (FITC) 
Magnification: 100X 
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5.4.1 RBBP6 mRNAs in breast carcinoma 
In chapter four, MCF-7 cells were shown to express DWNN and DWNN-containing 
RBBP6 variant 1and 2 mRNAs at low levels. This was also evident in breast tumour 
tissue using both ISH and FISH. With FISH, breast cancer showed very little 
accumulation of the RBBP6 mRNAs in the mass of tumours (Figure 5.2 C), in 
contrast to nuclear accumulation in normal fatty breast tissue (Figure 5.2 B), this 
with reference to sense probed breast tissue (5.2A). Qualitatively this suggests that in 
breast cancers the DWNN-associated RBBP6 mRNA products are down-regulated 
when compared to a normal tissue.  
 
5.4.2 RBBP6 mRNA in hepatocellular carcinoma (HCC) 
Liver tissues (both cancerous and non-cancerous) express the RBBP6 variants and its 
isoforms. In HCC tissue, RBBP6 mRNAs were detected in cellular areas between 
islands of tumours. Figure 5.3C shows that RBBP6 mRNAs were not localized in the 
tumour islands, while areas of tissue adjacent to the tumours show few cells 
localizing the RBBP6 mRNAs. In figure 5.3B some normal hepatocytes show both 
nuclear and cytoplasmic staining for RBBP6 mRNAs. This result contradicts 
previous reports that the liver lacks expression of the PP-R mRNA (Yoshitake et al., 
2004), as well as PACT mRNA (Simons et al., 1997). It is suggested here that the 
localization of PACT is possibly more likely to be DWNN localization, as the PP-R 
was initially thought to lack the 5’ DWNN. Colorimetric in situ hybridization and 
Fluorescence in situ hybridization can be used interchangeably. The latter has been 
reported to be more sensitive (Klinger, 1994) and was therefore used in this study. 
Figure 5.3A shows a negative control which was a HCC tissue probed. The negative 
controls clearly show no labelling. 
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Figure 5.2-Localisation of DWNN-containing RBBP6 mRNAs in Breast cancer: Micrograph A shows the sense probe, which lacks labelling, there was only pale 
background. The two micrographs B and C show a difference in expression and localization of DWNN and RBBP6 mRNAs between normal tissue (B) and breast 
tumour tissue (C). Figure 5.2B shows that RBBP6 mRNAs are localized in the normal tissue. Figure 5.2C shows little cytoplasmic localization of the RBBP6 
mRNAs. In both B and C, white arrows are pointing to labelling. Stain: Fluorescein isothiocyanate Magnification: 40X. 
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Figure 5.3 - Localisation of DWNN-containing mRNAs in HCC using FISH: The normal liver tissue was devoid of staining when a sense 
probe was used (Fig 5.3A). Micrograph B shows some hepatocytes staining positive for the DWNN-containing mRNAs. In contrast, 
hepatocellular tissue (C) some cells stained positively in the tissue adjacent to the island of tumours (T). Magnification: 40X Stain: Fluorescein 
isothiocyanate.  
 
T 
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5.4.3 RBBP6 mRNAs in cervical carcinoma 
The pattern of DWNN-containing RBBP6 mRNAs in cervical carcinoma tissue 
reported previously demonstrated that this gene is down-regulated in cervical 
carcinoma (Ledwaba, 2005). In the present study, there was no detectable 
localization of the RBBP6 mRNAs in the tumour islands. The normal tissue (fig 
5.4B) showed few labelled cells. This result is in agreement with prior studies 
which reported that cervix expresses low levels of RBBP6 (Yoshitake et al., 
2004). In the cervical tumour (T) (figure 5.4C), although tumour cells lacked 
RBBP6 mRNA, some cells in tissue located between the tumour islands were 
positive. 
 
5.4.4 Localization of RBBP6 mRNA in other cancers 
All the human carcinomas observed in this study showed cytoplasmic labelling in 
the normal tissues and normal tumour-associated tissue with no localization of the 
RBBP6 mRNAs in the tumour island itself, either nuclear or cytoplasmic. This 
trend was consistent in the tumours of the stomach, colon, rectum, ovary and 
kidney. Figure 5.5 summarizes the results from these tumours demonstrating a 
common pattern of RBBP6 localization. 
 
The oesophageal tissue (fig 5.5A) showed RBBP6 mRNA localization in the 
normal tissue around the tumour (T) while the sense probed oesophageal tissue 
showed no staining. This was also observed for serous papillary adenocarcinoma 
(Fig 5.5B). In colon cancer most of the RBBP6 mRNAs localized in the 
infiltrating lymphocytes (arrows) situated in the lamina propia. The goblet cells 
and the absorptive cells within the tubular crypts/glands did not show any RBBP6 
mRNA localization. There was no labelling in the tumour tissue (T) (Fig 5.5C). 
Similarly in rectal tissue, there was no labelling of the RBBP6 mRNAs in the 
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rectal adenocarcinoma for this gene. These results suggest that the infiltrating 
lymphocytes are over-expressing the DWNN and DWNN-containing mRNAs to 
aid the immune system in suppressing tumour formation.  
 
Cancer cells are known to express gene products that enable them to evade 
detection by the immune system. Cancer cells are also known to express 
programmed death-1-ligand 1 (PD-L1) that promotes PD-L1-mediated T cell 
apoptosis, thus increasing their chances of survival (Zhang et al., 2008). Greater 
expression of the DWNN mRNAs in lymphocytes may be due to excessive death 
of these cells caused by PD-L1 expression in cancer cells. It was previously 
reported that DWNN-over-expressing infiltrating lymphocytes undergo excessive 
apoptosis, at least in human immunodeficiency virus associated nephropathy 
[HIVAN] kidney tissues (Mbita, 2004). These results and the previous work on 
HIVAN suggest that the lymphocytes may be expressing the DWNN mRNAs as 
part of the apoptotic mechanism that they undergo. Another possible explanation 
is that the DWNN domain could be part of the CTL mediated immune system, as 
the initial studies showed that the knockout of the DWNN resulted in CHO 
resistance to CTL killing (George, 1995). 
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Figure 5.4 - RBBP6 mRNA localization in cervical carcinoma using FISH: This micrograph shows localization of the DWNN-containing RBBP6 mRNAs in 
cervical cancer. The sense control on cervical tissue in micrograph A shows no staining. The normal tissue in micrograph B shows a few positive cells staining. In 
cervical carcinoma (C), island of tumour (T) showed no nuclear localization in contrast to nuclear staining observed in cells found the normal tissue (arrows). 
Magnification 40X Stain: Fluorescein isothiocyanate. 
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Figure 5.5 – Localization of the DWNN-containing mRNAs (RBBP6 mRNA) in different carcinomas: Fig 5.5A shows mRNA localization in oesophageal 
carcinoma with its negative control (sense probed) in fig 5.7D. White arrows point to positive cells for RBBP6 mRNAs in-between the islands of tumour cells (T). 
Fig 5.5B shows cells staining (white arrows) between the tumour islands (T) in ovarian cancer, in contrast to sense probed control ovarian cancer tissue (fig 5.5E). 
Fig 5.5C shows colon cancer cells within the tumour (T) staining negatively, compared to cancer associated tissue in-between the tumours. The sense probed control 
colon cancer tissue (5.5F) showed no labelling. Magnification 40X Stain: Fluorescein isothiocyanate. 
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5.4.5 Quantitative analysis of the expression of DWNN in human 
cancers 
In this study, the FISH technique showed reliability and sensitivity for the 
localization of the DWNN and RBBP6 mRNAs. The numbers of positively 
labelled cells in these tissue areas were counted from the tissue arrays sourced 
from both US Biomax Incl. and Cybrd Tissue Array Tech (USA). Mean averages 
were used from three independent experiments for the above listed cancers and 
their respective normal tissues. A minimum of three images for each tissue was 
taken under 40X objective and subsequently used for these quantifications 
(section 3.3.10.4). 
 
In summary the pattern that was observed in all these cancers was: the absence of 
DWNN and RBBP6 mRNAs in the tumour islands, while the stromal tissue 
between the tumours showed labelling in the cytoplasm of these cells for these 
mRNAs. Interestingly, the tumour associated tissues had few cells staining 
positively for DWNN-containing RBBP6 mRNAs. Figure 5.6 shows the 
quantitative analysis of mRNA localization in the different tissues and in their 
respective tumours. Breast cancer was found to have down-regulated DWNN 
compared to normal breast tissue. The overall pattern that was observed in these 
tumours when FISH was used was a lack of DWNN mRNA expression in 
neoplastic cells. 
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Figure 5.6 – Analysis of FISH results for DWNN mRNA using GraphPad PRISM 5: 
This graph was plotted using the statistical software, PRISM 5 showing the number of 
positive cells (y-axis) in different cancers (Red-Breast, Green-Liver, Blue-Cervix, Purple-
Oesophagus, Yellow-Ovary and Black-Colon) and different areas within the cancer 
tissues (x-axis). The dotted bars show normal tissues and the striped bars showed the 
tumour associated tissue. The graph was plotted with mean ±SE (P < 0.05) from three 
independent experiments. At least 100 cells were counted in each field and this figure is 
accompanied by a column analysis (Appendix M). 
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5.5 DWNN-containing proteins in human cancers 
The correct localization of gene products or cellular molecules is crucial for 
cellular, biochemical and physiological functions of these molecules. One 
example documented by Wang et al. (2001) is that of the p53 protein where its 
nuclear localization is essential for its transcriptional activities that include p53-
dependent cell cycle arrest and subsequent apoptosis. They illustrated that the 
confiscation of p53 by a cytomegalovirus to the cytoplasm after its translation 
negated its cell cycle arrest function (Wang et al., 2001). Essentially, the virus 
sequestered the p53 protein in the cytoplasm through its NLS I resulting in the 
inactivation of p53. This process is dependent on the stage of infection with the 
cytomegalovirus. At stage I and II, partial sequestration occurs while at stage III 
total sequestration occurs. pRb, another important tumour suppressor protein is 
also confiscated in a similar manner to that described for p53 in the same 
situation. It is normally secured by an A-type nuclear lamin to the nuclear matrix, 
where it facilitates its cell cycle control activities and other functions (Markiewicz 
et al., 2002). These examples demonstrate the importance of the appropriate 
localization of a protein to enable it to carry out its function. 
 
It is therefore important to know the localization of the DWNN-containing 
RBBP6 proteins in order to be able to understand its cellular function/s. Different 
human carcinomas and normal tissue controls were examined for the localization 
of the RBBP6. Here, using the purified anti-human DWNN domain antibody, 
RBBP6 protein was found specifically within the cytoplasm of cancer cells. 
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5.5.1 RBBP6 proteins in breast carcinoma 
In breast cancer, the DWNN domain-containing RBBP6 showed cytoplasmic 
accumulation while the normal breast tissue exhibited both cytoplasmic and 
nuclear localization. Figure 5.7 shows a comparison between the normal breast 
tissue section (5.7A) and a breast cancer tissue section (5.7B) where nuclear 
staining is seen in normal tissue (A) as opposed to cytoplasmic localization in 
breast cancer cells (B). The cells surrounding the breast tumour also show some 
nuclear localization. 
 
 
 
Figure 5.7 - Micrographs showing localization of the DWNN domain-containing 
RBBP6 proteins in breast: These micrographs show localization of the DWNN domain 
and its associated proteins in normal breast tissue (A) and in invasive breast carcinoma 
(B). In normal breast tissue (A), there is both cytoplasmic and nuclear localization of 
RBBP6 proteins as demonstrated by the presence of a dark brown precipitate (DAB) 
(black arrows), while this precipitate is confined only to the cytoplasm of the tumour cells 
(B) showing blue nuclei (arrows). Magnification: 100X Stain: diaminobenzidine (DAB); 
haematoxylin. 
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5.5.2 RBBP6 proteins in hepatocellular carcinoma (HCC) 
Hepatocarcinogenesis involves a process where hepatic cells first change into 
intermediate cells that then evolve into HCC. The DWNN domain-containing 
RBBP6 proteins may contribute negatively towards this cancer phenotype either 
by its absence or its suppression. Figure 5.8 demonstrates that the RBBP6 is 
localized in both the nucleus and cytoplasm in normal hepatocytes (A) while the 
hepatocellular carcinoma cells (B) showed heavy localization in the cytoplasm.  
 
 
 
Figure 5.8 - Micrographs showing RBBP6 proteins in normal and HCC tissues: 
These micrographs show immunostaining of normal (A) and hepatocellular carcinoma 
(B) tissues with the DWNN antibody. The DWNN domain and associated protein 
products localized in both the nucleus and the cytoplasm (Black arrows) in normal liver 
tissues (A) while in hepatocellular carcinoma there was significant localization in the 
cytoplasm. The nuclei (blue) stain basophilically (red arrows) with haematoxylin 
counterstaining. Magnification: 100X Stain: DAB; haematoxylin. 
 
5.5.3 RBBP6 proteins in cervical carcinoma 
In a previous study conducted by Ledwaba (2005), RBBP6 showed little nuclear 
localization in normal cervix and no nuclear localization in cervical carcinoma 
(Ledwaba, 2005). In contrast, this study showed that little protein was localized in 
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the cervical cancer cell nuclei (figure 5.9B), when compared to normal cervix 
(figure 5.9A). 
 
 
 
Figure 5.9 - Micrographs showing localization of RBBP6 proteins in cervical carcinoma: 
Normal cervical cells (A) show localization of the DWNN proteins in the nucleus compared to 
cervical carcinoma (B). The nuclei are stained with haematoxylin (Arrows) within the tumour 
island. Magnification: 100X Stain: DAB; haematoxylin. 
 
5.5.4 Localization of the RBBP6 proteins in other human cancers 
The pattern of localization of the DWNN-containing proteins appears to be 
similar in the different tumours examined, with the exceptions of ovarian 
carcinoma and its corresponding normal tissue; these displayed very little 
expression of RBBP6 proteins; and also kidney clear cell carcinoma that showed 
more cytoplasmic expression of the protein. Unlike other normal organs that 
showed nuclear localization of RBBP6 proteins (Figure 5.10A), the normal kidney 
tissue showed a few tubular cells where the cytoplasm stained positive for the 
RBBP6 proteins.  
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In the colon, rectal and stomach adenocarcinomas (Figure 5.10 A and B), there 
seemed to be a down-regulation of the RBBP6 proteins. This was accompanied by 
cytoplasmic accumulation of these proteins, this in contrast to both nuclear and 
cytoplasmic localization in normal tissues. Ovarian cancer (Figure 5.10C) 
displayed no localization of the DWNN and its related proteins. This is shown in 
figure 5.10 A, B and C where normal tissues and corresponding cancers are 
shown. These micrographs show the localization and expression of the DWNN 
domain-containing proteins in cancers and their corresponding normal tissues. 
Negative controls show no localization only the counterstain, haematoxylin. This 
figure shows less localization in the tumour tissues compared to the normal 
tissues. Figure 5.10A shows the localization of the DWNN protein in kidney clear 
carcinoma and stomach adenocarcinoma. Figure 5.10B shows localization of the 
DWNN in rectal and colon adenocarcinoma while 5.10C shows localization in 
ovarian tissues. The cancer cells show no nuclear localization. 
 
Appendix G summarizes the localization of the RBBP6 gene product in different 
human tumours. The overall localization pattern of the DWNN and RBBP6 in 
human cancers was typified by the absence of these proteins in the tumour islands 
and the presence of these proteins in the cells adjacent to the tumours.  
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Figure 5.10 A – Localization of DWNN proteins in different carcinomas: Localization in kidney and stomach with their corresponding cancers and 
negative controls. Magnification: 100X Stain: DAB, Haematoxylin. 
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Figure 5.10B - Localization of the DWNN in rectal and colon adenocarcinoma: Localization of the DWNN in rectal and colon adenocarcinoma and 
their corresponding normal tissues and negative controls. Magnification: 100X Stain: DAB, Haematoxylin. 
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Figure 5.10C - Localization of the DWNN proteins in ovarian papillary adenocarcinoma: Localization of the DWNN in ovarian papillary 
adenocarcinoma and its corresponding normal tissue and negative control. Magnification: 100X Stain: DAB, Haematoxylin. 
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5.6 RBBP6 proteins in human cancer cell lines 
The DWNN domain was also localized using the same antibody used previously, 
in cell lines including, HepG2, HeLa, MCF-7, Hek 293 and CHO (Chinese 
Hamster Ovary) cell lines. The CHO cell line was used as a positive control 
because it is the original cell line that was used in the identification of the DWNN 
domain through promoter trap mutagenesis (Skepu, 2005). The cells were 
incubated with the anti-DWNN polyclonal primary antibody followed by a 
secondary antibody tagged with AlexaRed (3.3.9.2). 
 
Antibody localization demonstrated that the DWNN domain-containing RBBP6 
proteins are confined to the nucleus and cytoplasm of mitotic cells. Apoptotic 
cells also showed up-regulation of these proteins in the cytoplasm. Figures 5.11-
5.15 demonstrate RBBP6 localization in different cell lines. Hek 293T cells are a 
non-cancerous cell line and showed a similar pattern of localization to the cancer 
cell lines (HeLa-cervical cancer, HepG2-hepatocellular carcinoma and MCF-7-
breast cancer). 
 
5.6.1 RBBP6 proteins in CHO cells 
Chinese Hamster Ovary (CHO) cells showed DWNN protein expression as 
expected (figure 5.11), since the DWNN was previously identified in the DWNN 
knock-downs of these cells through promoter-trap mutagenesis (George, 1995). 
This technique resulted in abrogation of apoptosis induced by staurosporine and 
CTL killing. (This was the initial link of this gene to apoptosis).  
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5.6.2 RBBP6 proteins in the HeLa cell line 
Cervical cancer (HeLa) cells do express the DWNN domain-containing RBBP6 
gene products, at least at the mRNA level as demonstrated by FISH and RT-PCR 
(chapter 4). In this cell line RBBP6 exhibited both nuclear and cytoplasmic 
localization in mitotic cells (rearrangement of chromosomes as a marker for 
mitosis, with visible metaphase and anaphase) showing up-regulation of the 
RBBP6. Figures 5.12B and C show localization in the nucleus and the cytoplasm.  
 
5.6.3 DWNN domain-containing proteins in MCF-7 cells 
The panel of DWNN localization in human cancer cells seems to follow a similar 
pattern with both nucleus and cytoplasm staining positive. Breast cancer (MCF-7) 
cells were no exception to this pattern as figure 5.13 shows. The localization was 
the same as with CHO cells and HeLa cells. In figure 5.13 it was observed that the 
mitotic cells (arrows) stained more for the DWNN proteins. 
 
5.6.4 DWNN domain protein localization in HepG 2 cells 
The HepG2 cells showed a similar pattern to that of the other cells where there 
was both nuclear and cytoplasmic DWNN domain-containing RBBP6 
accumulation. Figure 5.14 shows that the dying cells (black arrows) had more 
expression of the RBBP6 proteins. Note that cells that showed cell shrinkage and 
acquisition  of a round small shape were regarded as dying cells and dead cells 
respectively; while those that showed mitotic cells (red arrows) and apoptotic 
bodies also showed higher expression levels of RBBP6 accumulation with 
apoptotic bodies (black arrows). Other cells showed no localization of the RBBP6 
proteins and were regarded as negative (yellow arrows). 
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5.6.5 DWNN domain protein localization in Hek 293T cells 
The localization of the DWNN in Hek 293T cells showed a relatively higher 
expression of the DWNN proteins compared to other cell lines, that is, cancerous 
cells that showed more expression in dying or dividing cells. 293T cells showed 
higher intensity in most of the cells as figure 5.15 shows. 
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Figure 5.11 - Localization of RBBP6 proteins in CHO cells: These micrographs show staining of the CHO cells with anti-human DWNN antibody. Figure 
5.11A shows DNA staining using DAPI. Figure 5.11B shows anti-human DWNN detected by Alexa Red and figure 5.11C shows an overlay of DAPI and anti-
human DWNN. The white arrows indicate mitotic cells that show increased staining levels. Magnification: 40X Stains: Alexa Red and DAPI. 
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Figure - 5.12 - Localization of DWNN-containing proteins in HeLa cells: These micrographs show RBBP6 proteins in situ in HeLa cells. DAPI stain of the nuclei 
is shown by figure 5.12A. Figure 5.14B shows anti-human DWNN detected by Alexa Red and figure 5.12C shows an overlay of DAPI and the white arrows indicate 
mitotic cells at telophase showing increased labelling levels. Magnification: 40X Stains: Alexa Red and DAPI-nuclear stain. 
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Figure 5.13 - Nuclear and cytoplasmic localization of RBBP6 in MCF-7 cells: Figure 5.13 shows a negative control (A), no labelling is seen. Micrographs B and 
C show positive DWNN staining in the nucleus and cytoplasm. White arrows point to mitotic cells with increased DWNN staining levels. Magnification: 40X 
Stains: Alexa Red and DAPI. 
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Figure 5.14 - Immunostaining of the HepG2 cells with anti-human DWNN: These micrographs show the DWNN domain and its related protein 
localization in HepG 2 cells. Cells lacking labelling are indicated by yellow arrows. Localization of the DWNN proteins was up-regulated in mitotic 
cells (red arrows) and dying cells (black arrows), while HepG 2 cells also show both nuclear and cytoplasmic localization. Magnification: 40X Stains: 
DAB and Haematoxylin. 
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Figure 5.15 – Micrograph showing localization of the DWNN in Hek 293T cells: Micrograph (A), negative control. These micrographs (B and C) show 
RBBP6 staining positively in the nucleus and cytoplasm in Hek 293T cells. Micrograph B shows the labelling of these cells for DWNN proteins detected using 
an Alexa Red while micrograph C shows an overlay with DAPI. Magnification: 40X Stains: Alexa Red and DAPI. 
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Chapter Six: The role of the DWNN in apoptosis and cell 
cycle 
 
6.1 Introduction 
In chapters four and five, it was demonstrated that the RBBP6 gene is expressed 
at both mRNA and protein levels in both human tissues and human cancer cell 
lines. There was differential expression and localization of the RBBP6 mRNAs 
and proteins between cancer and normal cells/tissues. Localization studies using 
Fluorescent In Situ Hybridization and immunocytochemistry (chapter 5) revealed 
a differential expression of RBBP6 between normal and cancerous cells. It was 
found that RBBP6 is down-regulated in cancers, while normal cells showed 
nuclear localization of RBBP6 mRNA and proteins. When immunolocalized, 
RBBP6 proteins (chapter five) were found to be up-regulated in mitotic cells, as 
well as apoptotic cells and this prompted an investigation of RBBP6 in normal 
cells. RNA knock-down technology was chosen to further elucidate the function 
of RBBP6 in cell homeostasis and RNA interference (3.3.11) was used to further 
investigate the role of RBBP6. 
 
6.2 Functional studies: summary of the methods 
This chapter addresses the following questions: (1) What would be the effect of 
RBBP6 knock-down in normal human cells (Hek 293T cells)? (2) What would be 
the effect of RBBP6 iso3 over-expression in human cancer cells that had been 
shown to have low expression of the RBBP6 isoforms 1 and 2 and 3? (3) Is there 
is a correlation between the expression of RBBP6, cell cycle and apoptosis 
induction in human cells? 
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6.3 The knock-down of the RBBP6 gene products 
The RNAi of the RBBP6 and the DWNN mRNAs showed that their proteins are 
required for both cell cycle control and apoptosis as previously suggested (Gao 
and Scott, 2002, Gao and Scott, 2003). The Hek 293T cells were used for the 
investigation of the role of the RBBP6 isoforms in human cells, as they were 
shown to express more RBBP6 family members than other cell types here. The 
RNAi constructs were confirmed by both PCR (figure 6.1A); RT-PCR (figure 6.1 
B and C) and real-time PCR (figure 6.2). 
 
The three RNAi constructs were shown to contain the cloned RNAi annealed 
oligos (Appendix D). Figure 6.1 shows the amplification of the annealed oligos 
and the vector control fragments. Lane 1 shows a molecular weight marker; lanes 
2-4 are PCR products from RNAi plasmid DNA (targeting DWNN and RBBP6 
transcripts 1 and 2) and lane 5 shows a PCR product from the vector, pEGFP-C1-
U6, a control vector with random sequence that is not specific to any mRNA. The 
figure shows that the plasmid DNA contained inserts, while pU6GFP had only the 
cloning site and U6 promoter fragments. Lanes 2-4 were pEGFP-C1-U6-
Rb1A/1B/3A PCR products amplified with RNAi colony PCR primers with a 
larger fragment than the EGFP-C1-U6 PCR product, amplified with the same 
primers in lane 5. A negative/Blank control in lane 6 was as expected, with no 
PCR product. 
 
Amplification of the DWNN domain with Iso 3 primers (Appendix C1) showed 
that the RBBP6 variants were knocked down in cells transfected with Rb1A/B and 
Rb3A. Figure 6.1 B shows the efficacy of the RNA interference in knocking down 
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the RBBP6 gene products. Both the RBBP6 mRNA and proteins were 
successfully knocked down when mRNA and proteins extracted from Hek 293T 
cells transiently transfected with Rb3A and Rb1A that were designed to knock 
down RBBP6 transcripts 3 and 1/2 respectively. Both the conventional PCR 
(figure 6.1A) and real-time PCR (figure 6.1B) showed that RBBP6 mRNAs were 
significantly reduced in the knockdown cells compared to untransfected and 
vector control cells. In all three samples, that is, Rb3A, Rb1A and U6GFP there 
was an equivalent amplification of the HPRT1 fragment. This figure demonstrates 
that equal amounts of cDNAs were used in the PCR setup. The real-time data was 
normalized with the hHPRT1 house keeping gene. Western blotting analysis also 
showed reduced expression of RBBP6 proteins (figure 6.1C). This result 
demonstrates that the RBBP6 RNAi constructs were effective in silencing the 
respective RBBP6 transcripts. Both Rb3A and Rb1A reduced the expression of 
the RBBP6 at the mRNA level. Both the vector control or untransfected cells 
(negative control) showed no reduction in RBBP6 transcript expression.  
 
Figure 6.2 shows the efficiency of the transfections of Hek 293T cells using 
Metafectene Pro transfection reagent, by analysing the percentage of cells 
fluorescing green (transfected cells) compared to untransfected cells. The transient 
transfection with RNAi constructs targeting the RBBP6 transcripts was shown to 
be effective and successful. Using the delta Ct value analysis, both DWNN and 
RBBP6 variant 1/2 were knocked down (figure 6.1).  
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Figure 6.1 – Confirmation of the DWNN and RBBP6 transcripts knockdown by RNAi: Figures 6.1 A shows the efficacy of the RNAi constructs in knocking 
down the RBBP6 isoform 3 (Lane 2) and RBBP6 mRNA transcripts (lane3) compared to U6GFP/untransfected Hek 293T cells (Lane 5). Lane 1 shows a molecular 
weight marker while lane 5 shows a blank control (no template DNA). HPRT amplification shows a uniform amplification of HPRT1 fragment of approximately 100 
bp from Rb3A (Lane 2) and Rb1A (Lane 3) knock-downs as well as from a vector control (Lane 4). The blank control was negative on lane 5. Figure 6.1B shows 
detection of RBBP6 mRNA transcripts by real-time PCR, showing significant reduction of both DWNN and RBBP6 mRNA from RNAi knockdown cells (P<0.05). 
Figure 6.1C confirms the reduced protein levels by Western blotting. 
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6.3 The effect of the RBBP6 knock-down in Hek 293T cells 
The RBBP6 gene products are down-regulated in MCF7; HeLa and HepG2 cells 
(see chapters four and five). The Hek 293T cells showed a higher expression than 
the other cells examined (figure 4.2 and 4.5). These cells were therefore suitable 
to study the knockdown of the DWNN domain (Isoform 3), while the MCF-7 cells 
were suitable for the analysis of the DWNN domain over-expression. Previously, 
the mouse RBBP6 homologue, P2P-R was shown to sensitize the MCF-7 cells to 
camptothecin-induced apoptosis (Gao and Scott, 2003) and it was important to 
investigate over-expression of the full RBBP6 isoform 1 and 3/DWNN in these 
breast cancer cells. The P2P-R that was introduced in the MCF-7 cells as reported 
in Gao and Scott study (2003), lacked the N-terminal DWNN domain, hence it 
was important to investigate this in the present study. In addition to the fore-
mentioned suitability of Hek 293T cells, these cells were shown to be less 
sensitive to apoptosis induced by camptothecin (as demonstrated in figure 6.3). 
Hek 293T cells were therefore suitable for the knockdown and over-expression 
studies while the MCF-7 cells were only suitable for over-expression studies. 
Thus the question therefore is, could the DWNN knockdown or its over-
expression sensitise these cells to apoptosis and affect cell cycle regulation? 
 
The Hek 293T cells are resistant to G418 (observed in this study and suggested in 
online forums), hence stable transfections were not achieved for these cells and 
instead transient transfections were done. After 24 and 48 hrs, the transfected cells 
were induced to undergo apoptosis with camptothecin and staurosporine, left for a 
further 24 hrs and then analysed for apoptosis using the APOPercentage assay 
(section 3.3.13.2).  
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Figure 6.2 – RNAi transfections and efficacy in Hek 293T cells: Figure 6.2 shows the 
transfection of the RBBP6 RNAi constructs. The figure shows over 50% transfection 
efficiency for all the constructs (DWNN RNAi, RBBP6 RNAi and U6GFP vector).  
 
Real-time PCR was used to analyse gene expression in knock-down cells; here, 
the increase in Ct values is interpreted as a decrease in the amount of the mRNA 
transcripts in such cells. The absence of the DWNN domain and RBBP6 were 
expected to show effects in cellular homeostasis processes, especially apoptosis, 
since the gene was originally identified as an apoptosis and cell cycle-related gene 
regulator. 
 
The DWNN and RBBP6 mRNA reduction/knock-down did not sensitize these 
cells to camptothecin-induced apoptosis, nor did it enhance resistance to the 
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compound (figure 6.3). Even though there was an observable reduction in the 
staurosporine-induced apoptosis, especially in RBBP6 RNAi reduced/knock-
down cells, the results was expected as the identification of the DWNN was 
initially through its knockout and resistance to staurosporine-induced apoptosis. It 
was noted here that the cells reached confluence faster than un-transfected and 
vector control cells. This result corroborated the results reported for cell labelling, 
as it was observed that the RBBP6 proteins were highly expressed in mitotic cells 
(figure 5.11-5.15), and this suggested that this gene might be involved in cell 
cycle arrest regulation, as its mouse homologue had been reported to play a role in 
cell cycle arrest (Scott and Gao, 2002). Arsenic trioxide had been reported to 
induce G2/M cell cycle arrest and apoptosis in human lung cancer cells (Ge-ping 
et al., 2009). The question therefore was, did the knock-down of the RBBP6 
mRNAs have an effect on arsenic trioxide-induced apoptosis and cell cycle arrest? 
Figure 6.3 shows that the knockdown of the DWNN/RBBP6 did not sensitise the 
Hek 293T cells to apoptosis, but on the contrary reduced the cells’ sensitivity to 
both staurosporine and arsenic trioxide-induced apoptosis. This result suggests 
that the absence or low expression of DWNN/RBBP6 favours the resistance to 
apoptosis and deregulation of cell cycle. It was thus important to study the role of 
the DWNN in the events of the cell cycle. 
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Figure 6.3 – Effect of the RBBP6 knock-down in apoptosis: Showing the RBBP6 RNAi effect on apoptosis in Hek293T cells. The figure shows apoptosis induced 
by camptothecin, staurosporine and arsenic trioxide, data presented as FACS histograms (A) and GraphPad Prism analyzed (B). Figure 6.3B shows that the apoptosis 
induced with arsenic trioxide was significantly reduced (P < 0.05) when both DWNN and RBBP6 were knocked-down. Staurosporine-induced apoptosis was also 
reduced but not significantly. 
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6.4 Cell cycle analysis of the DWNN domain in human cells 
In chapter five, cell labelling showed that the RBBP6 proteins are highly 
expressed at the G2/M phase of the cell cycle. Figure 6.4 confirms that the 
DWNN is a cell cycle regulator as the cell cycle analysis in Hek 293T cells 
showed that the expression of the DWNN is induced only in G2/M. Western blot 
analysis shows deglycosylation and/or dephosphorylation of the DWNN/Isoform 
3, since this particular isoform was prominent after the cells have been arrested at 
the G2/M transition. This result suggests that the 13 kDa isoform 3 and its 
deglycosylation and dephosphorylation are required for the G2 cell cycle arrest. 
The treatment of Hek 293T cells with 12.5 μM arsenic trioxide causes cell cycle 
arrest and so increased the population of cells that were in the G2 phase to 50% 
after 24 hours, while 3 μM did not show an increase in the G2 cell population. In 
cells where the RNA knockdown of the DWNN/isoform 3 occurred, a significant 
decrease in the population of cells at G2/M phase was seen at both concentrations. 
Western blot analysis showed that this form of induced cell cycle arrest is 
accompanied with up-regulation of the DWNN domain and appearance of the 13 
kDa DWNN domain that appears to be both deglycosylated and 
dephosphorylated. 
 
RBBP6 seems likely to be a player in this pathway (Gao and Scott, 2002), the 
effects of the RBBP6 isoform 3/DWNN over-expression in Hek 293T cells on p53 
was determined. Figure 6.5 showed that over-expression of DWNN (fig 6.5A) 
resulted in p53 stabilization (fig 6.5B). Figure 6.5C shows that the same quantity 
of lysates was loaded for both untransfected Hek 293T cells and transfected Hek 
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293T cells. This result suggests that DWNN cell arrest is likely to be in a p53-
dependent manner. 
 
Figure 6.4 – DWNN involvement in Cell cycle regulation: This figure shows that arsenic 
trioxide-induced cell cycle arrest at G2 is dependent on the presence of the DWNN/Isoform 
3. FACS data (A) shows that As2O3 induces cell arrest at G2 at 12.5μM concentration and 
this arrest is DWNN dependent. DWNN knockdown decreased the As2O3 effect. Figure 6.4B 
shows that As2O3 up-regulated the DWNN/isoform 3 in wild type cells. Figure 6.4C shows a 
loading control (Actin). 
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Figure 6.5 – RBBP6 isoform 3, a p53 stabilizer: This figure shows the over-expression 
of the DWNN in Hek 293 (A) and up-regulation of p53 in DWNN over-expressing cells 
(B). Figure 6.5C was an actin Western blot as a loading control. 
 
6.5 Over-expression of the RBBP6 gene products in human cancer cells 
and related apoptosis 
In chapters three and four, the MCF-7 cells were demonstrated to express RBBP6 
gene products at low levels. Solid tumour cells have previously been shown to 
respond to arsenic trioxide treatment and this toxic compound has been suggested 
as a potential drug for solid cancers (Jiang et al., 2010a, Siu et al., 2002, Zang et 
al., 1999, Zhou et al., 2008). Arsenic trioxide had been shown to cause cell cycle 
arrest in cancer cells at the G2/M phase and additionally induces apoptosis in a 
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cell cycle specific gene-dependent manner (Ling et al., 2002, Xie et al., 2002). 
Figure 6.4 showed that the DWNN domain is one of the cell cycle related gene 
products and DWNN is also induced by arsenic trioxide treatment. Figure 6.5 
showed that the DWNN over-expression resulted in p53 stabilization. 
 
Two stable MCF-7 cell lines expressing the DWNN domain and RBBP6 isoform 
1 were established and analyzed for arsenic trioxide-induced cell cycle and 
apoptosis susceptibility using propidium iodide, MTT and APOPercentage 
assays. Figure 6.6 shows the over-expression of both the DWNN domain and 
RBBP6 isoform 1 in MCF-7 cells and the effect of these proteins in arsenic 
trioxide-induced-apoptosis using APOPercentage and cell viability using MTT 
and apoptosis.  
 
The MTT assay (figure 6.7) showed that over-expression of the DWNN domain 
did not significantly decrease the percentage of viable cells compared to 
untransfected and vector control cells when treated with 50 µM Camptothecin. 
The RBBP6 isoform 1 caused a significant decrease in the percentage of viable 
MCF-7 cells when treated with the same concentration of camptothecin compared 
to untransfected and vector control MCF-7 cells.  
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Figure 6.6 – Over-expression of the DWNN/Isoform 3 and RBBP6 proteins in MCF-
7 cells: Two figures demonstrating over-expression of a 15 kDa DWNN domain and a 
250 kDa RBBP6 isoform 1 proteins (A) in MCF-7 cells. The beta actin antibody (B) was 
used as a loading control. 
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Figure 6.7 – The MTT viability assay in DWNN/Isoform 3 and RBBP6 isoform 1 
expressing MCF-7 cells: This figure shows the MTT viability assay in MCF-7 cells 
over-expressing DWNN domain and RBBP6 isoform 1. The control cells (untransfected 
and vector transfected cells) were treated together with the transfected cells with arsenic 
trioxide, camptothecin and staurosporine. The graph was plotted with mean ±SEM (P < 
0.05) from a mean of three independent experiments. 
 
The treatment of the MCF-7 cells expressing DWNN/Isoform 3 and RBBP6 
isoforms 1 with 3µM arsenic trioxide showed interesting results. The cells 
expressing the DWNN domain cells did show a decrease in viable cells but the 
cells over-expressing the RBBP6 bigger isoform 1 showed large decrease in the 
percentage of viable cells. This result was somewhat expected, as arsenic trioxide 
was shown here to induce G2/M cell cycle arrest and up-regulation of the DWNN 
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domain/isoform 3 (figure 6.4). This result suggests that the DWNN is indeed a 
G2/M cell cycle regulator while the RBBP6 isoform 1 and possibly isoform 2 are 
involved in the mitotic apoptosis in humans, as previously reported for the murine 
P2P-R (Gao and Scott, 2002, Gao and Scott, 2003).  
 
Over-expression of both the DWNN/Isoform 3 and RBBP6 isoform 1 did not 
cause resistance to staurosporine-induced apoptosis, but rather showed a one-fold 
decrease of viable MCF-7 cells. This result suggested that these two molecules 
may both be involved in staurosporine-induced cell cycle regulation. The question 
that followed then was whether the DWNN/isoform 3 and RBBP6 isoform 1 
sensitized MCF-7 breast cancer cells to apoptosis induced by these compounds. 
Camptothecin, arsenic trioxide and staurosporine were next used to treat the stable 
population of transfected MCF-7 cells and to assess them for apoptosis sensitivity 
using APOPercentage analysis. Figure 6.8 shows the effect of the over-expression 
of the DWNN/Isoform 3 and RBBP6 isoform 1 in MCF-7 in each of As2O3, 
camptothecin and staurosporine induced apoptosis, respectively.  
 
The RBBP6 isoform 1 sensitized the MCF-7 cells to camptothecin- (figure 6.8A), 
staurosporine- (figure 6.8B) and As2O3-induced (figure 6.8C) apoptosis. The over-
expression of the DWNN domain did not sensitize the MCF-7 cells to either 
camptothecin or staurosporine-induced apoptosis, but did significantly sensitize 
the MCF-7 cells to As2O3-induced apoptosis. The RBBP6 isoform 1 caused an 
over two-fold increase of apoptosis compared to control cells. Following this, the 
next question to be addressed was; whether As2O3 causes induction of the DWNN 
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domain expression in HeLa and HepG2 cells, if these cells are sensitized to 
apoptosis. 
 
Figure 6.9A shows that 3µM As2O3 treatment induced an increase in the 
expression of the DWNN/Isoform 3 in the MCF-7, HeLa and HepG2 cells after 24 
hours. Unlike the situation seen in normal Hek 293T cells, where the DWNN was 
dephosphorylated and/or deglycosylated (figure 6.4), in the above mentioned 
cancer cells the induced DWNN was phosphorylated and/or glycosylated. The 
difference between the DWNN concentrations in cancer and normal cells may 
partly determine the mechanisms of how cancer cells avoid cell cycle control. The 
induction of DWNN expression was not associated with increased apoptosis 
actively, but was associated rather with the G2/M cell cycle arrest that As2O3 
induces after 24 hours. Figure 6.9C showed that the population of apoptotic cells 
increased in all cancer cell lines after 48 hours of treatment with As2O3, when 
compared to apoptosis after 24 hours (figure 6.9B). These results further 
corroborate previous reports that documented the use of As2O3 in cancer therapy 
(Lu et al., 2007, Shen et al., 1997). This data also suggests a use for the 
DWNN/Isoform 3 and RBBP6 isoform 1 in cancer treatment. 
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Figure 6.8 – Apoptosis in the DWNN/Isoform 3 and RBBP6 isoform over-expressing MCF-7 cells: These figures show apoptotic induction by Camptothecin 
(A), staurosporine (B) and As2O3 (C) in MCF-7 cells that express the DWNN and RBBP6 isoform 1. The graph was plotted with mean ±SEM (P < 0.05) from a 
mean of three independent experiments for each compound. The DWNN domain does not show an apoptosis sensitizing effect in camptothecin and staurosporine-
induced apoptosis. In arsenic trioxide-induced apoptosis both the DWNN and RBBP6 isoform 1 in MCF-7 cells resulted in a one fold and a threefold increase 
respectively. 
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Figure 6.9 - The induction of the DWNN domain/Isoform 3 expression and Arsenic trioxide-induced apoptosis: These figures show the induced expression of 
the DWNN in MCF-7, HeLa and HepG2 cells (Figure 6.9A) after 24 hours (B) and 48 hours (C). Figures 6.9B and C show graphs with mean ±SEM (P < 0.05) from 
a mean of three independent experiments of arsenic trioxide in these cell lines. The percentage of apoptotic cells increased over 48 hour period but the DWNN 
expression was induced within the 24 hour periods. 
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Chapter Seven: General discussion 
 
7.1 Introduction 
After many years subsequent to its discovery, DWNN has no defined function that 
can be stated conclusively. This study was directed at determining the role of this 
protein in mammalian cells by firstly examining the ubiquitin-like nature of the 
DWNN through the combined use of proteomics, Western blotting analysis and 
MALDI-TOF mass spectrometry. Additionally, DWNN was also localized in 
human cancers, specifically breast cancer, hepatocellular carcinoma and cervical 
carcinoma. Finally functional studies including RNA interference and over-
expression were used here to elucidate the role(s) of DWNN in the cell cycle, 
apoptosis and carcinogenesis. 
 
This study shows that in humans, RBBP6 multiple splice variants are involved in 
the suppression of cellular proliferation and are inactivated by cell cycle 
dependent phosphorylation. RBBP6 has been reported to interact with two tumour 
suppressors, p53 and pRb (Sakai et al., 1995, Simons et al., 1997) and this 
interaction suggests an involvement of this gene in cell homeostasis, since these 
two tumour suppressors play a role in cell turnover. Previous studies have 
attempted to decipher the role of the mouse RBBP6 homologues (Gao and Scott, 
2002, Gao and Scott, 2003, Li et al., 2007a, Scott et al., 2003, Scott and Gao, 
2002, Scott et al., 2005, Witte and Scott, 1997, Yoshitake et al., 2004), all 
reporting a role in the cell cycle and apoptosis regulation. Currently, while there is 
little information regarding the RBBP6 human counterpart, it would be logical to 
postulate a similar role for RBBP6 in humans as that for mice, wherein P2P-R is 
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involved in both apoptosis and cell cycle (Gao and Scott, 2002, Gao and Scott, 
2003, Scott and Gao, 2002). Furthermore, the human RBBP6 was reported to have 
ubiquitin ligase activity through its RING finger domain (Chibi et al., 2008) and 
Yb-1, which has been reported to be a proliferation gene, at least in breast cancer 
cells (Basaki et al., 2010, Takahashi et al., 2010, Yu et al., 2010), and was shown 
to be one of the RBBP6 targets for ubiquitination (Chibi et al., 2008). Similarly, 
the Drosophila counterpart SNAMA was also shown to possess E3 ubiquitin 
ligase activity through its RING finger domain and additionally proved to be an 
apoptosis suppressor (Mather et al., 2005).  
 
Recently it was reported that the mouse homologue, P2P-R binds SRC-1 
transcription co-regulatory factor (steroid receptor co-activator-1) wherein its 
over-expression represses oestrogen-induced transcription, while its knock-down 
increased oestrogen-mediated transcription (Peidis et al., 2010). It was reported 
that over-expression of SRC-1 contributes to cell growth of human cancer cells, 
for example, MCF-7, breast cancer cells and SCC, cells derived from squamous 
cell carcinoma, in an oestrogen (E2)-dependent manner and may thus be involved 
in breast cancer tumourigenesis (Hudelist et al., 2003, Ku and Crowe, 2007, Tai et 
al., 2000). In this regard, oestrogen was reported to induce tumourigenesis by 
targeting tumour suppressor genes, for example, Protein Tyrosine Phosphatase, 
PTPRO (Ramaswamy et al., 2009). This evidence further links RBBP6 
involvement to tumourigenesis in humans. It should be mentioned that all of these 
reports present data concerning the larger RBBP6 products, with only very limited 
data concerning RBBP6 isoform 3 (DWNN), which has a ubiquitin-like fold 
(Pugh et al., 2006). 
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7.2 DWNN and its RBBP6 family relatives in human cancers 
7.2.1 RBBP6 transcripts 
In chapters four and five it was demonstrated that DWNN and RBBP6 gene 
products are down-regulated in human cancers. Figure 4.1 demonstrated that 
RBBP6 binding domains form part of the RBBP6 mRNA product and the 
amplification of a wild-type domain sequence suggested that this gene may not be 
the target of the mutagenesis that is often involved in cancer development. 
Previously it was shown that the two RBBP6 transcripts 1 and 2 (due to 
alternative splicing) are equally expressed in normal human cells (Mbita, 2004). 
In the present study however, using RT-PCR and real-time PCR (Figure 4.2), it 
was shown that human cancer cells generally have a low expression of the 
DWNN and RBBP6 transcripts, compared to non-cancerous cells. The exception 
to this was the high expression of the DWNN and RBBP6 transcripts seen in 
Jurkat cells. The reason for this result is unknown but this may imply that DWNN 
and RBBP6 play no role in the development of T cell leukaemia. It has previously 
been reported that DWNN is involved in CTL killing and its knock-down resulted 
in resistance to CTL killing and staurosporine-induced apoptosis (George, 1995). 
The low expression of the DWNN and RBBP6 reported here, with the exception 
of Jurkat cells, may facilitate the evasion of cell cycle control and subsequent 
apoptosis in cancer.  
 
7.2.2 RBBP6 isoforms 
It was previously reported that the DWNN domain shared a 22 % similarity with 
ubiquitin and has a similar tertiary structure to that of ubiquitin (Pugh et al., 
2006). Another important point is the presence of a highly conserved glycine 
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residue at the carboxyl terminus of the DWNN domain, analogous to that seen in 
ubiquitin. This conserved residue is required for covalent modification of targets 
for known modifiers but is not always the sole determinant (Wilkinson et al., 
2004), further suggesting that the DWNN domain may be involved in ubiquitin-
like modifications. It should be mentioned that ubiquitin-like proteins do not 
require a high sequence similarity to ubiquitin to possess ubiquitin like activities, 
for instance SUMO shares only 18 % sequence similarity (Buschmann et al., 
2001), while DWNN shares 22% sequence similarity (Pugh et al., 2006). 
 
The anti-human DWNN antibody used here detects two proteins, an 
approximately 250 kDa protein (isoform 1 and 2) and another protein of 
approximately 15 kDa (RBBP6 isoform3/DWNN domain). In the characterization 
of the anti-human DWNN polyclonal antibody, it was observed that the antibody 
reacted strongly with a protein of approximately 120 kDa (figures 4.3, 4.4 and 
4.5). This could either be due to degradation of the 250 kDa RBBP6 protein 
products that also contain the DWNN domain, or that the DWNN domain is 
attached to a high molecular weight protein, or that this represent a truncated 
RBBP6 isoform 1 and/or 2 protein. The degradation theory seemed unlikely 
because gel electrophoresis and Western blot analysis (figures 4.3, 4.4 and 4.5) 
showed intact protein bands at 120 kDa with no evidence of degradation. Figure 
4.1 suggested no evidence of truncating mutations in the sequenced RBBP6 
domains. A polyclonal anti-PACT antibody had been reported to detect a full 250 
kDa protein (Simons et al., 1997). This pointed to the second possibility that the 
DWNN domain is associated with a high molecular weight protein. This provides 
further credence for the nature of the DWNN domain as a modifier of other 
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proteins, binding to proteins and potentially facilitating the ubiquitination of these 
proteins. Two-dimensional Western blot analysis, using a purified antibody (see 
figure 4.9), suggests that DWNN may target more than one protein for 
modification. 
 
Further to this, as Pugh et al. (2006) resolved the DWNN structure as a ubiquitin-
like protein (UBL) [figure 7.1] and sequence similarity to ubiquitin, it was 
predicted that DWNN may be tagged to other proteins, as are many other UBL 
proteins (Kirkin and Dikic, 2007, Liao et al., 2010a). Indeed, in the present study 
the use of a polyclonal anti-human DWNN antibody confirmed that DWNN was 
attached to other proteins (figures 4.3 to figure 4.8) and could be described as 
“DWNNylation”. The Western blotting analysis using both 1D and 2D gel 
electrophoresis further implicated an association of DWNN with other proteins 
and moreover that DWNN is a likely UBL modifier, being able to target more 
than one protein for modification.  
 
The low protein expression levels reported here reflects the aforementioned low 
transcript levels. High quantities of protein samples had to be loaded to allow for 
Western analysis and detection. Secondly, the DWNN domain is bound to other 
proteins, as urea extraction facilitated the detection of the DWNN domain as 
shown in figure 4.5 and figure 4.7 and could be detected on the 2D Western Blots. 
RBBP6 isoform 3 may therefore be considered as a ubiquitin-like domain protein 
(UDP), which may be responsible for either degradation of other proteins or their 
stabilization. The latter seemed more possible since the 120 kDa protein was a 
very stable and consistent protein product across all of the cell lines (figure 4.3 to 
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4.8). Several other UBL proteins have been described that are either for 
degradation or stabilization (see table 7.1 in the following page). These ubiquitin-
like modifiers have a wide range of roles in cell homeostasis (table 7.2) and this 
study suggests a new ubiquitin-like modifier, DWNN to add to this list, which is a 
G2/M cell cycle regulator (chapter six). The DWNN may still have many 
substrates that require further characterization. From the additional results of the 
present study, especially analysis with MALDI-TOF Mass spectrometry, these 
substrates may include Recoverin and Hypothetical protein XP_002342450 and 
possibly many more (Table 4.1). As already mentioned in earlier chapters (chapter 
two and six) the RBBP6 gene encodes the DWNN and the two larger isoforms, 1 
and 2. The latter two may be ubiquitin ligases and/or even ambitiously “DWNN” 
ligases, all of which would require further investigation.  
 
Table 7.1: Ubiquitin and ubiquitin-like proteins. 
(Kirkin and Dikic, 2007) 
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Figure 7.1 – Structural and key amino acid similarities between ubiquitin and DWNN: Figures 7.1 A and B show the determined structure of the DWNN 
while figure 7.1 C shows the structures of Ubiquitin (Blue) and DWNN super-positioned (Yellow). Figure 7.1D shows sequence alignment of the DWNN and 
ubiquitin showing the highlighted amino acid residues that are important for ubiquitination and possible “DWNNylation”. An extract from Pugh et al., 2006. 
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Table 7.2: Ubiquitin-like protein modifiers, substrates and their functions. 
(Herrmann et al., 2007) 
 
 
In addition to the involvement of the DWNN in protein modifications, DWNN is 
itself posttranslationally modified, as shown in figures 4.7 and 4.8; here, the 
DWNN domain is present in both post-translationally modified and un-modified 
forms, these as such include both phosphorylation and glycosylation respectively. 
Figure 4.10 suggested that the other spots in 2D Western blotting analysis were 
GST related proteins, whiles the 2 spots in the 15 kDa region shown in figure 4.8, 
are likely to be DWNN domains. Bioinformatics analysis using Expasy 
confidently predicted that these 2 spots are DWNN products with one being 
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posttranslationally modified and one un-modified DWNN respectively. Figure 4.9 
showed that the DWNN domain had predicted phosphorylation sites when a 
NetPhos 2.0 server on Expasy was used to predict this (Blom et al., 1999). Even 
though there are more phosphorylation (figure 4.9) than glycosylation sites (figure 
4.10), figure 4.10 suggests that this variation may also be due to glycosylation. On 
2D gel electrophoresis, phosphorylation of a particular protein results in protein 
spots that migrate horizontally at different levels, with no size difference, while 
glycosylation results in size differences. The two protein spots detected at 15 kDa 
are therefore most likely due to glycosylation of the DWNN domain in human 
cells. Transfection of MCF-7 cells with the wild-type DWNN domain, as well as 
mutant form in the post-translational site, can further increase the understanding 
of this novel domain protein in cell homeostasis and carcinogenesis. The use of 
arsenic trioxide resulted in the appearance of a 13 kDa protein (discussed in 
section 6.4) suggesting that a DWNN function is post-translationally regulated by 
both glycosylation and phosphorylation.  
 
Using yeast-two-hybrid studies and immunoprecipitation Chibi et al. (2008) 
demonstrated that RBBP6 isoform 1 and 2 are E3 ubiquitin ligases by virtue of 
possessing a RING finger domain. They showed that RBBP6 ubiquitinated its target 
Yb1 (Chibi et al., 2008). The Drosophila RBBP6 homologue was shown to also have 
a ubiquitin ligase activity (Antunes, 2009, Mather et al., 2005), however the SNAMA 
DWNN domain is not a stand-alone protein domain as is its human counterpart. To 
date, this is the only work to our knowledge that has attempted to investigate the 
UBL nature of the DWNN. 
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Other factors associated with cell proliferation and survival are the Vav family of 
proteins (Madureira et al., 2005, Miller et al., 2005). RBBP6 has been involved 
with the ubiquitination of Vav2 and has thus been implicated in cancer cell 
signalling in pancreatic cancer cell lines (Thalappilly et al., 2008). The ubiquitin-
like functions of DWNN may be implicated in the suppression of cancer 
initialization. The implication of RBBP6 in the ubiquitination of Vav proteins 
may also actually be DWNNylation of Vav2 by the RBBP6 E3 ligase.  
 
The role of the DWNN and RBBP6 is more complex than initially thought. The 
RBBP6 isoforms 1 and 2 have previously been shown to induce or at least play a 
role in the intrinsic apoptotic pathway (Gao and Scott, 2002, Gao and Scott, 2003, 
Scott and Gao, 2002). Even though Pugh et al., (2006) demonstrated that the 
DWNN has a ubiquitin-like fold, there is to date no data showing that the DWNN 
behaves like ubiquitin in human cells (Pugh et al., 2006). The human DWNN is 
the only RBBP6 family protein that exists as a single domain protein. The 
Western blot analysis and MALDI-TOF mass spectrometry showed that the 
DWNN is associated with other proteins (Figures 4.11, 4.12 and table 4.1). The 
100kDa spot (spot 1 in table 4.1) did not possess any DWNN peptides, but was 
identified as Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 
11 protein isoform 4. This result could not be explained since there were no 
associated DWNN peptide masses, likewise for the spot representing the T-cell 
receptor delta chain. However it cannot be ruled out that these are also targets for 
“DWNNylation”. Two proteins that were found to be associated with the RBBP6 
isoform 3/DWNN peptides are Recoverin (Spot 6 in table 4.1) and Hypothetical 
protein XP_002342450 (spot 3 in table 4.1). This result further implicates the 
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DWNN as a novel ubiquitin-like protein that interacts with Recoverin and 
Hypothetical protein XP_002342450. 
 
7.3 DWNN, a novel ubiquitin-like protein (UBL) 
This study has further strengthened the possibility that the DWNN domain is a 
ubiquitin-like protein that has a role in cell cycle regulation. It has been well 
documented that these ubiquitin-like proteins can either contribute to protein 
degradation or stabilization. In this study it was demonstrated that the DWNN is 
associated with other proteins (Table 4.1). Using Western blotting analysis, 2D 
gel electrophoresis and MALDI-TOF Mass Spectrometry this study showed that 
the DWNN may be conjugated to other proteins to either increase their stability or 
degradation or for other biological functions so far un-elucidated. Unfortunately 
there is no available information regarding the Hypothetical protein 
XP_002342450, but the result showing that the DWNN is associated with 
Recoverin was very interesting. 
 
7.3.1 Recoverin 
Recoverin, a neuronal calcium binding protein is predominantly found in 
photoreceptor cells. Recoverin plays a role in the inhibition of rhodopsin kinase 
and is consequently involved in the regulation of rhodopsin phosphorylation 
(Sanada et al., 1996, Senin et al., 2004). As mentioned in this study DWNN, was 
found to be associated with this protein (Table 4.1) and is suggested to be a 
stabilizer of Recoverin. DWNN (in this study) and Recoverin have been shown to 
suppress cell proliferation, at least in the lung cancer cells, A549 cells (Maeda et 
al., 2000) and in gastric cells (Ohguro et al., 2004). The observed cell growth 
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inhibition by the DWNN (figure 6.7 to 6.9) may thus be associated with DWNN 
and Recoverin interactions. Additionally, over-expression of the DWNN in Hek 
293T cells resulted in the stabilization of p53, with no p53 being detected in wild 
type cells (figure 6.5). This growth inhibition by the DWNN may be p53-
dependent, involving Recoverin as well. Even though p53 was not identified as a 
target of possible “DWNNylation” in the MALDI-TOF mass spectrometry 
experiment, over-expression of the DWNN strongly suggests that the DWNN may 
be a p53 stabilizer. There may be more proteins that are DWNN targets since the 
anti-human DWNN antibody showed both laddering and scattering on 1D and 2D 
Western blot analysis respectively. 
 
7.3.2 Immune system components 
As previously mentioned, DWNN was first identified through genetic screening 
aimed at identifying novel components of the antigen processing and presentation 
pathway via major histocompatibility class I (MHC class I) molecules (George, 
1995). This initial study showed that somatic cell mutants lacking DWNN were 
resistant to cytotoxic T cell killing (George, 1995). A more recent study 
demonstrated that mutant Chinese Hamster Ovary (CHO) cells lacking the 
DWNN protein product were also resistant to staurosporine-induced apoptosis 
(Pretorius, 2007). These studies therefore demonstrated that the DWNN protein is 
important in cell death. The reaction of the anti-human DWNN antibody to 
protein spots identified using MALDI-TOF MS but lacking RBBP6 isoform 3 
peptides, suggests that the DWNN may be targeting many proteins, or is itself 
targeted by many proteins. Reaction to Immunoglobulin heavy chain FW2-JH 
region may either be interpreted as non-specific, or alternatively the DWNN 
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forms complex with these immunoglobulins. Pull-down assays with the DWNN 
will help to resolve the understanding of these complex interactions.  
 
This study has shown that the DWNN is expressed more by the T-lymphocytes, 
especially in the tumour stroma. This result further implicates the involvement of 
the DWNN in Cytotoxic lymphocyte induced cell killing and this corroborates the 
initial finding that the CHO cells lacking the DWNN were resistant to CTL 
killing. The high expression of the DWNN and its RBBP6 relatives in 
lymphocytes found in colon tissues (chapter five) further suggests the 
involvement of the RBBP6 gene products in cytotoxic lymphocyte killing.  
 
7.4 Localization of the DWNN and RBBP6 gene products 
In chapter one and two it was mentioned that apoptosis is inhibited in the process 
of carcinogenesis and apoptosis regulators are deregulated in cancer cells. Since 
RBBP6 homologues from other organisms have been implicated in RNA 
processing (Vo et al., 2001), cell cycle regulation (Gao and Scott, 2002, Gao and 
Scott, 2003) and ubiquitin ligase activities (Pugh et al., 2006), RBBP6 may be a 
target of this deregulation in cancer progression, as its expression pattern changes 
in human cancers. Moreover, alterations of its expression in different cell states 
also argue well for its involvement in carcinogenesis and apoptosis. 
 
Real-time PCR (chapter four) FISH, IHC and ICC (chapter five) all demonstrated 
that RBBP6 is down-regulated in human cancers at both mRNA and protein 
levels, respectively, especially in breast cancer. Down-regulation of this gene at 
both levels suggests that its impeded role favours carcinogenesis, or is at least pro-
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cell survival and proliferation. This study found that RBBP6 gene products 
accumulate in the nucleus in normal tissues, while cancer tissues exhibit a 
somewhat consistent pattern of expression in which RBBP6 gene products either 
translocate to the cytoplasm, or are completely absent. Thus deregulated RBBP6 
may be involved in carcinogenesis. Apoptosis is certain a gene-regulated 
mechanism and down-regulation and nuclear-cytoplasmic translocation of RBBP6 
in human cancers suggests the RBBP6 product as being one of the gene products 
that is targeted in tumourigenesis. 
 
RBBP6 protein products are nuclear proteins that are required for apoptosis and 
cell cycle regulation. Localization of the DWNN domain in cells revealed that the 
DWNN domain and its RBBP6 isoforms are localizing in the nucleus in viable 
human cells, while apoptotic and mitotic cells showed higher accretion of these 
proteins in both the cytoplasm and the nucleus. A mouse homologue of RBBP6, 
P2P-R has been reported to be involved in mitotic apoptosis and apoptosis in 
general (Gao and Scott, 2002, Gao et al., 2002). In all the human cell lines that 
were investigated in this study the RBBP6 was up-regulated in dividing cells and 
dying cells, thus pointing to its involvement in cell cycle regulation and apoptosis. 
It is suggested that RBBP6 products are likely involved in cell cycle check points 
and apoptosis that normally follows when the cells are damaged beyond repair. 
 
Localization and cell staining for RBBP6 suggest involvement in carcinogenesis, 
cell cycle regulation and apoptosis. RBBP6 homologues have been previously 
implicated in mitosis and apoptosis (Scott and Gao, 2002). Therefore it is fitting 
to suggest that the DWNN domain and its RBBP6 isoforms are important in cell 
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homeostasis and cell regulation and are involved in the carcinogenesis in different 
organs and tissues. It was observed that at both mRNA and protein levels, MCF-7 
cells had low expression of the gene and gene products. Recently, it was reported 
that the RBBP6 co-repress oestrogen receptor-alpha (ER-α) in rat adipocytes and 
mouse eye tissues where oestrogen-induced transcription occurs (Peidis et al., 
2010). In this study, the tissue that showed the highest expression of the DWNN 
mRNA was in normal adipose tissue, which suggests that this gene is also tissue 
specific. Cytoplasmic localization of the gene was expected to be similar to the 
reported murine P2P-R localization which showed heterogeneous nuclear 
ribonucleoprotein (hnRNP)-related protein (Witte and Scott, 1997) which is 
known to shuttle between the nucleus and the cytoplasm (Piñol-Roma and 
Dreyfuss, 1993). The identification of recoverin as a potential regulator of the 
DWNN or target for DWNNylation is very interesting and requires further 
analysis. 
 
7.5 The role of the RBBP6 proteins in cell cycle and apoptosis 
In chapter six, the results of this study suggested that deglycosylation and 
dephosphorylation of the DWNN domain/RBBP6 isoform 3 may be required for 
G2/M cell cycle arrest. Two-dimensional gel electrophoresis and Western blotting 
showed that the DWNN domain is both glycosylated and phosphorylated, two 
post-translational modifications that may allow the cells to progress through the 
cell cycle. The abolition of both may result in increased cell cycle arrest and 
consequently, apoptosis.  
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RBBP6 isoforms 1 or 2 are possible tumour suppressors since over-expression of 
isoform 1 of the RBBP6 protein sensitized cancer cells (HepG2 and MCF-7) to 
apoptosis. Interestingly, isoform 1 also sensitized non-malignant cells, human 
embryonic 293T cells, to apoptosis induced by Camptothecin and arsenic trioxide. 
Gao and Scott (2003) showed that over-expression of the mouse P2P-R lacking 
the DWNN domain promoted Camptothecin-induced apoptosis in MCF-7 cells. 
Similarly, the use of the full human RBBP6 isoform 1 in this study had the same 
effect. This result further implies that the DWNN domain may not be necessary 
for apoptosis, but important for cell cycle regulation. 
 
Arsenic trioxide induces G2/M cell cycle arrest and enhances Chk2/p53-mediated 
apoptosis (Yoda et al., 2008). Induced expression of the DWNN by arsenic 
trioxide further suggests the involvement of the DWNN in arsenic trioxide 
induced G2/M cell cycle arrest and possibly apoptosis in a p53-dependent and 
independent manners. In p53 compromised states, arsenic trioxide can cause cell 
abnormalities that may lead to carcinogenesis (Liao et al., 2010b). 
 
7.5.1 Arsenic trioxide in phosphorylation and DWNN function 
Arsenic compounds can interfere with the phosphorylation and dephosphorylation 
processes by replacing the phosphate groups in the biochemical pathways (Xie et 
al., 2002). The treatment of the 293T cells with arsenic trioxide resulted in the up-
regulation of the RBBP6 isoform 3 (DWNN) and dephosphorylation of the 
DWNN domain as observed by the existence of the 13 kDa DWNN in figure 6.4. 
This up-regulation was accompanied by the stabilization of the p53 tumour 
suppressor (figure 6.5). The DWNN may influence the cell cycle arrest in a p53-
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dependent manner. The dephosphorylation was not observed in the human cancers 
(figure 6.9A) even though arsenic trioxide treatment resulted in the up-regulation 
of the DWNN. This suggests that the DWNN is de-regulated in human cancers, 
possibly through its post-translational modification. While the exact mechanism 
that As2O3 uses to induce cell cycle arrest and apoptosis remains unclear, cell 
cycle and apoptosis regulators have nevertheless been reported to be regulated by 
this compound (Xie et al., 2002). The DWNN domain can certainly be added to 
this list of cell homeostasis regulators. 
 
Figure 5.4A showed that the knock-down of the DWNN domain resulted in the 
reduction of G2/M population after the arsenic trioxide treatment, indicating that 
the DWNN domain is required for the G2/M cell cycle arrest and may be 
important in p53 regulation. Casitas B-lineage Lymphoma (Cbl) has been shown 
to also play a role in regulation of the G2/M cell cycle arrest. Treatment of gastric 
cancer cells with arsenic trioxide up-regulated Cb1 proteins and increased the 
G2/M cell populations (Li et al., 2009d). This effect was reported to be due to 
PI3K/Akt inhibition by Cb1 in a p53-dependant manner. These findings are 
similar to the findings of this study and raise a possible link of the DWNN in 
PI3K/Akt signalling pathway in cancer development. Arsenic trioxide has been 
reported to induce or up-regulate cell cycle and cytotoxic related functional genes 
(Zhao et al., 2008). Arsenic trioxide induced DWNN up-regulation further 
substantiates the implication of DWNN as a cell cycle regulator. 
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7.6 Summary of the study 
Using a real-time PCR technique in chapter 4, it was demonstrated that the breast 
cancer cell line, MCF-7 had low levels of DWNN expression at both the mRNA 
and protein levels. In chapter 5, using FISH, it was shown that the DWNN-
containing mRNAs were not expressed in the islands of tumours, while the adjacent 
tumour associated tissues included cells that were positive for DWNN-containing 
mRNAs. 
 There were no mutations or short nucleotide polymorphisms (SNPs) when 
different RBBP6 binding domains were investigated as a target for 
mutagenesis, a process that is often involved in carcinogenesis. Figure 4.1 
showed that the RBBP6 transcripts are fully expressed in human cell lines 
even though the amplification of the RING finger, RbBD and p53BD 
required nested PCR before a PCR product could be observed in the 
human cancer cell lines. 
 
 Hek 293T cell line and MCF-7 cell lines were found to be the best suited 
for the RNA interference and DWNN and RBBP6 isoform 1 over-
expression studies respectively. This was investigated in chapter six. 
 
 The anti-human DWNN antibody, after affinity purification was shown to 
detect the RBBP6 protein products including the DWNN domain under 
denaturing conditions. The data presented with this antibody corroborated 
with the RT-PCR and real-time PCR data in that the MCF-7 cells were the 
low expressers of the RBBP6 gene products. It would be very informative 
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if a non-cancerous breast cell line could be used for the comparison of the 
DWNN and RBBP6 expression. 
 
The DWNN domain was found to be possibly a ubiquitin-like modifier of proteins 
that were tabulated in table 4.1, these being identified here using MALDI-TOF 
MS. One of the interesting proteins identified with MALDI-TOF was Recoverin, 
which has been implicated in human cancers. Reaction of the antibody to 
immunoglobulins suggests non-specificity or that the DWNN forms part of the 
immune system. 
 
Figures 5.2-5.5 showed that the islands of breast, cervix, liver and other cancers 
lacked expression of the DWNN mRNAs. The corresponding normal tissues had 
few cells that were positive for RBBP6 gene products. Interestingly there were 
cells that were positive for this gene’s mRNAs in the tissue associated with 
(surrounding) the tumours, which suggests that the gene may be a possible 
inhibitor of cell proliferation and carcinogenesis within the surrounding tissue. 
This result suggests possible functions for DWNN protein and gene products in 
the initialization of carcinogenesis and further indicates an involvement of the 
DWNN in tumourigenesis. As seen in figure 5.6, in all the cancers that were 
investigated, DWNN mRNAs were significantly reduced in the tumours (p < 
0.05). Since RBBP6 homologues from other organisms have been implicated in 
RNA processing (Vo et al., 2001), cell cycle regulation (Gao and Scott, 2002, Gao 
and Scott, 2003) and ubiquitin ligase activities (Pugh et al., 2006), RBBP6 may be 
deregulated in human cancers, especially as it had been reported that its murine 
homologue was found to be up-regulated in oesophageal cancer cells (Yoshitake 
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et al., 2004). In this chapter it was found that the DWNN mRNA was up-regulated 
in the tumour associated stromal tissue, but not in the islands of tumours. These 
results additionally suggest that the DWNN probe can be used as a diagnostic 
marker for cancer development and possibly staging, of these cancers at least. 
These results also affirm the sensitivity of FISH over chromogenic in situ 
hybridization. 
In chapter three, the DWNN antibody was shown to detect many proteins, most 
likely because the DWNN has a ubiquitin-like-modifier. Cancer tissues stained 
positively for the DWNN-containing proteins, even in the tumour islands. The 
DWNN may thus be a stabilizing protein rather than a destructive protein, but also 
may stabilize undesired proteins. Some ubiquitin-like modifications are not ideal 
for cell homeostasis; Sumo1, for example, post-translationally modifies VHL 
through the action of the protein inhibitors of activated STAT y (PIASy), a Sumo 
E3 ligase (Cai et al., 2010b). This modification negates the inhibitory function of 
the VHL tumour suppressor on tumour growth, migration and clonogenicity.  
 
Immunonohistochemical staining of human cancers with the anti-human DWNN 
antibody demonstrated discriminative staining between the cancers and their 
corresponding normal tissues. Figure 5.7A showed both nuclear and cytoplasmic 
staining in the normal breast tissue while the tumour tissue showed much 
increased cytoplasmic staining, this being restricted to the tumour island (Figure 
5.7B). This result is in contrast to mRNA localization, which was absent in the 
tumour islands (Figure 5.6). Figure 5.8 A and B showed the same localization 
pattern in hepatocellular carcinoma where nuclei in the islands of tumours (figure 
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5.8 B) were negative compared to diffuse staining in the nuclei and cytoplasm of 
the normal tissues. Cervical cancer (figure 5.9), adenocarcinomas of the stomach, 
rectum and the colon (figure 5.10) also showed differential staining between the 
cancer tissue and their corresponding normal tissues. The kidney clear cell 
carcinoma displayed more staining than the normal kidney tissue and overall the 
ovarian tissues generally had a low expression DWNN-proteins over. 
RBBP6 protein products are nuclear proteins that are required for apoptosis and 
cell cycle regulation. Cell staining (5.11-5.15) revealed that the DWNN domain 
and its RBBP6 isoforms are localized in the nucleus in viable human cells, with 
apoptotic and mitotic cells showing higher accretion of these proteins in both the 
cytoplasm and the nucleus. A mouse homologue of RBBP6, P2P-R has been 
reported to be involved in mitotic apoptosis and apoptosis in general (Scott and 
Gao, 2002). In all the human cell lines that were investigated in this study, the 
RBBP6 was up-regulated in dividing cells and dying cells and this points to its 
involvement in cell cycle regulation and apoptosis. RBBP6 products should be 
involved in cell cycle check points and apoptosis that normally follow when the 
cells are damaged beyond repair. 
 
The localization and cell staining for RBBP6 suggest involvement in 
carcinogenesis, cell cycle regulation and apoptosis. RBBP6 homologues have 
been previously implicated in mitosis and apoptosis (Scott and Gao, 2002). 
Therefore it is fitting to suggest that the DWNN domain and its RBBP6 isoforms 
are important in cell homeostasis and cell regulation and are involved in the 
carcinogenesis in different organs and tissues. 
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The construction of RNAi molecules was successful and their effectiveness in the 
cells was also clearly demonstrated. The RBBP6 cloned RNAi molecules were 
found to be very specific to their targets and this provided a useful means of 
investigating the involvement of the DWNN domain and the RBBP6 transcripts, 
1, and 3 in cell cycle control and apoptosis. RT-PCR and real-time PCR (figures 
6.1 and 6.2) were used to show the knock-down of the RBBP6 variants by the 
RNAi constructs.  
 
Transient transfection (+/-50%) of the Hek 293T cells with RNAi constructs did 
not sensitise these cells to camptothecin-induced apoptosis. As shown in Figure 
6.3, the knock-down of the RBBP6 isoform three and isoform 1/2 favours an anti-
apoptotic fate for the cells. This result suggests that cancerous cells might abolish 
the expression of this gene, if their excessive proliferation agenda is to be met. 
Figure 6.4 demonstrated that the DWNN is a G2/M cell cycle phase specific gene 
product. Figure 6.4 also demonstrates that arsenic trioxide, a cell cycle arrestor, 
induces the DWNN expression. The stabilization of p53 by the DWNN domain 
shown in figure 6.5, further suggests that this protein product will modify other 
proteins, thus suggesting that cell cycle arrest caused by DWNN is in a p53-
dependent manner. RNAi of p53 or alternatively use of a p53 negative cell line 
will confirm this result. 
 
This chapter also documented the establishment of the MCF-7 cells over-
expressing DWNN domain and RBBP6 isoform 1 (figure 6.6). The MCF-7 cells 
over-expressing RBBP6 have been previously shown to be sensitized to 
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camptothecin-induced apoptosis (Gao and Scott, 2003). MCF-7 cells over-
expressing RBBP6 were also shown in the present study to have been sensitized 
to camptothecin, staurosporine and arsenic trioxide-induced apoptosis (figure 5.7 
and 6.8). The DWNN domain over-expressing MCF-7 cells were shown to have 
been sensitized to arsenic trioxide-induced apoptosis. This result further 
implicates the DWNN domain as a ubiquitin-like protein specific to cell cycle 
regulation. The DWNN domain was further shown to be a possible target during 
carcinogenesis since G2/M cell cycle arrest induced in non-carcinogenic cells, 
Hek 293T cells, was accompanied by dephosphorylation and deglycosylation of 
the DWNN, but not in the cancer cells tested (figure 6.9A), where this molecule 
remained phosphorylated and glycosylated. The induction of the DWNN 
expression in arsenic trioxide-treated cells was shown to be an early event (figure 
6.9B) and increased levels of apoptosis (figure 6.9C) were not necessary for the 
DWNN domain induction. 
 
The data presented in this study shows that the DWNN domain is a cell cycle 
regulator, while the RBBP6 isoforms 1 and 2 are probably key players in cell 
cycle-mediated apoptosis as previously shown for the murine RBBP6 homologue. 
 
7.7 Conclusions 
 It is very important to note that the function of a gene may also be determined 
by the environment and species that the gene is expressed in. This is no 
exception for the RBBP6 gene: while in mice the evidence suggests a role as 
an anti-apoptotic gene, in humans, the data presented in this study suggests a 
pro-apoptotic function for this gene. 
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 Using RT-PCR and real-time PCR it was found that the DWNN and RBBP6 
gene products are down-regulated in human cancer cells. This was 
corroborated by the Western blotting results, wherein human cancers 
preferentially lacked expression of the DWNN domain.  
 
 Through the use of 1D and 2D gel electrophoresis and MALDI-TOF mass 
spectrometry, it was shown that the DWNN domain is a ubiquitin-like 
modifier that DWNNylates other proteins, in particular Recoverin and 
possibly p53, for purposes of stabilization. 
 
 Cancer is characterized by the loss of cell cycle control and resistance to 
apoptosis. DWNN and RBBP6 gene products were found to be down-
regulated in human tumours at least at the mRNA level. FISH, showed that 
DWNN and RBBP6 may be involved in carcinogenesis. 
 
 Cell staining implicates a requirement for that the DWNN and RBBP6 
proteins in cell cycle regulation in human cells. In this regard, the DWNN 
may be both hyperphosphorylated and hyperglycosylated to evade its effect 
of cell cycle regulation. Use of RNAi for knockdown of DWNN resulted in 
high proliferation rates; while conversely, over-expression of the DWNN 
resulted in inhibited growth. This was substantiated by the induced DWNN 
expression when cell growth was inhibited by arsenic trioxide treatment. It 
was previously thought that RBBP6 isoform 1 and 2 were responsible for 
RBBP6 cell cycle and apoptosis regulation. This study however showed that 
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the DWNN, the smallest RBBP6 family member, is responsible for the cell 
cycle regulation and may be a key cell cycle progression regulator in a p53-
dependent manner. 
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Appendices 
 
Appendix A: Stock solutions recipes 
 
Note: The working solutions were diluted down to the desired concentrations with DEPC-treated 
water or sterile distilled water. It was stated when a different solvent was used. 
 
10x TBE: 0.9 M Tris, 0.89 M boric acid and 25 mM EDTA, pH 8.3. This stock solution was 
diluted 1/10 for the electrophoresis of agarose and polyacrylamide gels. 
10x TE: 100 mM Tris-HCl (pH 7.5); 10 mM EDTA 
4 Stacking gel Buffer: 0.5 M Tris-HCl, pH 6.8 
10x SDS Electrophoresis buffer: 250 mM Tris, 10 % SDS and 1.92 M glycine, pH 8.3 
6 Glycerol BPB Gel-loading Buffer: 30 % glycerol, 0.3 % Bromophenol blue and 0.3 % Xylene 
cyanol. 
12 Separating gel Buffer: 1.5 M Tris-HCl, pH 8.8. 
10x MOPS: 200 mM 3-[N-mophonolino] propane sulphuric acid (MOPS), 50 mM sodium acetate, 
10 mM EDTA. 
0.5% Acetic Anhydride: Dilute to 5% using 100 mM Tris pH 7.5, just before use. 
Ammonium persulphate: A 10 % stock solution was prepared in deionised water. This solution 
was stored at 4 C. 
Ampicillin: A 100 mg/ml stock solution was prepared in 70% ethanol and filter-sterilised using a 
0.22 micron filter and stored at –20C. 
Camptothecin Stock Solution: A 14.35X103 µM stock solution was prepared in DMSO; filter-
sterilized and stored at –20 ºC in aliquots (0.5 ml). 
Coomassie Staining Solution: 0.25% Coomassie Brilliant Blue R 250, 45 % methanol and 5 % 
acetic acid. 
0.1%v/v DEPC treated water: Diethylpyrocarbonate (DEPC) was diluted in a litre of dH2O and 
incubated at 37°C with shaking and then autoclaved. 
Destaining Solution: 30 % methanol and 10 % acetic acid in dH2O. 
DTT (Dithiothreitol): A 1 M stock solution was prepared in 0.001 M Sodium acetate, pH 5.2. 
This solution was sterilised by filtration (0.22µm filter), aliquoted and stored at –20 C. 
40% Dextran (w/v): Dextran sulphate sodium salt was dissolved in DEPC water by heating in a 
68°C water bath for 3-four hrs. This was filtered (0.2µM) and aliquoted and stored at 4°C. 
2D Equilibration Buffer: 6 M Urea, 2% SDS, 0.05 M Tris pH 8.8 and 20% glycerol. 
Hybridisation buffer (ISH): 2 X SSC, 10% Dextran, 0.2% SDS, 50% formamide and up to a 
required volume with DEPC water. Store as aliquots at -20°C. 
IPTG: A 1 M stock solution was prepared in sterile deionised water. The solution was further 
sterilised by filtration; stored in aliquots at – 20 C. 
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Luria Broth: 10 g/l Tryptone, 5 g/l Yeast extract and 5 g/l NaCl and 2 g/l glucose in distilled 
water. 
Lysis Buffer: PBS containing 1 % Triton X-100 and protease inhibitor cocktail tablet (Roche 
Diagnostics, Germany). 
PBS, pH 7.4: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.4. 
PCR reaction buffer: 50 mM Tris-HCL (pH 9.0), 50 mM NaCl and 5 mM MgCl2. 
0.2 M Phosphate buffer: 23 mM Na2HPO4 and 77 mM NaH2PO4 in DEPC treated water. 
PI Master Mix: 100 μg/ml RNAse, 40 μg/ml propidium iodide in PBS. 
PMSF: A 10 mM stock solution was prepared in isopropanol. The solution was aliquoted and 
stored at –20 C. 
Propidium Iodide staining solution: 1 mg/ml in 3.8 mM sodium citrate. 
Protein Elution Buffer: 10 mM glutathione and 50 mM Tris-HCl, pH 8.0. 
10 mg/ml Proteinase K: 10 mg Proteinase K was dissolved in DEPC treated water and stored in 
100 µl aliquots. 
RIPA Buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1 tablet of total protease inhibitors (Roche 
Diagnostics, Germany), 1% Triton X-100, 1% Sodium deoxycholate. 
2X Sample buffer: 100 mM Tris pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol blue and 
10 mM DTT. 
20x SSC: 3 M NaCl and 0.3 M Tri-sodium Citrate in DEPC treated water. Adjust to pH 7.0 with 
HCl and autoclave. 
Staurosporine: A 2 mM concentration was made in DMSO 
TBS: 20 mM Tris-HCl and 150 mM NaCl, pH 7.4. 
TBS-MT: 5% Low fat dried milk powder and 0.1% Tween 20 in TBS. 
TBS-T: 0.1% Tween 20 in TBS. 
Tfb1 Buffer: 30 mM Potassium acetate, 50 mM MnCl2, 0.1 M KCl, 6.7 mM CaCl2 and 15% 
glycerol (v/v). 
Tfb2 Buffer: 9 mM MOPS, 50 mM CaCl2, 10 mM KCl and 15% glycerol (v/v). 
Transfer Buffer: 25 mM Tris, 192 mM glycine and 20 % methanol. 
TYM Broth: 20 g/l Tryptone, 5 g/l Yeast extract 3.5 g/l NaCl and 2g / MgCl2 
Urea extraction buffer: 9 M Urea, 2 M ThioUrea, 4% CHAPS. 
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Appendix A2: Reagents 
Chemicals and suppliers 
Absolute ethanol Merck KGaA, Darmstadt, Germany 
Acetic Anhydride Reidel-de Haen, Seelze (Hanover), 
Germany 
40% 37.5:1 Acrylamide:bis-acrylamide BioRAD, Hercules CA, USA 
Agarose Promega, San Luis CA, USA 
Ammonium persulphate Merck KGaA, Darmstadt, Germany 
Ampicillin Fermentas, Maryland, USA 
Bacteriological agar Merck KGaA, Darmstadt, Germany 
Boric acid Merck KGaA, Darmstadt, Germany 
Bovine serum albumin V Roche, Mannheim, Germany 
Bromophenol blue Sigma, Munich, Germany 
Camptothecin Merck KGaA, Darmstadt, Germany 
Chloroform Merck KGaA, Darmstadt, Germany 
Coomassie Brilliant Blue R 250 Sigma, Munich, Germany 
DAPI (4’, 6’-diamidino-2-phenylindole) Sigma, Munich, Germany 
DMSO (Dimethyl sulphoxide) Sigma, Munich, Germany 
Diethylpyrocarbonate Sigma, Munich, Germany 
DTT (Dithiothreitol) Sigma, Munich, Germany 
EDTA (Ethylene diamine tetra acetic acid) Merck KGaA, Darmstadt, Germany 
Entellan Merck KGaA, Darmstadt, Germany 
Ethidium bromide Sigma, Munich, Germany 
Glacial acetic acid Merck KGaA, Darmstadt, Germany 
Glucose Merck KGaA, Darmstadt, Germany 
Glycine Sigma, Munich, Germany 
Hydrochloric acid Merck KGaA, Darmstadt, Germany 
IPTG (Isopropyl -D-thiogalactopyranoside) Fermentas, Maryland, USA 
Methanol Merck KGaA, Darmstadt, Germany 
MOPS (4-Morpholine propanesulphonic acid) Sigma, Munich, Germany 
Paraformaldehyde Sigma, Munich, Germany 
PMSF (phenylmethylsulphonyl fluoride) Roche, Mannheim, Germany 
Poncheau S Sigma, Munich, Germany 
Premixed Protein marker Fermentas, Maryland, USA 
Proteinase K Roche, Mannheim, Germany 
PVDF (Polyvinylidene difluoride)membrane Roche, Mannheim, Germany 
SDS (Sodium dodecyl sulphate) Sigma, Munich, Germany 
Sodium hydroxide Merck KGaA, Darmstadt, Germany 
Staurosporine Roche, Mannheim, Germany 
TEMED (N, N, N’, N’-Tetra methylethylene-
diamine) 
Promega, San Luis CA, USA 
Tris (Tris[hydroxymethyl] aminoethane) Merck KGaA, Darmstadt, Germany 
Tri-sodium Citrate B&M Scientific cc., SA 
Triton X-100 (iso-octylphenoxypoly-ethoxyethanol) Sigma, Munich, Germany 
Trypsin Invitrogen, Paisley, UK 
Tryptone Sigma, Munich, Germany 
Tween 20 (Polyoxyethylene [20] sorbitan) Sigma, Munich, Germany 
Urea Merck KGaA, Darmstadt, Germany 
Xylene Merck KGaA, Darmstadt, Germany 
Xylene Cyanol BDH, Leicestershire, UK 
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Appendix A3: Equipment 
Equipment Manufacturer 
Power Pac HC 300W BioRAD, Hercules CA, USA 
MiniOpticon  BioRAD, Hercules CA, USA 
LightCycler 1.5 Roche, Mannheim, Germany 
Thermocycler 2700 Applied Biosystems, Foster City CA, USA 
Beckon Dickson Flow Cytometer BD, Oxford, UK 
Lab Rotator Digisystems Laboratory Instruments Inc., Taipei 
Hsien, Taiwan 
Labotec Laminar Flow Labotec, Midrand, South Africa 
Forma Range CO2 Incubator Forma Scientific, Marietta OH, USA 
Thermo Fisher Incubator Shaker Thermo Fisher Scientific Inc., Asheville NC, USA 
NanoDrop ND1000 NanoDrop technologies, Wilmington DE, USA 
BioRAD Gel Doc XR system BioRAD, Hercules CA, USA 
Eppendorf 5415D microfuge  Eppendorf, Cambridge, UK 
Axio Scope Microscope Carl Zeiss, Munich, Germany 
Hybaid OmnSlide Flat Block Hybaid Ltd., Cambridge, UK 
IEF Focusing Machine BioRAD, Hercules CA, USA 
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Appendix C, primer sets 1-6: Different primer sets, sequences, product sizes and pGEM T Easy vector 
PRIMER SETS PRIMER SEQUENCES AMPLICON PRODUCT SIZE 
 
1 
Iso3 Forward: 
Iso3 Reverse or 
RT-RBBP6 F 
RT-RBBP6 R 
 5΄GGTCCTTCGGTGTCTTTG 3΄  
5΄AGGTGACGGTATCATAGTTG 3 ΄  
5΄GCATTATCATCAGTATATTCTTCTTTCG 3΄ 
5΄ GGCTCCACATCTCCCTCTG 3΄ 
 
 
DWNN Fragment 
 
128 bp  
 
200 bp 
 
2 
Iso2&1 Forward 
Iso2&1 Reverse 
5 TTGGACCGTCTGAATGAAC 3 ΄  
5΄TGGAACTTGAATACTCTCTGG 3΄ 
RBBP6 Transcripts 1 
and 2 fragments 
 
200bp 
 
3 
RING F 
RING R 
 5 GCTGGATCCCCTCCCTTCTTACCAGAG 3΄ 
5 GCTCTCGAGTCATTACTGTTTTCGTAGTCTTTTTG 3΄ 
RBBP6 RING FINGER  
300bp 
 
4 
RbBD F  
RbBD R 
5΄GAGGCGGGATCCACAGGTGTTGAAGAAAATAAAACAGAC 3 ΄  
5 GAGGCGCTCGAGTTATCATTTGACATCTTTGGAATAGTCCTTCTT 3΄ 
 
RBBP6 RbBD 
 
500bp 
 
5 
ABI F 
ABI R 
5 GAGGCGGGATCCAGCACTCAGCCAGAGAAAGAGAGT 3΄ 
5 GAGGCGCTCGAGTTATCAGCTGTCCTGACTTTCTGCTGAGCT 3΄ 
 
RBBP6 p53BD 
 
914bp 
 
6 
Fc primer 
Rc primer 
5’CTGCGTTATCCCCTGATTCTGTG 3΄ 
5’ GTAACGCGGAACTCCATATGG 3΄ 
 
RNAi Vector primers 
 
517bp 
7 hHPRT1 F 
hHPRT1 R 
5’TGACACTGGCAAAACAATGCA 3΄ 
5’GGTCCTTTTCACCAGCAAGCT 3΄ 
Housekeeping gene 
primers 
200bp 
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Vector map 1: pGEM-T Easy 
 
pGEM-T Easy vector: This pGEM-T Easy vector map shows the different restriction 
endonucleases cut/digest sites in the pGEM-T Easy multiple cloning sites (MCS). This vector was 
used for the insertion/cloning of PCR products of the RBBP6 domains for sequencing. This vector 
map was obtained from Promega, USA, (www.promega.com). 
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Appendix D: A table showing different RBBP6 RNAI oligos, annealing of oligos and RNAi vector 
Table 1: RBBP6 RNAi oligos 
Oligos Oligo sequence 
 
Rb1AF 
  Bgl II 
5΄ GATCCCCTCAAGACTTGGTTCAACACGTTCAAGAGACGTGTTGAACCAGATCTTGATTTTTGG AAA 3΄ 
Rb1AR  Hind III 
5΄AGCTTTTCCAAAAATCAAGATCTGGTTCAACACGTCTCTTGAACGTGTTGAACCAGATCTTGAGGG 3΄ 
Rb1BF    Bgl II 
5΄GATCCCCTCTCCCTATAGTGGTTCTTCGTATTCAAGAGATACGAAGAACCACTATAGGGAGATTTTTGGAAA 3΄ 
Rb1BR  Hind III 
5΄AGCTTTTCCAAAAATCTCCCTATAGTGGTTCTTCGTATCTCTTGAATACGAAGAACCACTATAGGGAGAGGG 3΄ 
Rb3AF     Bgl II 
5΄GAT CCC CTC TCA CAC TTT TTC TAC ACA TTG CTT CAA GAG AGC AAT GTG TAG AAA AAG TGT GAG ATT TTT GGA AA 3΄ 
Rb3AR   Hind III 
5΄AGC TTT TCC AAA AAT CTC ACA CTT TTT CTA CAC ATT GCT CTC TTGAAG CAA TGT GTA GAA AAA GTG TGA GAG GG 3΄ 
Table showing the different RBBP6 RNAi oligos where different regions are coloured with different colours, sense target sequence (red); loop region (blue) and antisense target sequence 
(green). 
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RNAi oligo designing 
RNAi oligos were designed using Ambion search engine: 
http://www.ambion.com/techlib/misc/siRNA_finder.html. The following parameters were set 
when searching for the silencing fragments: 
1. Standard start with two AA residues/nucleotides on the 5ʹ end. 
Standard ends with two TT residues/nucleotides on the 3ʹ end. 
2. Length should be 19 to 25 bp 
3. Avoid stretches of TT or AAs nucleotides longer than two. 
4. GC content between 30 and 70% (Preferably between 40 and 60) 
5. Choose 3 or more targets 
6. Search for a pattern: AA-[N]19-TT. 
7. Insert cloning restriction sites (Hind III and Bgl II were used). 
The resultant hits were blasted against NCBI database: 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm the targeted sequences. 
 
Table 2: Cloning of the annealed RNAi oligos. 
Reaction component Final Quantity 
RNAi vector 10ng 
RNAi annealed oligos 10pmol of each 
2X Ligation buffer (Promega) 1X 
T4 Ligase 3u 
A summary of the steps required for the cloning of the annealed oligos. 
NOTE: RNAi vector was pEGFP-C1-U6 vector as shown in vector map 2 below. The cloned 
RNAi constructs were sent for sequencing to Inqaba Biotech, Pretoria, and SA. 
 
Vector map 2: pEGFP-C1-U6 vector 
 
 
pEGFP-C1-U6 vector: The MCS was replaced with the U6 promoter containing with Bgl II and 
Hind III sites flanking a random a random sequence for cloning of the annealed RNAi oligos 
downstream the U6 promoter. The random sequence in-between the two cloning sites was used as 
a control. Fc/Rc primer sites are also available for colony PCR screening. This map was obtained 
from Pretorius et al. (2007). 
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Appendix E: Vector maps 3-5 
 
Vector map 3: pGEX 6p-2 vector 
 
 
pGEX 6p-2 vector: The pGEX-6p-2 vector is characterized by its PreScission Protease 
recognition site for the cleavage of the GST tag from the fussed protein fragment or domain. The 
multiple cloning sites facilitate the cloning of the fragment to be recombinantly expressed. This 
vector map was obtained from www.gelifesciences.com. 
 
Vector map 4: pGFP-DWNN-13 
 
pGFP-DWNN-13: This vector shows a DWNN-13 fragment cloned between Bgl II and Sal I sites 
in the multiple cloning sites of the pGFP-C1 vector. This expression is under the CMV promoter 
that is downstream of the GFP. This vector map is a modification of a map obtained from 
www.clontech.com.  
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Vector map 5: pDsRed1-C1-DWNN-200 
 
pDsRed1-C1-DWNN-200: This figure shows the DWNN-200/RBBP6 isoform 1 cloned between 
the Bgl II and Sal I sites of the MCS and the expression is driven by a CMV promoter. DWNN-
200 is RBBP6 isoform 1 and not 2. This vector map is a modification of a map obtained from 
www.clontech.com. 
Appendix F: Supporting tables 
Table 3: Template preparation for reverse transcription. 
Total RNA  1 µg 
Oligo dT15 0.5 µg 
Nuclease free H2O Up to 5 µl 
Final reaction volume 5 µl 
 
Table 4: Cocktail of the reverse transcription (RT) mix. 
 Volume  Final concentration 
5x Improm II reaction buffer 4 µl 1x 
Magnesium chloride (25 mM) 5 µl 5 mM 
dNTP mix 1 µl 0.5 mM each dNTP 
Recombinant RNAsin (40 u/μl)  0.5 µl 20 u 
Nuclease free water - Up to 15 μl 
Improm II Reverse transcriptase (1 
u/µl) 
1.0 µl 1 u 
Final Volume 15 µl  
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Table 5: Cocktail for Polymerase Chain Reaction. 
Reagent Volume Final Conc. 
Master Mix (2X) 
Promega, USA 
12.5 µl 1X 
Forward primer (10 pmoles)  1.0 µl 0.4 pmoles 
Reverse primer (10 pmoles)  1.0 µl 0.4 pmoles 
MgCl2 (25 mM)  2.0 µl 2 mM 
Nuclease free water  7.5 µl - 
Template DNA/colony mix  1.0 µl - 
Total Volume 25.0 µl - 
 
Table 6: Restriction digestion for EcoR1, Pst I and ApaI. 
 
Components 
EcoR I 
digest 
Pst I digest Apa I digest Final concentration 
pGEM-T-Easy plasmid 
(50 ng/µl) 
10.0 µl 10.0 µl 10.0 µl 500 ng 
Buffer B 10X 
5.0 µl 5.0 µl 5.0µl  
EcoR1 (3u/ µl) 
Pst (3u/ µl) 
Apa I (3u/ µl) 
1.0 µl  
1.0 µl 
 
 
1.0µl 
1 u 
1 u 
1 u 
Sterile distilled Water 34 µl 34 µl 34µl - 
Total volume 50 µl 50 µl 50µl - 
 
Table 7: Real-time PCR setup. 
Component Quantity Final Concentration 
Sybr Green (5X) 2µl 1X 
Forward primer (10pmoles) 0.5 µl 0.5 pmoles 
Reverse primer (10 pmoles) 0.5 µl 1-5pmoles 
sdH2O 5 µl Up to 10 μl 
cDNA (1 µg) 2 µl 200 ng 
Final reaction volume  10 µl - 
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Table 8: Typical real-time conditions. 
 
From Roche applied Science 
 
Table 9: Linearization of pGEM-T Easy-DWNN plasmid DNA. 
Components Volume Final concentrations 
pGEM-T Easy-DWNN plasmid DNA  
(100 ng/μl) 
10 l 1 µg 
Buffer O [Fermentas]  
(10X) 
2 l 1X 
Pst I/Apa I (10 u/l) 2 l  20 u 
Sterile dH2O 16 l - 
Total Volume 30 l - 
 
Table 10: PCR mix for DIG labelling. 
Reagents 
Antisense 
RNA 
Sense 
RNA 
Control 
RNA 
Final 
concentrations 
DWNN cDNA- Pst I/Apa I 
digested (40 ng/μl).  
25.0 µl 25.0 µl - 1 µg 
Control DNA PSPT 18-
Neo/PvuII (125 ng/µl) 
-  - 8.0 µl 1 µg 
10X NTP labelling mix 4.0 µl 4.0 µl 4.0 µl 1X 
10X Transcription buffer 4.0 µl 4.0 µl 4.0 µl 1X 
T7 RNA polymerase 
20 u/µl 
2.0 µl - - 40 u 
Sp6 RNA polymerase 
20 u/µl 
- 2.0 µl 4.0 µl 40 u 80 u 
DEPC-treated water 5 µl 5 µl 20.0 µl - 
Total volume 40.0 µl 40.0 µl 40.0 µl - 
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Table 11: Dilutions for the estimation of the probes. 
Dilution DIG-labelled cRNA  DIG labelled cRNA to 
control DNA-Pspt-18-
Neo 
DWNN probe 
(Antisense & sense) 
Initial 
conc. 
0.1 µg/µl 0.005 µg/µl ~ 0.2 µg/µl 
Dilution 1 1:5 (0.02μg/µl)  1:10 (0.02 μg/μl) 
Dilution 2 1:20 (0.001μg/μl) 1:5 (0.001 μg/μl) 1:20 (0.001 μg/μl) 
Dilution 3 1:10 (0.0001 μg/μl) 1:10 (0.0001 μg/μl) 1:10 (0.0001 μg/μl) 
Dilution 4 1:10 (0.00001 μg/μl) 1:10 (0.00001 μg/μl) 1:10 (0.00001 μg/μl) 
Dilution 5 1:10 (0.000001 μg/μl) 1:10 (0.000001 μg/μl) 1:10 (0.000001 μg/μl) 
Dilution 6 1:10 (0.0000001 μg/μl) 1:10 (0.0000001 μg/μl) 1:10 (0.0000001 μg/μl) 
Dilution 7 1:10 (0.00000001 μg/μl) 1:10 (0.0000001 μg/μl) 1:10 (0.0000001 μg/μl) 
 
Table 12: Preparation of the transfection mix. 
Tube 1 DNA Tube DNA Tube DNA Tube DNA Tube 
Component Rb1A Rb1B Rb3A U6GFP 
siRNA 2 µg 2 µg 2 µg 2 µg 
1XPBS Up to 100 µl Up to 100 µl Up to 100 µl Up to 100 µl 
Tube 2 Transfection 
Reagent Tube 
Transfection 
Reagent Tube 
Transfection 
Reagent Tube 
Transfection 
Reagent Tube 
Metafectene Pro 12 µl 12 µl 12 µl 12 µl 
1XPBS 88 µl 88 µl 88 µl 88 µl 
 
NOTE: The control included the RNAi vector with no insert and this was used to assess whether 
the GFP protein expression had an effect on the cells and additionally to monitor the GFP 
expression. Another control was Metafectene Pro without a DNA molecule to assess the toxicity of 
the transfection. 
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Table 13: Preparation of protein standards for the Bradford Assay. 
[STD] µg/µl Volume Stock 
Standard (µl) 
5 mg/µl 
Volume of the 
Extraction Buffer 
0.1M HCL 
(µl) 
dH2O (µl) 
0 0 10 10 80 
5 1 9 10 80 
10 2 8 10 80 
20 4 6 10 80 
40 8 2 10 80 
50 10 0 10 80 
 
In each tube, 900 µl of the Bradford Reagent was added and mixed well. The samples’ 
concentrations were determined by preparing the sample reaction as tabulated in table 14. The 
samples were done in triplicates and the absorbance readings were taken using a 
spectrophotometer at 595nm. The mean value (of 3) was used to plot a standard curve on 
Microsoft excel 2007. 
 
Table 14: Sample preparation for a Bradford Assay. 
Volume of 
Sample (µl) 
Volume of Extraction 
Buffer 
0.1M HCL 
(µl) 
dH2O (µl) Bradford Reagent 
(µl) 
5 5 10 80 900 
 
The samples were also measured in a spectrophotometer at 595nm and the concentrations were 
extrapolated from the linear equation of the standard curve. The concentration obtained was 
µg/5µl; therefore the value was divided by 5 to obtain the concentration in µg/µl. 
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Appendix G: RBBP6 quantitative assessment of tissues on arrays 
 
Cybrdi Tissue Array (CC00-11-001) 
Organ  Pathology 
Diagnosis 
Sex Age Grade Labelling 
intensity 
Stromal 
staining 
Oesophagus Squamous cell 
carcinoma 
M 62 III + Yes 
Oesophagus Squamous cell 
carcinoma 
M 56 III + Yes 
Oesophagus Squamous cell 
carcinoma 
M 48 III + Yes 
Stomach Inflammatory tissue F 55 - + - 
Stomach Adenocarcinoma M 57 III - Yes 
Stomach Adenocarcinoma M 74 III - Yes 
Colon Adenocarcinoma M 37 II - Yes  
Colon Adenocarcinoma M 62 II - Yes 
Colon Adenocarcinoma M 58 II - Yes 
Oesophagus Inflammatory tissue M 62 - ++ - 
Oesophagus Normal tissue F 72 - + - 
Oesophagus Inflammatory tissue M 54 - + - 
Stomach  Normal tissue F 55 - ++ - 
Stomach Normal tissue M 57 - ++ - 
Stomach Normal tissue M 66 - ++ - 
Colon Normal tissue F 56 - ++ - 
Colon Inflammatory tissue M 62 - ++ - 
Colon Inflammatory tissue M 58 - ++ - 
Rectum Adenocarcinoma M 55 I - Yes  
Rectum Adenocarcinoma M 67 I - Yes 
Rectum Adenocarcinoma F 55 I - Yes 
Liver Hepatocellular 
carcinoma 
F 32 II + Yes 
Liver Hepatocellular 
carcinoma 
M 39 II + Yes 
Liver Hepatocellular 
carcinoma 
F 55 II + Yes 
Lung Squamous cell 
carcinoma 
M 66 II ++ Yes 
Lung Squamous cell 
carcinoma 
F 59 II ++ Yes 
Lung Squamous cell 
carcinoma 
M 55 II ++ Yes 
Colon Normal tissue M 68 - +++ - 
Rectum Normal tissue F 58 - +++ - 
Rectum Fatty tissue M 67 - +++ - 
Liver Liver fatty 
degeneration 
M 63 - + - 
Liver Inflammatory tissue F 66 - + - 
Liver Inflammatory tissue M 48 - + - 
Lung Normal tissue F 69 - +++ - 
Lung Normal tissue F 43 - +++ - 
Lung Normal tissue M 65 - +++ - 
Kidney Transitional cell 
carcinoma 
M 72 I ++ - 
Kidney Transitional cell M 50 I ++ - 
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carcinoma 
Kidney Transitional cell 
carcinoma 
M 54 I ++ - 
Breast Adenosis F 29 - + Yes 
Breast Infiltrating duct 
carcinoma 
F 45 - + Yes 
Breast Infiltrating duct 
carcinoma 
F 52 - + Yes 
Uterine Cervix Transitional cell 
carcinoma 
F 76 - ++ Yes 
Uterine Cervix Transitional cell 
carcinoma 
F 47 - ++ Yes 
Uterine Cervix Transitional cell 
carcinoma 
F 42 - ++ Yes 
Kidney Normal tissue M 54 - ++ - 
Kidney Normal tissue F 61 - ++ - 
Kidney Normal tissue F 47 - ++ - 
Breast Fibrofatty tissue F 43 - ++ - 
Breast Normal tissue F 39 - ++ - 
Breast Adenosis F 54 - + - 
Breast Normal tissue F 73 - ++ - 
Breast Normal tissue F 50 - ++ - 
Breast Normal tissue F 43 - ++ - 
Ovary Serous papillary 
adenocarcinoma 
F 56 III - Yes 
Ovary Serous papillary 
adenocarcinoma 
F 49 III - Yes 
Ovary Serous papillary 
adenocarcinoma 
F 24 III - Yes 
Ovary Normal tissue F 40 - + - 
Ovary Normal tissue F 39 - + - 
Ovary Smooth muscle F 31 - + - 
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Biomax.us Tissue array (BC001111) 
 
Organ  Pathology 
Diagnosis 
Sex Age Grade Labelling 
intensity 
Stromal 
staining 
Oesophagus Squamous cell 
carcinoma 
M 62 II ++ Yes 
Oesophagus Squamous cell 
carcinoma 
M 56 III + Yes 
Oesophagus Squamous cell 
carcinoma 
F 72 - ++ Yes 
Stomach Adenocarcinoma F 55 III - Yes 
Stomach Adenocarcinoma M 56 II + Yes 
Stomach Adenocarcinoma M 74 III - Yes 
Colon Adenocarcinoma M 37 - - Yes 
Colon Adenocarcinoma M 82 I - Yes 
Colon Adenocarcinoma M 58 I - Yes 
Oesophagus Normal mucosa of 
the oesophagus 
M 38 - + Yes 
Oesophagus Normal mucosa of 
the oesophagus 
F 72 - + Yes 
Oesophagus Normal mucosa of 
the oesophagus 
M 53 - + Yes 
Stomach Normal mucosa of 
the stomach 
M 54 - ++ - 
Stomach Normal mucosa of 
the stomach 
M 54 - ++ - 
Stomach Normal mucosa of 
the stomach 
M 66 - ++ - 
Colon Normal mucosa of 
the colon 
F 56 - +++ - 
Colon Normal mucosa of 
the colon 
M 62 - +++ - 
Colon Normal mucosa of 
the colon 
M 58 - +++ - 
Rectum Adenocarcinoma M 55 II - Yes 
Rectum Adenocarcinoma M 67 II - Yes 
Rectum Adenocarcinoma F 55 II - Yes 
Liver Hepatocellular 
carcinoma 
F 32 II +  
Liver Hepatocellular 
carcinoma 
M 39 III - Yes 
Liver Hepatocellular 
carcinoma 
F 55 II + Yes 
Lung Squamous cell 
carcinoma 
M 66 II ++ Yes 
Lung Squamous cell 
carcinoma 
F 59 III ++ Yes 
Lung Chronic 
inflammation of 
lung 
M 55 - ++ - 
Rectum Normal mucosa of 
the rectum 
F 43 - +++ - 
Rectum Normal mucosa of 
the rectum 
M 33 - +++ - 
Rectum Normal mucosa of 
the rectum 
M 67 - +++ - 
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Liver Normal tissue M 63 - + - 
Liver Normal tissue F 66 - + - 
Liver Normal tissue F 48 - + - 
Kidney Clear cell 
carcinoma 
M 72 - ++ - 
Kidney Clear cell 
carcinoma 
M 50 - ++ - 
Kidney Clear cell 
carcinoma 
M 54 - ++ - 
Breast Intraductal 
carcinoma 
F 29 - + Yes 
Breast Infiltrating duct 
carcinoma 
F 45 - + Yes 
Breast Malignant fatty 
tissue 
F 52 - - Yes 
Uterine cervix Squamous cell 
carcinoma 
F 76 II + Yes 
Uterine cervix Squamous cell 
carcinoma 
F 47 II + Yes 
Uterine cervix Squamous cell 
carcinoma 
F 42 III - - 
Kidney Normal tissue M 54 - ++ - 
Kidney Normal tissue F 61 - ++ - 
Kidney Normal tissue F 47 - ++ - 
Breast Normal tissue F 43 - ++ - 
Breast Normal tissue F 48 - ++ - 
Breast Normal tissue F 41 - ++ - 
Breast Normal tissue F 37 - ++ - 
Breast Normal tissue F 50 - ++ - 
Breast Normal tissue F 43 - ++ - 
Ovary Serous papillary 
adenocarcinoma 
F 56 III - Yes 
Ovary Serous papillary 
adenocarcinoma 
F 49 III - Yes 
Ovary Serous papillary 
adenocarcinoma 
F 39 I - Yes 
Ovary Normal tissue F 40 - + - 
Ovary Normal tissue F 39 - + - 
Ovary Normal tissue F 31 - + - 
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Appendix H: Method schedules 
Schedule 1: Plasmid DNA Miniprep (Promega kit) 
1. Grow a single colony containing a plasmid of interest in 6 ml LB overnight. 
2. Collect the cells by centrifugation at 12 000 rpm for 5 min. Discard the supernatant. 
3. Resuspend the cell pellet in 250 µl Resuspension Solution (Promega Corp., USA) 
4. Lyse the cells in 250 µl Cell Lysis Solution (Promega Corp., USA) and mix by inverting the 
tube 4-5 times. 
5. Add 10 µl Alkaline Phosphatae Solution (Promega Corp., USA), mix by inverting 4-5 times and 
incubate for 5 min at room temperature. 
6. Add 350 µl Neutralization Solution (Promega Corp., USA) to precipitate chromosomal DNA 
and proteins. Mix by inverting 4-5 times. 
7. Centrifuge at 9676 x g at room temperature for 10 min. 
8. Decant the supernatant into a collection/collection tubes assemble and incubate for 1 min at 
room temperature. 
9. Centrifuge at 9676 x g at room temperature for 1 min. 
10. Discard the flow through and reassemble the column/collection tubes assemble. 
11. Wash the column with 750 µl Wash Solution (Promega Corp., USA) and centrifuge at 9676 x g 
at room temperature for 1 min. 
12. Repeat the wash with 250 µl Wash Solution (Promega Corp., USA) at 9676 x g for 2 min. 
13. Transfer the column to a 1.5 ml micro-centrifuge tube. 
14. Elute the plasmid DNA by adding 100 µl 1XTE and centrifuge at 11 709 x g for 1 min. 
15. Store the DNA at -20˚C for further use. 
 
Schedule 2: Immunohistochemical staining 
1. Dewax the tissue arrays in xylene for 20 min (2 changes of 10 min each) at room temperature. 
2. Rehydrate the slides in 100% ethanol for 10 min (2 changes of 5 min each). 
3. Quench endogenous peroxidases by immersing the tissue arrays in 100% methanol for 20 min at 
room temperature.  
4. Rehydrate the slides in 95% ethanol for 8 min (2 changes of 4 min) at room temperature. 
5. Rehydration in 70% ethanol at room temperature for 3 min. 
6. Perform antigen retrieval in 0.1M Sodium citrate (pH 6.0) at 80˚C for 2 min at a high microwave 
setting and for 5 min at a low microwave setting. 
7. Wash the slides with 1XTBST1%BSA for 2 min at room temperature. 
8. Block the endogenous peroxidases in TBST3%H2O2 for 20 min at room temperature. 
9. Wash the slides in TBST1%BSA for 2 min at room temperature. 
10. Incubate the slides in anti-human DWNN dilution 1:4000 (Optimised) prepared in TBST3%BSA. 
Incubate at 4˚C overnight in a humid chamber (Hybaid Ltd., UK). 
11. Wash the slides in TBST1%BSA for 2 min. 
12. Apply a biotinylated antibody linker (DAKO, Denmark) on each slide and incubate for 15 min at 
room temperature. 
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13. Wash the slides in TBST1%BSA for 2 min room temperature. 
14. Apply the secondary anti-rabbit IgG-conjugated with horse radish peroxidase (HRP) [DAKO, 
Denmark] and incubate at room temperature for 15 min. 
15. Wash the slides with TBST1%BSA for 5 min. 
16. Prepare the chromogen substrate according to the manufacturer’s instructions (DAKO, 
Denmark). Apply the chromogen preparation on each slide. 
17. Allow a colour change to develop for approximately 30 seconds and immediately immerse in 
water. 
18. Counterstain the slides with Mayer’s haematoxylin for 10 min and wash in tap for 5 min. 
19. Dehydrate the slides in 70%, 95% and 100% ethanol for 1 min in each. 
20. Clear the slides in xylene for 1 min X2. 
21. Mount the slides in Entellan (Merck, USA) and allow to completely dry. 
22. Examine the slides under the Axioplan 2 imaging system (Zeiss, Germany) 
23. Store the mounted slides in the dark for further referencing. 
 
Schedule 3: Promega SV DNA gel purification kit 
1. Perform 0.8% agarose gel electrophoresis on the linearized clone. 
2. Cut the linearized DNA with a sterile blade and transfer it into a 1.5 ml micro-centrifuge tube. 
3. Dissolve the gel slice in Membrane Binding Solution (Promega Corp., USA) [10µl Membrane 
Binding Solution for each 10 mg of the gel slice]. 
4. Incubate the gel slice in Membrane Binding Solution at 65˚C for 10 min with occasional mixing 
until the gel has completely dissolved. 
5. Transfer the dissolved gel mix onto the SV mini-column-collection tube assemble (Promega 
Corp., USA) and incubate at room temperature for 1 min. 
6. Centrifuge at 4480 x g for 1 min. Remove the mini-column and discard the flow through. Re-
assemble the SV mini-column-collection tubes assemble. 
7. Wash the SV mini-column with 700 µl Membrane Wash Solution (Promega Corp., USA). 
Centrifuge at 4480 x g for 1 min. 
8. Repeat the wash with 500 µl Membrane Binding Solution and centrifuge at 4480 x g for 5 min. 
9. Transfer the mini-column carefully to a 1.5 ml micro-centrifuge tube. 
10. Add 65 µl Nuclease-free DEPC treated water onto the centre of the mini-column. Incubate for 1 
min. 
11. Centrifuge at room temperature at 4480 x g for 1 min. 
12. Discard the SV mini-column and quantify the DNA spectrophotometrically and store for labelling 
a later stage. 
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Schedule 4: Estimation of the concentration of the probes 
1. Mark the spot points light with pencil on the nylon membrane (Hybond, Amersham, USA). 
2. Spot 1 µl of each dilution onto the membrane and allow to dry for 10 min. 
3. Fix the probes on the membrane by placing the membrane under UV light for 5 min. 
4. Wash the membrane with 1XWashing Buffer (Roche Diagnostics, Germany)on a shaker for 5 
min. 
5. Incubate the membrane in 1X Blocking Buffer (Roche Diagnostics, Germany) while shaking for 
30 min. 
6. Incubate the membrane in Anti-DIG-Alkaline Phosphatase (Roche Diagnostics, Germany) diluted 
1:10 000 in 1X Blocking Buffer for 30 min. Make sure that the membrane is covered. 
7. Wash twice with 1X Washing buffer while shaking for 15 min each. 
8. Immerse the membrane in 1X Detection buffer (Roche Diagnostics, Germany) for 2 min while 
shaking. 
9. Immerse the membrane in NBT/BCIP (Roche Diagnostics, Germany) diluted 1:50 and develop in 
the dark overnight. 
10. Terminate the reaction in 1X TE buffer (pH 8.0) for 5 min while shaking. 
11. Air-dry the membrane and estimate the probe concentrations from the known DIG-labelled 
control RNA probe concentrations by comparing the intensities of the developed colour spots on 
the membrane. 
 
Schedule 5: In situ hybridization treatments: Pre-hybridization treatment 
1. Dewax the tissue array slides in clean xylene (Merck) for 30 min (3 changes of 10 min). 
2. Rehydrate the tissues in fresh absolute ethanol for 6 min (2 changes of 3 min each) at room 
temperature (RT). 
3. Further rehydrate the tissues in 90%, 70%, 50% and DEPC treated water for 3 min in each 
solution at RT. 
4. Fix the tissues in freshly prepared 4% paraformaldehyde for 20 min at RT. 
5. Denature the proteins in 0.1M HCl for 10 min at RT. 
6. Rinse three times in fresh TBS for 1 min at RT. 
7. Limit non-specific labelling with freshly prepared 0.5% Acetic anhydride in 100 mM Tris pH 8.0 
for 10 min at RT. 
8. Rinse in TBS three time for 1 min for each rinse. 
9. Permeabilize the cell membranes using 20 µg/µl Proteinase K (Roche Diagnostics, Germany) 
prepared in TBS for 20 min at RT 
10. Rinse the tissues for 1 min 3 times in TBS. 
11. Terminate the Proteinase K activity by immersing the slides in chilled TBS for 5 min at 4 ˚C. 
12. Dehydrate the tissues in 50%, 70%, and 90% ethanol for 1 min in each solution. 
13. Dehydrate the tissues in 100% ethanol for 2 min (2 changes of 1 min each). 
14. Dry the tissues in chloroform for 10 min on the fume hood. 
15. Tissues can be stored in a dust-free slide box in the dark and probed at a convenient time or 
probed immediately. 
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Schedule 6: Post-hybridization washes and detection of bound probes 
1. After hybridization, remove the slides from the human chamber and discard the excess probe. 
2. Wash off the un-bound probe in 2X SSC for 30 min at 37 ˚C in the hybridization oven 
(Biosystems, USA) 
3. Wash in 2X SSC, 1X SSC, 0.1X SSC at 55 ˚C for 20 min in each. 
4. Rinse the slides in TBS for 3 min (3 changes of 1 min each) at RT. 
5. Block non-specific binding using 1X blocking buffer (Roche Diagnostics) in the humid chamber 
for 2 hours. 
6. Incubate the slides with anti-DIG IgG conjugated with alkaline phosphatise (Roche Diagnostics, 
Germany) diluted 1:500 in 1X blocking buffer. Incubate for 1 hour at RT. 
7. Rinse the slides in TBS for 3 min (3 changes of 1 min each) at RT. 
8. Incubate the slides with the chromogen; NBT/BCIP (Roche Diagnostics, Germany) diluted 1:50 
in detection buffer (Roche Diagnostics, Germany). 
9. Develop in the dark humid chamber overnight at RT. 
10. Stop the reaction in 1XTE for 5 min at RT. 
11. Wash the slides in tap water for 5 min at RT. 
12. Counterstain with Mayer’s Haematoxylin at RT for 5 min. 
13. Wash the slides in tap water for 10 min. 
14. Mount the slides with permanent aqueous mounting medium (Serotec, UK). 
15. Dry the mounted-slides and view them under the light microscope. 
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Appendix I: hHPRT1 and DWNN standard curve constructed with dilutions made from a Hek 293T cDNA 
 
 
hHPRT1 and DWNN standard curve constructed with dilutions made from a Hek 293T cDNA: Appendix I demonstrates a good PCR amplification by the house-
keeping genes, in this case a hHHPRT1 primer pair. The Hek 293T cDNA was diluted (1 is 1:10, 2 is 1:100, 3 is 1:1000, 4 is 1:10000 and 5 is 1:100000) to construct the 
hHPRT1 standard curve. The melting curves on the right show that only one product was amplified. Figure 6.5B shows the efficiency and the melting point of the DWNN 
primers. Different dilutions (1-1:10; 2-1:100; 3-1:1000; 4-1:10000 and 5-1:100000) were made from the Hek 293T cDNA. 
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Table 15: Relative expression of DWNN normalized using hHPRT1. 
Cell lines DWNN Av Ct hHPRT1 Av Ct Delta Ct Relative expression 
Hek 293T 23 15 -8 0.0039 
MCF-7 35 15 -20 9.5X10-7 
HeLa 31 14 -17 7.6X10-6 
HepG2 30 14 -16 1.53X10-5 
Jurkats 18 15 -3 0.125 
WHCO 30 15 -14 1.53X10-5 
 
Table 16: Relative expression of RBBP6 normalized using hHPRT1. 
Cell lines RBBP6 Av Ct hHPRT1 Av Ct Delta Ct Relative expression 
Hek 293T 33 15 -18 3.8X10-6 
MCF-7 42 15 -27 7.5X10-9 
HeLa 40 14 -26 1.4X10-8 
HepG2 40 14 -26 1.4X10-8 
Jurkats 28 15 -13 1.2X10-4 
WHCO 40 15 -25 2.9X10-8 
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Appendix J: The GST-DWNN construct, an antigen for the generation of Anti-human DWNN antibody 
 
 
 
The GST-DWNN construct, an antigen for the generation of anti-Human DWNN antibody: This figure shows the antigen that was used for immunization for anti-Human DWNN 
antibody production. The GST (Blue) can be cleaved from the DWNN -87 (Black) by using a 3C protease recognition site (Red) between the two proteins. 
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Appendix K: Sequence alignment of RBBP6 domains versus reference sequence (NM006910) 
 
This sequence alignments of the T7/Sp6 generated sequences from MCF-7 against the reference sequence for the sequenced RING finger domain coding region of the RbBP6 
gene. It is a representation of the RING finger domain sequences from the human cancer cell lines. 
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This sequence alignments of the T7/Sp6 generated sequences from MCF-7 against the reference sequence for the sequenced RbBD domain coding region of the RbBP6 gene. It 
is a representation of the RbBD domain sequences from the human cancer cell lines. 
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This sequence alignments of the T7/Sp6 generated sequences from MCF-7 against the reference sequence for the sequenced p53BD domain coding region of the RbBP6 gene. It 
is a representation of the p53BD domain sequences from the human cancer cell lines. 
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Chromatogram presentation of the resultant sequences 
 
 
Chromatograms from sequences of different RBBP6 domains: The sequences obtained were edited 
according to chromatographic picks (e.g. G was not called and was added in the p53BD sequence) and the final 
sequence was then used to determine any alterations in the clones from different cancers. 
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Appendix L1 An amplified DWNN fragment for probe labelling and sequence analysis 
 
 
An amplified DWNN fragment for probe labelling and sequence analysis: (A) shows a fragment that was amplified for probe synthesis. A 128 bp fragment was amplified (lane 2), 
cloned and sequenced before labelling. Lane 3 represents a negative control (reaction with no template DNA). The obtained sequence gave 100% identity to all RBBP6 transcripts (B). 
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Appendix L2 - Dot plots for the estimation of the labelled probe concentrations 
 
 
 
Dot plots for the estimation of the labelled probe concentrations: The figure shows the control 
labelled RNA of known concentrations (Panel A) used for estimating the concentration of labelled 
probes. The figure demonstrates successful labelling of the RNA probe (B-labelled control RNA; 
C-labelled DWNN antisense RNA probe and D- labelled DWNN sense RNA probe).  
 
Panel A shows a comparison of the labelled RNA (Roche Diagnostic, Germany) to labelled control 
RNA (Panel B), the DWNN antisense probe (Panel C) and sense probe (Panel D). The lowest 
dilution of the antisense probe that could be detected was found to be 0.1 pg/μl when compared to 
the labelled RNA, while the lowest dilution for the sense probe was determined to be 0.3 pg/μl. 
This figure also demonstrates that the labelling was successful. 
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Appendix M: Summary of the results for the Column Analysis 
 
Table Analyzed Data 1     
        
Repeated Measures ANOVA       
P value P<0.0001     
P value summary ***     
Are means signif. different? (P < 0.05) Yes     
Number of groups 18     
F 146.2     
R squared 0.9865     
        
Was the pairing significantly effective?       
R squared 0.00001817     
F 0.02288     
P value 0.9774     
P value summary ns     
Is there significant matching? (P < 0.05) No     
        
ANOVA Table SS df MS 
Treatment (between columns) 6034 17 354.9 
Individual (between rows) 0.1111 2 0.05556 
Residual (random) 82.56 34 2.428 
Total 6116 53   
        
Post test for linear trend       
Slope 0.2822     
R squared 0.07573     
P value P<0.0001     
P value summary ***     
Is linear trend significant (P < 0.05)? Yes     
 
Column analysis showed significance for mean differences (P<0.0001) and linear trend in Post test 
linear test (P<0.05). 
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Appendix O: Real-time PCR analysis 
 
 
Confirmation of RNAi constructs by PCR. These constructs were also sequenced to further 
confirm their identities. Figure shows PCR products of 517 bp fragments from the amplification of 
RNAi plasmid DNA inserts (Lanes 2-4), a smaller PCR fragment for from the RNAi vector only 
control (pU6GFP) [Lane 5] and a negative control (PCR reaction with no template DNA, replaced 
with sterile distilled water) [lane 6]. 
 
 
Table 17: Relative knockdown of RBBP6 mRNAs normalized to hHPRT1 expression. 
 
Untransfected 293T (DWNN primers) 0.000513±1.2X10-5 
Vector transfected 293T (DWNN primers) 0.00052±2X10-5 
DWNN RNAi transfected 293T (DWNN primers) 0.0000157±1X10-5 
Untransfected 293T (RBBP6 primers) 0.000064±3.52X10-5 
Vector transfected 293T (RBBP6 primers) 0.000061±9.0310-6 
RBBP6 RNAi transfected 293T (RBBP6 primers) 0.000012±1X10-6 
 
 
